[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 406
1. Attlmayr B, Garrido C, Alderson DJ: Difficulty in establishing a diagnosis in an uncommon presentation of a minor salivary gland tumour. BMJ Case Rep; 2010;2010
MedlinePlus Health Information. consumer health - Swallowing Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Difficulty in establishing a diagnosis in an uncommon presentation of a minor salivary gland tumour.
  • We report the case of a man presenting with a large, airway obstructing, minor salivary gland tumour arising from the right tonsillar base.
  • A firm diagnosis of malignancy could not be made histologically.
  • The differential diagnosis included polymorphous low-grade adenocarcinoma, basal cell adenoma and adenoid cystic carcinoma.
  • However, on balance, based on the clinical presentation, a diagnosis of malignancy was favoured and appropriate treatment was considered.
  • [MeSH-major] Adenoma / diagnosis. Adenoma / pathology. Airway Obstruction / etiology. Deglutition Disorders / etiology. Salivary Gland Neoplasms / diagnosis. Salivary Gland Neoplasms / pathology. Salivary Glands, Minor. Tongue Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Biopsy. Cooperative Behavior. Diagnosis, Differential. Endoscopy. Humans. Interdisciplinary Communication. Lymphatic Metastasis / pathology. Lymphatic Metastasis / radiotherapy. Magnetic Resonance Imaging. Male. Middle Aged. Palliative Care. Tongue / pathology. Tracheostomy

  • MedlinePlus Health Information. consumer health - Choking.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oral Dis. 2002 Sep;8(5):229-40 [12363107.001]
  • [Cites] Am J Surg. 1991 Oct;162(4):330-6 [1659242.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Jun 1;35(3):443-54 [8655366.001]
  • [Cites] Cancer Treat Rev. 1996 Nov;22(6):395-423 [9134002.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999 Apr;87(4):485-92 [10225632.001]
  • [Cites] Ann Surg. 1956 Sep;144(3):366-83 [13363274.001]
  • [Cites] Oral Oncol. 2008 Apr;44(4):407-17 [17825603.001]
  • (PMID = 22798299.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC3029651
  •  go-up   go-down


2. Gupta G, Singh R, Shanmugasamy K, Kotasthane DS, Kotasthane VD: Basal cell adenocarcinoma in the tongue: an unusual presentation. Clin Med Insights Oncol; 2010 Nov 21;4:127-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenocarcinoma in the tongue: an unusual presentation.
  • We present a case of basal cell adenocarcinoma (BCAC) in the tongue in a 65-year old male.
  • BCAC generally occurs in the parotid gland and rarely involves the minor salivary glands.
  • The clinicopathological features and the cellular immunophenotype addressed the diagnosis towards BCAC of the tongue.
  • The goal of this report is to increase awareness of this rare disease and to review and discuss the differential diagnosis and important considerations in treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21151583.001).
  • [ISSN] 1179-5549
  • [Journal-full-title] Clinical Medicine Insights. Oncology
  • [ISO-abbreviation] Clin Med Insights Oncol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2999957
  • [Keywords] NOTNLM ; basal cell adenocarcinoma / minor salivary gland / tongue
  •  go-up   go-down


3. Jingu K, Hasegawa A, Mizo JE, Bessho H, Morikawa T, Tsuji H, Tsujii H, Kamada T: Carbon ion radiotherapy for basal cell adenocarcinoma of the head and neck: preliminary report of six cases and review of the literature. Radiat Oncol; 2010;5:89
Hazardous Substances Data Bank. CARBON .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carbon ion radiotherapy for basal cell adenocarcinoma of the head and neck: preliminary report of six cases and review of the literature.
  • BACKGROUND: Basal cell adenocarcinoma accounts for approximately 1.6% of all salivary gland neoplasms.
  • METHODS: Case records of 6 patients with diagnosis of basal cell adenocarcinoma of the head and neck, who were treated by carbon ion radiotherapy with 64.0 GyE/16 fractions in our institution, were retrospectively reviewed.
  • CONCLUSIONS: Carbon ion radiotherapy should be considered as an appropriate curative approach for treatment of basal cell adenocarcinoma in certain cases, particularly in cases of unresectable disease and postoperative gross residual or recurrent disease.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Carbon / therapeutic use. Head and Neck Neoplasms / radiotherapy. Heavy Ions / therapeutic use

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):737-43 [11020570.001]
  • [Cites] Histopathology. 2003 Jun;42(6):610-4 [12786899.001]
  • [Cites] Arch Otolaryngol. 1978 Feb;104(2):111-6 [629699.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1990 Apr;69(4):461-9 [2326038.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22 [2032882.001]
  • [Cites] Am J Clin Oncol. 1992 Oct;15(5):441-5 [1326226.001]
  • [Cites] Cancer. 1996 Dec 15;78(12):2471-7 [8952553.001]
  • [Cites] Cancer. 1998 Feb 1;82(3):439-47 [9452259.001]
  • [Cites] HNO. 1998 Sep;46(9):821-5 [9816537.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Apr 1;44(1):201-10 [10219815.001]
  • [Cites] Cancer. 2005 Jul 1;104(1):71-82 [15915466.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):396-401 [16182466.001]
  • [Cites] Med Oral Patol Oral Cir Bucal. 2006 Mar;11(2):E206-9 [16505803.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Jan;103(1):77-84 [17178498.001]
  • (PMID = 20920325.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 7440-44-0 / Carbon
  • [Other-IDs] NLM/ PMC2958970
  •  go-up   go-down


Advertisement
4. Ward BK, Seethala RR, Barnes EL, Lai SY: Basal cell adenocarcinoma of a hard palate minor salivary gland: case report and review of the literature. Head Neck Oncol; 2009 Dec 23;1:41
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenocarcinoma of a hard palate minor salivary gland: case report and review of the literature.
  • OBJECTIVE: Basal cell adenocarcinoma of a minor salivary gland is extremely rare.
  • The goal of this report is to increase awareness of this rare disease and to review and discuss the differential diagnosis and important considerations in treatment.
  • METHODS: Case report of a basal cell adenocarcinoma of a hard palate minor salivary gland and review of the literature of basal cell adenocarcinoma.
  • RESULTS: Basal cell adenocarcinomas are slow-growing tumours that most commonly involve the parotid gland and very rarely involve minor salivary glands.
  • Histological diagnosis is important to distinguish this tumour from adenoid cystic carcinoma given the significant difference in disease prognosis.
  • CONCLUSIONS: Diagnosis of these tumours must be made histologically.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Otolaryngol. 1978 Feb;104(2):111-6 [629699.001]
  • [Cites] J Oral Pathol. 1985 Jul;14(6):500-9 [2991488.001]
  • [Cites] Arch Pathol Lab Med. 1988 Feb;112(2):209-11 [2827601.001]
  • [Cites] J Laryngol Otol. 1989 Aug;103(8):756-9 [2769045.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1990 Apr;69(4):461-9 [2326038.001]
  • [Cites] Cancer. 1996 Dec 15;78(12):2471-7 [8952553.001]
  • [Cites] Oral Oncol. 2008 Apr;44(4):407-17 [17825603.001]
  • [Cites] HNO. 1998 Sep;46(9):821-5 [9816537.001]
  • [Cites] Int J Oral Maxillofac Surg. 2005 Jul;34(5):528-32 [16053873.001]
  • [Cites] Int J Oral Maxillofac Surg. 2006 Feb;35(2):150-4 [16181771.001]
  • [Cites] Med Oral Patol Oral Cir Bucal. 2006 Mar;11(2):E206-9 [16505803.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Jan;103(1):77-84 [17178498.001]
  • [Cites] J Oral Pathol Med. 2007 Apr;36(4):207-14 [17391298.001]
  • [Cites] Acta Otolaryngol. 1998 Jul;118(4):588-93 [9726688.001]
  • (PMID = 20030819.001).
  • [ISSN] 1758-3284
  • [Journal-full-title] Head & neck oncology
  • [ISO-abbreviation] Head Neck Oncol
  • [Language] ENG
  • [Grant] United States / NIDCR NIH HHS / DE / K08 DE018061
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2806868
  • [General-notes] NLM/ Original DateCompleted: 20100629
  •  go-up   go-down


5. Salem A, Phillips JS, Joseph JA, O'Donovan DG, Jani P: Basal cell adenocarcinoma of the ethmoid sinuses. J Laryngol Otol; 2007 Sep;121(9):889-91

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenocarcinoma of the ethmoid sinuses.
  • Basal cell adenocarcinoma is a rare and relatively recently characterised malignant salivary gland tumour.
  • It accounts for 5 per cent of parotid gland tumours and 1 per cent of salivary gland malignancies.
  • It is very rarely documented in anatomical sites other than the major salivary glands.
  • Basal cell adenocarcinoma has only been described once before in the ethmoid sinus.
  • We report a case of basal cell adenocarcinoma in the ethmoid sinus, extending into the right orbit and anterior cranial fossa.
  • We describe the clinical aspects of the patient's management and detail the histopathological features of this very rare diagnosis.
  • [MeSH-major] Adenocarcinoma. Ethmoid Sinus. Paranasal Sinus Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17295935.001).
  • [ISSN] 1748-5460
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


6. Markkanen-Leppänen M, Mäkitie AA, Passador-Santos F, Leivo I, Hagström J: Bilateral Basal cell adenocarcinoma of the parotid gland: in a recipient of kidney transplant. Clin Med Insights Pathol; 2010 Feb 18;3:1-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral Basal cell adenocarcinoma of the parotid gland: in a recipient of kidney transplant.
  • We report a rare case of bilateral basal cell adenocarcinoma (BcAC) of the parotid gland in a male patient 30 years after kidney transplantation and continuous administration of immunosuppressive therapy.
  • BcAC is a salivary gland malignancy first recognized as a distinct neoplastic entity in WHO classification of salivary gland tumours in 1991.
  • Over 90% of BcACs are detected in the parotid gland.
  • The most important differential diagnosis is basal cell adenoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21151548.001).
  • [ISSN] 1179-5557
  • [Journal-full-title] Clinical medicine insights. Pathology
  • [ISO-abbreviation] Clin Med Insights Pathol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2999998
  • [Keywords] NOTNLM ; basal cell adenocarcinoma / immunohistochemistry / post transplantation malignancy / salivary gland cancer
  •  go-up   go-down


7. Farrell T, Chang YL: Basal cell adenocarcinoma of minor salivary glands. Arch Pathol Lab Med; 2007 Oct;131(10):1602-4
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenocarcinoma of minor salivary glands.
  • Basal cell adenocarcinoma of minor salivary glands is a relatively rare slow-growing tumor with an infiltrating growth pattern.
  • The infiltrating growth pattern and likelihood of vascular and perineural involvement distinguishes basal cell adenocarcinoma from basal cell adenoma.
  • Basal cell adenocarcinomas show strong immunoreactivity to cytokeratin 7 and variable myoepithelial staining with S100.
  • It is necessary to differentiate basal cell adenocarcinoma from other basaloid cell tumors of the minor salivary glands because of the prognosis and potential differences in treatment, particularly adenoid cystic adenocarcinoma and basaloid squamous carcinoma.
  • Surgical excision with a wide margin to ensure complete removal has been suggested as the primary treatment for basal cell adenocarcinoma.
  • Radiotherapy has been proposed for lesions in the minor salivary glands because of the higher likelihood of vascular and neural invasion and for those that are diffusely infiltrative.
  • [MeSH-major] Adenocarcinoma / diagnosis. Salivary Gland Neoplasms / diagnosis. Salivary Glands, Minor / pathology
  • [MeSH-minor] Adenoma / diagnosis. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Squamous Cell / diagnosis. Combined Modality Therapy. Diagnosis, Differential. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17922602.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Sanchis García JM, Dualde Beltrán D, Ramírez Sabio JB, Vera González A, Palmero da Cruz J: [Well-differentiated basal cell adenocarcinoma of the lacrimal sac: a case report]. Radiologia; 2007 May-Jun;49(3):201-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Well-differentiated basal cell adenocarcinoma of the lacrimal sac: a case report].
  • [Transliterated title] Adenocarcinoma de células basales del saco lacrimal bien diferenciado. A propósito de un caso.
  • Basal cell adenocarcinoma is a rare tumor first considered to be a separate entity by the WHO in 1991.
  • We present a case of adenocarcinoma of the lacrimal sac diagnosed at histological study.
  • We discuss the differential diagnosis and treatment for this tumor.
  • [MeSH-major] Adenocarcinoma / diagnosis. Lacrimal Apparatus

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17524341.001).
  • [ISSN] 0033-8338
  • [Journal-full-title] Radiología
  • [ISO-abbreviation] Radiologia
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


9. Hirai H, Harada H, Okada N, Omura K: A case of basal cell adenocarcinoma of the upper gingiva. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 Apr;107(4):542-6
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of basal cell adenocarcinoma of the upper gingiva.
  • Basal cell adenocarcinoma arising from the minor salivary gland is extremely rare.
  • We report a 76-year-old Japanese man with basal cell adenocarcinoma originating in the upper gingiva.
  • [MeSH-major] Adenocarcinoma / surgery. Gingival Neoplasms / surgery. Maxillary Neoplasms / surgery. Oral Surgical Procedures. Reconstructive Surgical Procedures / methods. Salivary Gland Neoplasms / surgery
  • [MeSH-minor] Aged. Humans. Male. Salivary Glands, Minor / pathology. Salivary Glands, Minor / surgery. Surgical Flaps

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19157926.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Zheng J, Chen Y, Zhang J: [Basal cell adenocarcinoma of nasal septum: a case report and review of literatures]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2009 Mar;23(5):209-10
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Basal cell adenocarcinoma of nasal septum: a case report and review of literatures].
  • OBJECTIVE: To summarize clinical features, diagnosis, differential diagnosis, treatment and prognosis of basal cell adenocarcinoma.
  • METHOD: A retrospective study were subjected to one case with basal cell adenocarcinoma of the nasal septum, and the related literature were reviewed.
  • RESULT: Basal cell adenocarcinoma often occurred in the salivary glands and minor salivary glands of salivary palate and other parts.
  • CONCLUSION: Basal cell adenocarcinoma is rare seen in the salivary gland tumors.
  • It has a tendency of low-grade malignancy but need long-term follow-up of a large samples.
  • [MeSH-major] Adenocarcinoma. Nasal Septum / pathology. Nose Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19522187.001).
  • [ISSN] 1001-1781
  • [Journal-full-title] Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery
  • [ISO-abbreviation] Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] China
  •  go-up   go-down


11. Manor E, Sion-Vardy N, Bodner L: Cytogenetic and fluorescence in situ hybridization analysis of a basal cell adenocarcinoma of the mandible. Cancer Genet Cytogenet; 2006 Apr 15;166(2):186-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic and fluorescence in situ hybridization analysis of a basal cell adenocarcinoma of the mandible.
  • Basal cell adenocarcinoma (BCAC) of the salivary glands is rare.
  • Distant metastasis to the mandible from a salivary gland tumor is also considered rare.
  • The cytogenetic finding of a case of metastatic BCAC of the mandible is described.
  • An 80-year-old female with primary BCAC of the parotid salivary gland underwent parotidectomy and chemotherapy.
  • The characteristic histologic architecture of BCAC found in the mandible was similar to that of the earlier findings of the tumor in the parotid gland.
  • [MeSH-major] Adenocarcinoma / genetics. Mandibular Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16631478.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Parashar P, Baron E, Papadimitriou JC, Ord RA, Nikitakis NG: Basal cell adenocarcinoma of the oral minor salivary glands: review of the literature and presentation of two cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Jan;103(1):77-84
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenocarcinoma of the oral minor salivary glands: review of the literature and presentation of two cases.
  • Basal cell adenocarcinoma (BCA) is an unusual salivary gland malignancy that very rarely affects the minor glands.
  • Here we present 2 cases of BCA arising in the minor salivary glands of the left cheek and junction of the hard and soft palate, respectively.
  • A comprehensive literature review revealed only 21 previously reported cases of BCA of oral minor salivary glands.
  • This is an exceptionally rare salivary gland tumor, which, despite its low-grade behavior, demands complete surgical removal with adequate margins.
  • Immunohistochemical studies may complement a thorough histopathologic analysis in discriminating BCA from other salivary gland tumors.
  • [MeSH-major] Adenocarcinoma / pathology. Salivary Gland Neoplasms / pathology. Salivary Glands, Minor / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17178498.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 35
  •  go-up   go-down


13. Petersen SK, Bjørndal K, Krogdahl A, Godballe C: [Basal cell adenocarcinoma of the sublingual gland]. Ugeskr Laeger; 2010 Feb 15;172(7):551-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Basal cell adenocarcinoma of the sublingual gland].
  • The cause of a swelling in the floor of the mouth will in most cases be benign.
  • Tumors of the sublingual gland are very rare, but 90% are malignant and therefore malignancy should always be excluded in case of an asymptomatic swelling covered by intact mucosa.
  • [MeSH-major] Adenocarcinoma / pathology. Sublingual Gland Neoplasms / pathology
  • [MeSH-minor] Biopsy, Fine-Needle. Diagnosis, Differential. Edema / diagnosis. Female. Humans. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20156409.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


14. Chung SW, Kwon SY, Jung KY, Woo JS: Synchronous double primary cancers of the unilateral parotid gland. Acta Otolaryngol; 2007 Feb;127(2):209-12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous double primary cancers of the unilateral parotid gland.
  • To the best of our knowledge, there has been no report of synchronous unilateral double primary carcinomas of the parotid gland.
  • Here we report a 39-year-old woman who exhibited basal cell adenocarcinoma and mucoepidermoid carcinoma simultaneously in the left parotid gland.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Mucoepidermoid / pathology. Neoplasms, Multiple Primary / pathology. Parotid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17364354.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


15. Kazakov DV, Benkova K, Michal M, Vanecek T, Kacerovska D, Skalova A: Skin type spiradenoma of the parotid gland with malignant transformation: report of a case with analysis of the CYLD gene. Hum Pathol; 2009 Oct;40(10):1499-503

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin type spiradenoma of the parotid gland with malignant transformation: report of a case with analysis of the CYLD gene.
  • A distinctive variant of basal cell adenoma called membranous basal cell adenoma is well recognized in salivary glands.
  • We present a case of a tumor involving the parotid gland that appeared identical to cutaneous spiradenoma.
  • In addition, the lesion had a malignant component identical to basal cell adenocarcinoma.
  • This is the first report of a "dermal analogue tumor" of the salivary gland that resembled a cutaneous spiradenoma and not a cylindroma.
  • [MeSH-minor] Aged. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / pathology. DNA Mutational Analysis. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19454360.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CYLD protein, human; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


16. Kawahara A, Harada H, Akiba J, Yokoyama T, Kage M: Fine-needle aspiration cytology of basal cell adenoma of the parotid gland: characteristic cytological features and diagnostic pitfalls. Diagn Cytopathol; 2007 Feb;35(2):85-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration cytology of basal cell adenoma of the parotid gland: characteristic cytological features and diagnostic pitfalls.
  • We retrospectively studied the cytological features of aspiration cytology in 12 cases of basal cell adenoma (BCA) and 5 cases mistakenly diagnosed as BCA.
  • The characteristic cytological features of solid type BCA were three-dimensional clusters in 71%, sharp-angle small clusters in 86%, basement membrane- like material in 71%, and cell crush in 86%.
  • In contrast, 3 of the 5 cystic type BCA cases showed inadequate cellular components or no basaloid tumor cells, and the cytological diagnosis of BCA could not be determined.
  • In the 5 cases misdiagnosed as BCA, there were 2 cases of pleomorphic adenoma, 2 cases of benign lymphoepithelial cyst, and 1 case of basal cell adenocarcinoma.
  • Accurate differential cytological diagnosis of BCA is relatively easy to determine the solid type BCA, but is more difficult for cystic type BCA.
  • [MeSH-major] Adenoma / diagnosis. Parotid Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Biopsy, Fine-Needle. Diagnosis, Differential. Diagnostic Errors. Female. Humans. Male. Middle Aged. Prospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17230571.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. González-García R, Nam-Cha SH, Muñoz-Guerra MF, Gamallo-Amat C: Basal cell adenoma of the parotid gland. Case report and review of the literature. Med Oral Patol Oral Cir Bucal; 2006 Mar;11(2):E206-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenoma of the parotid gland. Case report and review of the literature.
  • Basal cell adenoma of the salivary glands is an uncommon type of monomorphous adenoma.
  • Its most frequent location is the parotid gland.
  • Histologically, isomorphic cells in nests and interlaced trabecules with a prominent basal membrane are observed.
  • It is also characterized by the presence of a slack and hyaline stroma and the absence of myxoid or condroid stroma.
  • Due to prognostic implications, differential diagnosis with basal cell adenocarcinoma, adenoid cystic carcinoma and basaloid squamous cell carcinoma is mandatory.
  • We describe a case of basal cell adenoma of the parotid gland.
  • We also review the literature and discuss the diagnosis and management of this rare entity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16505803.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng; spa
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 21
  •  go-up   go-down


18. Daneshbod Y, Daneshbod K, Khademi B: Diagnostic difficulties in the interpretation of fine needle aspirate samples in salivary lesions: diagnostic pitfalls revisited. Acta Cytol; 2009 Jan-Feb;53(1):53-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic difficulties in the interpretation of fine needle aspirate samples in salivary lesions: diagnostic pitfalls revisited.
  • OBJECTIVE: To present our experience in diagnostic errors and pitfalls on aspiration cytology of salivary region in a high volume of cases.
  • STUDY DESIGN: In a retrospective review of cytology files of a head and neck referral center from 1990 to 2005, the false positive and false negative interpretations on fine needle aspiration (FNA) of salivary lesions were retrieved.
  • These records and slides were reviewed to identify cytologic characteristics that contributed to false diagnosis.
  • RESULTS: Of a total of 1,040 salivary FNA samples, 376 cases had a final histologic diagnosis with interpretations of benign or malignant.
  • The most common false negative cases were acinic cell carcinoma, epithelial myoepithelial carcinoma, adenoid cystic carcinoma and basal cell adenocarcinoma.
  • Benign cases with false positive diagnosis were Warthin tumor and pleomorphic adenoma.
  • CONCLUSION: Knowledge of cytologic overlaps and pitfalls on salivary gland FNA, as well as clinical and radiologic features, may help clinicians arrive at the appropriate diagnosis and reduce false interpretations.
  • [MeSH-major] Salivary Gland Neoplasms / diagnosis. Salivary Glands / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Child. Child, Preschool. Diagnosis, Differential. False Negative Reactions. False Positive Reactions. Female. Humans. Infant. Male. Middle Aged. Retrospective Studies. Sensitivity and Specificity. Young Adult

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19248555.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Seethala RR, Pasha TL, Raghunath PN, Livolsi VA, Zhang PJ: The selective expression of CD43 in adenoid cystic carcinoma. Appl Immunohistochem Mol Morphol; 2008 Mar;16(2):165-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CD43 immunoreactivity with 2 different antibodies was detected mainly in ACC but also 1 membranous type basal cell adenocarcinoma and 1 colonic adenocarcinoma.
  • Nine of 20 (45%) ACC (8/17 salivary/mucoserous and 1/3 mammary) showed immunoreactivity with clone MT1 whereas 4 (23.5%) salivary ACC also showed immunoreactivity with clone DF-T1.
  • Hence, CD43 seems to be selectively expressed in a subset of ACC and its significance in salivary tumors is discussed.

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18227725.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD43; 0 / RNA, Messenger; 0 / UN1 sialoglycoprotein, human
  •  go-up   go-down


20. Farah-Klibi F, Ferchiou M, Kourda J, El Amine O, Ferjaoui M, Ben Jilani S, Zermani R: [Parotid basal cell adenoma of membranous type]. Tunis Med; 2009 Feb;87(2):149-51
MedlinePlus Health Information. consumer health - Sarcoidosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Parotid basal cell adenoma of membranous type].
  • [Transliterated title] Adenome a cellules basales de type membraneux de la parotide.
  • INTRODUCTION: Basal cell adenoma (BCA) is a rare benign neoplasm characterized by the basaloid appearance of the tumour cells and the lack of myxo-chondroid stromal component present in pleomorphic adenoma.
  • AIM: We report a case of basal cell adenoma of membranous type, highly suspected of malignancy because of the presence of mediastinal lymph nodes and pulmonary nodules which finally were related to an associated sarcoidosis.
  • So the diagnosis of metastatic malignant salivary gland tumor was suspected.
  • Finally, the histological examination concluded to a basal cell adenoma of membranous type with sarcoidosis granulomas in the parotid and in the lymph nodes.
  • CONCLUSION: The BCA is a benign tumor located generally in the parotid gland.
  • When the malignancy is suspected, like in our case, this tumor must be differentiated from the basal cell adenocarcinoma using histological criteria.
  • [MeSH-major] Adenoma / diagnosis. Parotid Neoplasms / diagnosis. Sarcoidosis / diagnosis
  • [MeSH-minor] Aged, 80 and over. Diagnosis, Differential. Female. Humans. Lymphatic Metastasis. Mediastinum / radiography. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19522450.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


21. Campos MS, Modolo F, de Oliveira JS, Pinto-Júnior DS, de Sousa SC: Atypical presentation of oral basaloid squamous cell carcinoma. J Contemp Dent Pract; 2009;10(2):98-104
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical presentation of oral basaloid squamous cell carcinoma.
  • AIM: The purpose of this report is to present the clinical and histological features of a basaloid squamous cell carcinoma (BSCC) occurring in the retromolar trigone of a 59-year-old man and to relate its immunohistochemical characteristics.
  • BACKGROUND: BSCC is an aggressive distinct variant of squamous cell carcinoma (SCC) requiring recognition as a separate entity from SCC due to its peculiar behavior.
  • SUMMARY: Since this tumor can mimic other neoplasms such as adenoid cystic carcinoma, neuroendocrine carcinoma, and basal cell adenocarcinoma, histological features are essential to differentiate between them.
  • Clinicians are advised to conduct a mucosal evaluation during oral examinations and take a thorough medical history which could ultimately save the life of a patient.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Carcinoma, Transitional Cell / diagnosis. Mouth Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Neuroendocrine / diagnosis. Cell Nucleus / ultrastructure. Diagnosis, Differential. Follow-Up Studies. Humans. Immunohistochemistry. Keratins / analysis. Ki-67 Antigen / analysis. Laminin / analysis. Male. Middle Aged. Mitosis. Necrosis. Tumor Suppressor Protein p53 / analysis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19279978.001).
  • [ISSN] 1526-3711
  • [Journal-full-title] The journal of contemporary dental practice
  • [ISO-abbreviation] J Contemp Dent Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Laminin; 0 / Tumor Suppressor Protein p53; 68238-35-7 / Keratins
  •  go-up   go-down


22. Chetty R, Serra S, Hsieh E: Basaloid squamous carcinoma of the anal canal with an adenoid cystic pattern: histologic and immunohistochemical reappraisal of an unusual variant. Am J Surg Pathol; 2005 Dec;29(12):1668-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two cases of a distinctive variety of basaloid squamous carcinoma (BSC) of the anal canal are described.
  • The histologic differential diagnosis is true salivary gland-type adenoid cystic carcinoma and basal cell adenocarcinoma.
  • Immunohistochemistry and awareness of this unusual pattern of BSC will facilitate the correct diagnosis being reached.
  • [MeSH-major] Anal Canal / pathology. Anus Neoplasms / pathology. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Basal Cell / pathology. Carcinoma, Basosquamous / pathology
  • [MeSH-minor] Antibiotics, Antineoplastic / therapeutic use. Antigens, CD20 / metabolism. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / metabolism. Cell Nucleus / metabolism. Cisplatin / therapeutic use. DNA-Binding Proteins. Female. Fluorouracil / therapeutic use. Follow-Up Studies. Genes, Tumor Suppressor. Humans. Immunohistochemistry. Keratins / metabolism. Middle Aged. Mitomycin / therapeutic use. Phosphoproteins / metabolism. Radiotherapy. Time Factors. Trans-Activators / metabolism. Transcription Factors. Treatment Outcome. Tumor Burden. Tumor Suppressor Proteins

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16327441.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antigens, CD20; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Phosphoproteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 50SG953SK6 / Mitomycin; 68238-35-7 / Keratins; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


23. Akrish S, Peled M, Ben-Izhak O, Nagler RM: Malignant salivary gland tumors and cyclo-oxygenase-2: a histopathological and immunohistochemical analysis with implications on histogenesis. Oral Oncol; 2009 Dec;45(12):1044-50
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant salivary gland tumors and cyclo-oxygenase-2: a histopathological and immunohistochemical analysis with implications on histogenesis.
  • The classification system for malignant salivary gland tumors (MST) is largely dependent on its histogenesis.
  • Fifty six primary major and minor gland MST were stained with anti-cox-2 antibody and rated with a combined score that added a scale of intensity to the percentage of tumor cells that overexpressed the cox-2 protein.
  • Strong cox-2 overexpression was noted in all MST of proposed excretory duct origin: salivary duct carcinoma (100%), mucoepidermoid carcinoma (MEC) (92%), and adenocarcinoma nos (AdC nos) (83%).
  • Primary squamous cell carcinoma (PSCC) was the exception.
  • Negative expression was noted in all tumors of proposed intercalated duct origin (adenoid cystic carcinoma, basal cell adenocarcinoma and acinic cell carcinoma) with the exception of one case of polymorphous low grade adenocarcinoma.
  • Strong cox-2 overexpression was noted in the epidermoid cells of MEC, abluminal duct cells surrounding the duct-like structures and ductal cells of AdC nos and salivary duct carcinoma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cyclooxygenase 2 / analysis. Salivary Gland Neoplasms / enzymology. Salivary Gland Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19729335.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


24. Yamagata K, Oka K, Yoshida H, Yanagawa T, Onizawa K, Yusa H, Ishikawa A, Okada N: Basal cell adenocarcinoma arising from the minor salivary gland in the soft palate: a case report. Pathol Res Pract; 2006;202(6):475-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenocarcinoma arising from the minor salivary gland in the soft palate: a case report.
  • Basal cell adenocarcinomas (BCACs) of the oral minor salivary gland are very rare neoplasms.
  • We report on an 86-year-old woman with BCAC arising from the minor salivary gland in the soft palate.
  • [MeSH-major] Adenocarcinoma / pathology. Palate, Soft / pathology. Salivary Gland Neoplasms / pathology. Salivary Glands, Minor / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16487667.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


25. Vasudev P, Boutross-Tadross O, Radhi J: Basaloid squamous cell carcinoma: two case reports. Cases J; 2009;2:9351
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basaloid squamous cell carcinoma: two case reports.
  • Basaloid squamous cell carcinoma (BSCC) is a rare and aggressive variant of squamous cell carcinoma (SCC) that occurs preferentially in the upper aerodigestive tract.
  • BSCC of the head and neck should be distinguished from adenoid cystic carcinoma, small cell neuroendocrine carcinoma, basal cell adenocarcinoma, adenosquamous carcinoma, squamous cell carcinoma, spindle cell squamous carcinoma, mucoepidermoid carcinoma, and adenoid cystic carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2008 Jan;44(2):244-50 [18096379.001]
  • [Cites] Auris Nasus Larynx. 2007 Mar;34(1):119-23 [17141998.001]
  • [Cites] Histopathology. 2000 Sep;37(3):218-23 [10971697.001]
  • [Cites] Hum Pathol. 1986 Nov;17(11):1158-66 [3770734.001]
  • [Cites] Ophthalmology. 1993 Nov;100(11):1720-2 [8233401.001]
  • (PMID = 20062602.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2804002
  •  go-up   go-down


26. Hara H, Oyama T, Saku T: Fine needle aspiration cytology of basal cell adenoma of the salivary gland. Acta Cytol; 2007 Sep-Oct;51(5):685-91
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration cytology of basal cell adenoma of the salivary gland.
  • OBJECTIVE: To formulate cytologic features for differential diagnosis of basal cell adenoma (BCA).
  • STUDY DESIGN: The usefulness of 5 items for a cytologically definitive diagnosis of BCA was examined.
  • The 5 items in 8 BCA and 22 non-BCA cases (adenoid cystic carcinoma [ADCC], basal cell adenocarcinoma, myoepithelioma, pleomorphic adenoma and polymorphous low-grade adenocarcinoma) that displayed mimicking cytology were examined cytologically.
  • RESULTS: The useful items were < 5.1 microm in mean of epithelial nuclear short diameter; mild atypia on definitive diagnosis; stromal cell cluster combining smooth margin surrounding the epithelial cell cluster or containing the epithelial cell cluster; epithelial clusters surrounded by or adhered to a thick, hyalinized smooth margin without stromal cluster; and closely fastened, tight clusters with denser cytoplasm than ADCC, but an indistinct border, with oval nuclei and no hyaline cells.
  • [MeSH-major] Adenoma / pathology. Salivary Gland Neoplasms / pathology. Salivary Glands / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Biopsy, Fine-Needle. Carcinoma, Adenoid Cystic / pathology. Cell Nucleus / pathology. Diagnosis, Differential. Epithelium / pathology. Epithelium / ultrastructure. Humans. Immunohistochemistry. Myoepithelioma / pathology. Organelle Size. Stromal Cells / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17910337.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


27. Toida M, Shimokawa K, Makita H, Kato K, Kobayashi A, Kusunoki Y, Hatakeyama D, Fujitsuka H, Yamashita T, Shibata T: Intraoral minor salivary gland tumors: a clinicopathological study of 82 cases. Int J Oral Maxillofac Surg; 2005 Jul;34(5):528-32
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoral minor salivary gland tumors: a clinicopathological study of 82 cases.
  • We present a retrospective study of 82 patients with intraoral minor salivary gland tumors which were diagnosed from 1979 to 2003 in Gifu University Hospital.
  • Histologically, the tumors were classified as pleomorphic adenoma (n = 54), papillary cystadenoma (n = 1), adenoid cystic carcinoma (n = 10), mucoepidermoid carcinoma (n = 8), acinic cell carcinoma (n = 3), adenocarcinoma (n = 2), basal cell adenocarcinoma (n = 1), papillary cystadenocarcinoma (n = 1), and carcinoma in pleomorphic adenoma (n = 2).
  • From the results of the present study and review of the literature, it is suggested that the minor salivary gland tumors in Japan may be characterized by a higher incidence of benign tumors, especially of pleomorphic adenoma; a more marked tendency for female predominance; a higher incidence of palatal involvement; and a rarer occurrence of polymorphous low grade adenocarcinoma, in comparison with those reported in the literature from outside of Japan.
  • [MeSH-major] Salivary Gland Neoplasms / epidemiology. Salivary Glands, Minor / pathology
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenoma, Pleomorphic / epidemiology. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Adenoid Cystic / epidemiology. Carcinoma, Mucoepidermoid / epidemiology. Cheek / pathology. Child. Female. Humans. Japan / epidemiology. Lip / pathology. Male. Middle Aged. Palate / pathology. Retrospective Studies. Sex Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16053873.001).
  • [ISSN] 0901-5027
  • [Journal-full-title] International journal of oral and maxillofacial surgery
  • [ISO-abbreviation] Int J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


28. Asadi-Amoli F, Khoshnevis F, Haeri H, Jahanzad I, Pazira R, Shahsiah R: Comparative examination of androgen receptor reactivity for differential diagnosis of sebaceous carcinoma from squamous cell and basal cell carcinoma. Am J Clin Pathol; 2010 Jul;134(1):22-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative examination of androgen receptor reactivity for differential diagnosis of sebaceous carcinoma from squamous cell and basal cell carcinoma.
  • Early diagnosis and proper treatment significantly improve the outcome.
  • SEB should be differentiated histopathologically from basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).
  • Along with other markers and morphologic features, AR can be helpful in the diagnosis of SEB and its differentiation from SCC and BCC.
  • [MeSH-major] Adenocarcinoma, Sebaceous / diagnosis. Carcinoma, Basal Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Eyelid Neoplasms / diagnosis. Receptors, Androgen / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Male

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20551262.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Androgen
  •  go-up   go-down


29. Cheng L, Bostwick DG: Atypical sclerosing adenosis of the prostate: a rare mimic of adenocarcinoma. Histopathology; 2010 Apr;56(5):627-31
MedlinePlus Health Information. consumer health - Prostate Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical sclerosing adenosis of the prostate: a rare mimic of adenocarcinoma.
  • AIMS: Sclerosing adenosis of the prostate is a benign, small, acinar proliferation in dense spindle cell stroma, with a distinct immunohistochemical profiles.
  • METHODS AND RESULTS: We describe five cases of sclerosing adenosis with significant cytological atypia, referred to as atypical sclerosing adenosis (ASA), which were initially considered suspicious or diagnostic of adenocarcinoma.
  • All cases of typical and atypical sclerosing adenosis displayed an intact basal cell layer, which was immunoreactive for high-molecular-weight keratin, S100 protein, smooth muscle actin, and prostate-specific antigen, with no differences between ASA and the control group.
  • CONCLUSIONS: ASA is an unusual small, acinar proliferation of the prostate that may be mistaken for adenocarcinoma, and should be distinguished from other mimics, including atypical adenomatous hyperplasia, mesonephric remnant hyperplasia, and post-atrophic hyperplasia.
  • [MeSH-major] Adenocarcinoma / diagnosis. Prostatic Diseases / diagnosis. Prostatic Hyperplasia / diagnosis
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Biopsy, Needle. Diagnosis, Differential. Humans. Male. Middle Aged. Sclerosis

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20459573.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


30. DiMeo TA, Anderson K, Phadke P, Fan C, Perou CM, Naber S, Kuperwasser C: A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Cancer Res; 2009 Jul 1;69(13):5364-73
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer.
  • In epithelial cancers, such as those of the breast, the epithelial-mesenchymal transition (EMT) is associated with basal-like breast cancers, generates cells with stem-like properties, and enables cancer cell dissemination and metastasis.
  • However, the molecular mechanism(s) that connects stem cell-like characteristics with EMT has yet to be defined.
  • The wnt genes identified in this signature were strongly associated with human basal-like breast cancers.
  • Collectively, these results provide a molecular link between self-renewal, EMT, and metastasis in basal-like breast cancers.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Mammary Gland Biol Neoplasia. 2007 Sep;12(2-3):153-62 [17566854.001]
  • [Cites] Oncogene. 2007 Aug 16;26(38):5680-91 [17353908.001]
  • [Cites] J Cell Biochem. 2007 Dec 15;102(6):1519-28 [17471511.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19506-11 [18048329.001]
  • [Cites] Br J Cancer. 2008 Mar 25;98(6):1147-56 [18283316.001]
  • [Cites] Cancer Res. 2008 May 1;68(9):3108-14 [18451135.001]
  • [Cites] Cell. 2008 May 16;133(4):704-15 [18485877.001]
  • [Cites] Breast Cancer Res. 2008;10(2):R25 [18366788.001]
  • [Cites] Clin Exp Metastasis. 2008;25(6):629-42 [18461285.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4262-6 [10759547.001]
  • [Cites] J Biol Chem. 2001 Aug 10;276(32):30350-8 [11402039.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):563-72 [12154349.001]
  • [Cites] N Engl J Med. 2002 Dec 19;347(25):1999-2009 [12490681.001]
  • [Cites] Breast Cancer Res. 2003;5(2):101-6 [12631389.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1906-13 [12702582.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):537-49 [12842083.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10393-8 [12917485.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5679-84 [14522883.001]
  • [Cites] J Cell Biol. 2003 Nov 24;163(4):847-57 [14623871.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15901-5 [14665696.001]
  • [Cites] Neoplasia. 2004 Jan-Feb;6(1):1-6 [15068665.001]
  • [Cites] Cancer Cell. 2004 Jun;5(6):607-16 [15193263.001]
  • [Cites] Cell. 2004 Jun 25;117(7):927-39 [15210113.001]
  • [Cites] Int J Oncol. 2004 Sep;25(3):641-9 [15289865.001]
  • [Cites] Cell. 2004 Aug 6;118(3):277-9 [15294153.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 21;101(38):13756-61 [15356343.001]
  • [Cites] Int J Cancer. 2005 Feb 10;113(4):515-24 [15472907.001]
  • [Cites] Oncogene. 2005 Jul 7;24(29):4660-71 [15897907.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6130-8 [16024614.001]
  • [Cites] Nature. 2005 Jul 28;436(7050):518-24 [16049480.001]
  • [Cites] Cancer Biol Ther. 2005 Apr;4(4):365-70 [15846061.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13550-5 [16141321.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13909-14 [16172383.001]
  • [Cites] Nat Genet. 2005 Oct;37(10):1047-54 [16142232.001]
  • [Cites] Mol Biol Cell. 2005 Nov;16(11):5283-93 [16135532.001]
  • [Cites] J Leukoc Biol. 2006 Feb;79(2):339-50 [16282532.001]
  • [Cites] Breast Cancer Res. 2005;7(6):R953-64 [16280042.001]
  • [Cites] Cancer Cell. 2006 Feb;9(2):121-32 [16473279.001]
  • [Cites] Cancer Biol Ther. 2006 Mar;5(3):281-6 [16410723.001]
  • [Cites] BMC Genomics. 2006;7:96 [16643655.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4236-44 [16896004.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10292-301 [17079448.001]
  • [Cites] Cell. 2006 Nov 3;127(3):469-80 [17081971.001]
  • [Cites] Nat Cell Biol. 2006 Dec;8(12):1398-406 [17072303.001]
  • [Cites] Oncogene. 2006 Dec 4;25(57):7469-81 [17143291.001]
  • [Cites] Oncogene. 2006 Dec 4;25(57):7531-7 [17143297.001]
  • [Cites] Breast Cancer Res. 2006;8(5):R59 [17062128.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):259-73 [17349583.001]
  • [Cites] Clin Cancer Res. 2007 Jun 1;13(11):3207-14 [17545524.001]
  • [Cites] Genome Biol. 2007;8(5):R76 [17493263.001]
  • [ErratumIn] Cancer Res. 2009 Aug 1;69(15):6366. Feng, Chang [corrected to Fan, Cheng]
  • (PMID = 19549913.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA125554-02; United States / NCI NIH HHS / CA / R01 CA125554; United States / NCI NIH HHS / CA / R01 CA125554-02; United States / NCI NIH HHS / CA / R01CA12555
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nuclear Proteins; 0 / TWIST1 protein, human; 0 / Transcription Factors; 0 / Twist Transcription Factor; 0 / Wnt Proteins; 0 / snail family transcription factors
  • [Other-IDs] NLM/ NIHMS154900; NLM/ PMC2782448
  •  go-up   go-down


31. Zhang X: Simultaneous exposure to dietary acrylamide and corn oil developed carcinogenesis through cell proliferation and inhibition of apoptosis by regulating p53-mediated mitochondria-dependent signaling pathway. Toxicol Ind Health; 2009 Mar;25(2):101-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous exposure to dietary acrylamide and corn oil developed carcinogenesis through cell proliferation and inhibition of apoptosis by regulating p53-mediated mitochondria-dependent signaling pathway.
  • Colonic apoptosis and cell proliferation, expression of Wild type (wt) p53, Bcl-2, Bax and caspase-3, were detected at 48 week post ACR-exposure.
  • Apoptosis was decreased and cell proliferation was increased in colonic mucosa in ACR-treated rats on dietary corn oil compared to vehicle rats on basal diet (P < 0.05).
  • [MeSH-major] Acrylamide / toxicity. Apoptosis / drug effects. Cell Proliferation / drug effects. Corn Oil / administration & dosage. Gene Expression Regulation, Neoplastic / drug effects. Precancerous Conditions / chemically induced. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adenocarcinoma / chemically induced. Adenocarcinoma / pathology. Adenoma / chemically induced. Adenoma / pathology. Animals. Carcinogenicity Tests. Cocarcinogenesis. Colon / drug effects. Colon / pathology. Colonic Neoplasms / chemically induced. Colonic Neoplasms / pathology. Diet. Injections, Intraperitoneal. Intestinal Mucosa / drug effects. Intestinal Mucosa / pathology. Male. Mitochondria / drug effects. Mitochondria / metabolism. Rats. Rats, Sprague-Dawley. Signal Transduction / drug effects

  • Hazardous Substances Data Bank. ACRYLAMIDE .
  • Hazardous Substances Data Bank. Corn oil .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19458132.001).
  • [ISSN] 0748-2337
  • [Journal-full-title] Toxicology and industrial health
  • [ISO-abbreviation] Toxicol Ind Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; 20R035KLCI / Acrylamide; 8001-30-7 / Corn Oil
  •  go-up   go-down


32. Prayaga AK, Loya AC, Gottimukkala SR, Digumarti RR, Maddali LS, Challa S: Cytologic features of primary malignant tumors of skin and adnexae. Acta Cytol; 2008 Nov-Dec;52(6):702-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Melanoma was the most common (n=12), followed by squamous cell carcinoma (SCC) (n=5).
  • There were 3 basal cell carcinomas and 2 cases each of sebaceous carcinoma, Paget's disease of the breast and lymphoma.
  • There were single cases of eccrine carcinoma, malignant trichilemmal tumor, undifferentiated carcinoma and extramedullary myeloid cell tumor.
  • [MeSH-minor] Adenocarcinoma, Sebaceous / pathology. Breast Neoplasms / pathology. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Cytodiagnosis. Humans. Lymphatic Metastasis. Medical Records. Melanoma / pathology. Paget's Disease, Mammary / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19068675.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Samaratunga H, Delahunt B: Ductal adenocarcinoma of the prostate: current opinion and controversies. Anal Quant Cytol Histol; 2008 Aug;30(4):237-46
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ductal adenocarcinoma of the prostate: current opinion and controversies.
  • OBJECTIVE: To evaluate the morphologic spectrum and clinical significance of ductal adenocarcinoma of the prostate (DAP).
  • STUDY DESIGN: We reviewed diagnostic criteria, including the value of immunohistochemistry, and outlined the prognostic implications of a diagnosis of DAP.
  • A basal cell layer can be seen in some of these tumors, which is probably due to tumor growth into preexisting ducts.
  • CONCLUSION: DAP are neoplasms of prostatic origin, and the terms endometrioid or endometrial adenocarcinoma are best avoided.
  • DAP are aggressive tumors with a shortened average time to progression compared with acinar adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18773743.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 36
  •  go-up   go-down


34. Colucci R, Blandizzi C, Ghisu N, Florio T, Del Tacca M: Somatostatin inhibits colon cancer cell growth through cyclooxygenase-2 downregulation. Br J Pharmacol; 2008 Sep;155(2):198-209
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatostatin inhibits colon cancer cell growth through cyclooxygenase-2 downregulation.
  • BACKGROUND AND PURPOSE: Cyclooxygenase-2 (COX-2) is expressed in colonic neoplasms, where it supports cell proliferation via prostaglandin E(2) (PGE(2)) production.
  • EXPERIMENTAL APPROACH: Human colon adenocarcinoma cell lines Caco-2, HT-29 and HCT116 were used.
  • The following techniques were employed: colourimetric assay for cell growth; 5-bromo-2'-deoxyuridine assay for DNA synthesis; enzyme immunoassay for PGE(2); COX-2 mRNA silencing; RT-PCR or Western blot for somatostatin receptor subtypes, cyclooxygenase isoforms, phosphorylated-ERK-1/ERK-2 and phosphorylated-Akt.
  • Somatostatin-14 inhibited basal COX-2 expression, PGE(2) production, DNA synthesis and growth in Caco-2 cells and these effects were prevented by BN81658 (sst(3) receptor antagonist).
  • Basal proliferation of HT-29, HCT116 and COX-2-silenced Caco-2 cells was not affected by somatostatin-14.
  • Stimulation of HT-29 cells with gastrin-17 elicited increments of ERK-1/ERK-2 and Akt phosphorylation, COX-2 expression, PGE(2) production, DNA synthesis and cell growth, which were all counteracted by somatostatin-14.
  • CONCLUSIONS AND IMPLICATIONS: Somatostatin decreases COX-2 expression and function in colon cancer cells via activation of sst(3) or sst(5) receptors, and these effects contribute to the inhibitory action of somatostatin on cell proliferation.
  • [MeSH-major] Cell Proliferation / drug effects. Colonic Neoplasms / pathology. Cyclooxygenase 2 / metabolism. Cyclooxygenase 2 Inhibitors / pharmacology. Somatostatin / pharmacology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Colorectal Dis. 2001 Aug;16(4):202-10 [11515678.001]
  • [Cites] Science. 1998 Oct 23;282(5389):737-40 [9784130.001]
  • [Cites] Eur J Endocrinol. 1999 Apr;140(4):362-6 [10097257.001]
  • [Cites] Cancer Biol Ther. 2004 Aug;3(8):726-30 [15197339.001]
  • [Cites] Br J Pharmacol. 2005 Feb;144(3):338-48 [15655524.001]
  • [Cites] N Engl J Med. 2005 Mar 17;352(11):1092-102 [15713943.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2840-55 [15837998.001]
  • [Cites] J Clin Oncol. 2005 Jul 10;23(20):4553-60 [16002847.001]
  • [Cites] Oncology. 2005;69 Suppl 1:28-32 [16210874.001]
  • [Cites] Science. 2005 Dec 2;310(5753):1504-10 [16293724.001]
  • [Cites] Int J Oncol. 2006 Feb;28(2):543-9 [16391811.001]
  • [Cites] World J Gastroenterol. 2006 Apr 7;12(13):2011-5 [16610049.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9705-13 [17018629.001]
  • [Cites] N Engl J Med. 2007 May 24;356(21):2131-42 [17522398.001]
  • [Cites] Br J Pharmacol. 2008 Mar;153 Suppl 2:S1-209 [18347570.001]
  • [Cites] Mol Endocrinol. 2001 Oct;15(10):1838-52 [11579215.001]
  • [Cites] Eur J Clin Invest. 2001 Sep;31(9):812-20 [11589724.001]
  • [Cites] Gastroenterology. 2001 Oct;121(4):915-30 [11606505.001]
  • [Cites] J Mol Neurosci. 2002 Feb-Apr;18(1-2):15-27 [11931345.001]
  • [Cites] J Biol Chem. 2003 Feb 28;278(9):6992-7000 [12493747.001]
  • [Cites] Endocrinology. 2003 Apr;144(4):1574-84 [12639942.001]
  • [Cites] Carcinogenesis. 2003 Apr;24(4):637-42 [12727790.001]
  • [Cites] Biochim Biophys Acta. 2003 Sep 22;1616(1):1-84 [14507421.001]
  • [Cites] Nat Rev Drug Discov. 2003 Dec;2(12):999-1017 [14654798.001]
  • [Cites] Pharmacol Ther. 2004 Apr;102(1):61-85 [15056499.001]
  • [Cites] Biochem Pharmacol. 2004 Sep 15;68(6):1089-100 [15313405.001]
  • [Cites] N Engl J Med. 1991 Dec 5;325(23):1593-6 [1669840.001]
  • [Cites] Cancer Res. 1992 Feb 15;52(4):917-23 [1737355.001]
  • [Cites] Life Sci. 1993;53(1):85-90 [8515684.001]
  • [Cites] Biochem Biophys Res Commun. 1993 Sep 15;195(2):844-52 [8373420.001]
  • [Cites] J Mol Endocrinol. 2000 Jun;24(3):397-408 [10828833.001]
  • [Cites] Annu Rev Physiol. 2001;63:49-76 [11181948.001]
  • [Cites] J Clin Endocrinol Metab. 2001 May;86(5):2161-9 [11344221.001]
  • [Cites] Gastroenterology. 1994 Oct;107(4):1183-8 [7926468.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1580-4 [7878022.001]
  • [Cites] Cancer. 1995 Sep 15;76(6):961-6 [8625221.001]
  • [Cites] Biochem J. 1996 Mar 1;314 ( Pt 2):401-4 [8670047.001]
  • [Cites] Br J Pharmacol. 1996 Jun;118(3):445-7 [8762063.001]
  • [Cites] Br J Cancer. 1997;75(3):360-6 [9020480.001]
  • [Cites] Am J Physiol. 1997 May;272(5 Pt 1):E769-74 [9176174.001]
  • [Cites] Mol Endocrinol. 1997 Jul;11(8):1062-9 [9212054.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9343-8 [9256484.001]
  • [Cites] Life Sci. 1997;61(10):1009-18 [9296339.001]
  • [Cites] Gastroenterology. 1998 Aug;115(2):275-80 [9679032.001]
  • [Cites] Diabetes. 1999 Jan;48(1):77-85 [9892225.001]
  • (PMID = 18587421.001).
  • [ISSN] 0007-1188
  • [Journal-full-title] British journal of pharmacology
  • [ISO-abbreviation] Br. J. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BIM 23056; 0 / Cyclooxygenase 2 Inhibitors; 0 / Gastrins; 0 / Oligopeptides; 51110-01-1 / Somatostatin; 60748-06-3 / gastrin 17; EC 1.14.99.1 / Cyclooxygenase 2; EC 2.7.11.13 / Protein Kinase C; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 3.1.3.48 / Protein Tyrosine Phosphatases
  • [Other-IDs] NLM/ PMC2538699
  •  go-up   go-down


35. El Demellawy D, Escott N, Salama S, Alowami S: Sebaceoma of the external ear canal: an unusual location. Case report and review of the literature. J Cutan Pathol; 2008 Oct;35(10):963-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We highlight the differential diagnosis, particularly sebaceous carcinoma and basal cell carcinoma with sebaceous differentiation.
  • [MeSH-major] Ear Canal / pathology. Sebaceous Gland Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Sebaceous / pathology. Aged. Carcinoma, Basal Cell / pathology. Diagnosis, Differential. Female. Humans. Immunohistochemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18564279.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


36. Kanno A, Satoh K, Masamune A, Hirota M, Kimura K, Umino J, Hamada S, Satoh A, Egawa S, Motoi F, Unno M, Shimosegawa T: Periostin, secreted from stromal cells, has biphasic effect on cell migration and correlates with the epithelial to mesenchymal transition of human pancreatic cancer cells. Int J Cancer; 2008 Jun 15;122(12):2707-18
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Periostin, secreted from stromal cells, has biphasic effect on cell migration and correlates with the epithelial to mesenchymal transition of human pancreatic cancer cells.
  • Periostin is a secretory protein that has been suggested to function as a cell adhesion molecule and promote the invasiveness or growth rate of tumors.
  • However, little is known about the association of its expression and epithelial to mesenchymal transition (EMT), which is considered to play a crucial role in cancer cell metastasis.
  • In vitro, pancreatic stellate cells (PSCs) exhibited a much higher basal expression of periostin compared with cancer cells.
  • To assess the direct role of periostin in pancreatic cancer cells, the authors generated pancreatic cancer cell lines that stably express periostin.
  • The induced expression of periostin (to 150 ng/ml) altered the morphology of cancer cells, changing them from mesenchymal to epithelial phenotypes with the induction of epithelial markers and a reduction of mesenchymal markers, and showed reduced cell migration in vitro and formed smaller tumors as well as suppressed metastasis in vivo.
  • On the other hand, high concentration of recombinant periostin (1 microg/ml) promoted cell migration with AKT activation.
  • [MeSH-major] Adenocarcinoma / pathology. Cell Adhesion Molecules / physiology. Cell Movement / physiology. Epithelium / pathology. Mesoderm / physiology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Animals. Base Sequence. Cell Line, Tumor. Coculture Techniques. DNA Primers. Humans. Mice. Rats. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18381746.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / DNA Primers; 0 / POSTN protein, human
  •  go-up   go-down


37. Prasad ML, Barbacioru CC, Rawal YB, Husein O, Wen P: Hierarchical cluster analysis of myoepithelial/basal cell markers in adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma. Mod Pathol; 2008 Feb;21(2):105-14
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hierarchical cluster analysis of myoepithelial/basal cell markers in adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma.
  • Distinguishing adenoid cystic carcinoma from polymorphous low-grade adenocarcinoma of the salivary glands is important for their management.
  • We studied the expression of several myoepithelial and basal/stem cell markers (smooth muscle actin, calponin, smooth muscle myosin heavy chain, metallothionein, maspin, and p63) by immunohistochemistry in 23 adenoid cystic carcinoma and 24 polymorphous low-grade adenocarcinoma, to identify the most useful marker or combination of markers that may help their diagnoses.
  • We noted diffuse expression of smooth muscle actin in 20 adenoid cystic carcinoma vs one polymorphous low-grade adenocarcinoma (P<0.0001), calponin in 15 adenoid cystic carcinoma vs one polymorphous low-grade adenocarcinoma (P<0.0001), smooth muscle myosin heavy chain in 15 adenoid cystic carcinoma vs one polymorphous low-grade adenocarcinoma (P=0.001), metallothionein in 22 adenoid cystic carcinoma vs eight polymorphous low-grade adenocarcinoma (P<0.001), maspin in 22 adenoid cystic carcinoma vs 14 polymorphous low-grade adenocarcinoma, and p63 in 21 adenoid cystic carcinoma vs 14 polymorphous low-grade adenocarcinoma.
  • In differentiating adenoid cystic carcinoma from polymorphous low-grade adenocarcinoma, smooth muscle actin as a single ancillary test in support of the histological findings, appears to be as efficient as multiple immunohistochemical tests.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Adenoid Cystic / metabolism. Epithelial Cells / metabolism. Myocytes, Smooth Muscle / metabolism. Neoplasm Proteins / metabolism. Salivary Gland Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cluster Analysis. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Recurrence, Local. Salivary Glands, Minor / metabolism. Salivary Glands, Minor / pathology. Treatment Outcome


38. Chi DB, Li L, Sun LS, Ma WF: [Koumine-induced apoptosis of human colonic adenocarcinoma cells: the cell biological mechanism]. Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jul;27(7):994-7
Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Koumine-induced apoptosis of human colonic adenocarcinoma cells: the cell biological mechanism].
  • OBJECTIVE: To investigate the cell biological mechanism of koumine-induced apoptosis of human colonic adenocarcinoma cells.
  • METHODS: The effects of LoVo cell koumine on the membrane potential, mitochondrial membrane potential, concentration of cytosolic free calcium, reactive oxygen species (ROS) and gap junctional intercellular communication was observed by laser scanning confocal microscopy.
  • RESULTS AND CONCLUSION: Koumine lowered the membrane potential and mitochondrial membrane potential of LoVo cells and decreased the concentration of free cytosolic calcium, which was increased to a level higher than the basal one after addition of EDTA.
  • These findings may explain the possible mechanisms of koumine-induced LoVo cell apoptosis.
  • [MeSH-major] Adenocarcinoma / pathology. Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Colonic Neoplasms / pathology. Indole Alkaloids / pharmacology
  • [MeSH-minor] Calcium / metabolism. Cell Communication / drug effects. Cell Line, Tumor. Gap Junctions / drug effects. Gap Junctions / metabolism. Humans. Membrane Potential, Mitochondrial / drug effects. Microscopy, Confocal. Reactive Oxygen Species / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17666335.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Indole Alkaloids; 0 / Reactive Oxygen Species; 0 / koumine; SY7Q814VUP / Calcium
  •  go-up   go-down


39. Hameed O, Humphrey PA: Stratified epithelium in prostatic adenocarcinoma: a mimic of high-grade prostatic intraepithelial neoplasia. Mod Pathol; 2006 Jul;19(7):899-906
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stratified epithelium in prostatic adenocarcinoma: a mimic of high-grade prostatic intraepithelial neoplasia.
  • Typically glands of prostatic adenocarcinoma have a single cell lining, although stratification can be seen in invasive carcinomas with a cribriform architecture, including ductal carcinoma.
  • The histomorphological features and immunohistochemical profile of cases of non-cribriform prostatic adenocarcinoma with stratified malignant glandular epithelium were analyzed.
  • These cases were identified from needle biopsy cases from the consultation files of one of the authors and from a review of 150 consecutive in-house needle biopsy cases of prostatic adenocarcinoma.
  • The main attribute in all these foci was the presence of glandular profiles lined by several layers of epithelial cells with cytological and architectural features resembling flat or tufted high-grade prostatic intraepithelial neoplasia, but lacking basal cells as confirmed by negative 34betaE12 and/or p63 immunostains in all cases.
  • The AMACR staining profile of the stratified foci was variable, with 4 foci showing positivity, and 3 foci being negative, including two cases that displayed AMACR positivity in adjacent non-stratified prostatic adenocarcinoma.
  • Prostatic adenocarcinoma with stratified malignant glandular epithelium can be identified in prostate needle biopsy samples harboring non-cribriform prostatic adenocarcinoma and resembles glands with high-grade prostatic intraepithelial neoplasia.
  • Recognition of this pattern of prostatic adenocarcinoma is necessary to correctly diagnose such cases as invasive carcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Epithelium / pathology. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy, Needle. Diagnosis, Differential. Humans. Immunohistochemistry. Keratins / metabolism. Male. Membrane Proteins / metabolism. Middle Aged. Neoplasm Invasiveness. Prostate-Specific Antigen / blood. Racemases and Epimerases / metabolism. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16607376.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CKAP4 protein, human; 0 / Membrane Proteins; 68238-35-7 / Keratins; EC 3.4.21.77 / Prostate-Specific Antigen; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


40. Amici SA, Dunn WA Jr, Murphy AJ, Adams NC, Gale NW, Valenzuela DM, Yancopoulos GD, Notterpek L: Peripheral myelin protein 22 is in complex with alpha6beta4 integrin, and its absence alters the Schwann cell basal lamina. J Neurosci; 2006 Jan 25;26(4):1179-89
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral myelin protein 22 is in complex with alpha6beta4 integrin, and its absence alters the Schwann cell basal lamina.
  • In the absence of PMP22, myelination of peripheral nerves is delayed, and numerous axon-SC profiles show loose basal lamina, suggesting altered interactions of the glial cells with the extracellular matrix.
  • The levels of beta4 integrin, a molecule involved in the linkage between SCs and the basal lamina, are severely reduced in nerves of PMP22-deficient mice.
  • During early stages of myelination, PMP22 and beta4 integrin are coexpressed at the cell surface and can be coimmunoprecipitated together with laminin and alpha6 integrin.
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / pathology. Animals. Basement Membrane / metabolism. Basement Membrane / ultrastructure. Binding Sites. Cell Line, Tumor / chemistry. Coculture Techniques. Colonic Neoplasms / chemistry. Colonic Neoplasms / pathology. Exons / genetics. Ganglia, Spinal / cytology. Humans. Lac Operon. Laminin / metabolism. Mice. Mice, Knockout. Mice, Transgenic. Multiprotein Complexes. Organ Specificity. Peripheral Nervous System Diseases / genetics. Peripheral Nervous System Diseases / metabolism. Peripheral Nervous System Diseases / pathology. Phenotype. Protein Binding. Protein Interaction Mapping. Rats. Sciatic Nerve / metabolism. Sciatic Nerve / ultrastructure

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16436605.001).
  • [ISSN] 1529-2401
  • [Journal-full-title] The Journal of neuroscience : the official journal of the Society for Neuroscience
  • [ISO-abbreviation] J. Neurosci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Integrin alpha6beta4; 0 / Laminin; 0 / Multiprotein Complexes; 0 / Myelin Proteins; 0 / PMP22 protein, human; 0 / Pmp22 protein, mouse; 0 / Pmp22 protein, rat
  •  go-up   go-down


41. Midi A, Tecimer T, Bozkurt S, Ozkan N: Differences in the structural features of atypical adenomatous hyperplasia and low-grade prostatic adenocarcinoma. Indian J Urol; 2008 Apr;24(2):169-77

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differences in the structural features of atypical adenomatous hyperplasia and low-grade prostatic adenocarcinoma.
  • AIM: Atypical adenomatous hyperplasia (AAH) is a small glandular proliferation that has histological similarities with Gleason grade 1 and 2 prostatic adenocarcinoma (PACG1,2).
  • Basal cell-specific antikeratin was applied to these lesions.
  • We assumed that PACG1,2 lesions did have not basal cells and we grouped the lesions as AAH and PACG1,2 based on this assumption.
  • RESULTS: We found differences between AAH and PACG1,2 lesions for some parameters including the number of glands, structures such as the main ductus and basal cells.
  • We found similar properties in the two lesions for the following parameters: localization, multiplicity, diameter of the lesion, focus asymmetry, distance between glands, inflammatory cells in and out of the lesions, secretory cell shape on the luminal side, papillary projection towards the luminal side of gland, the shape of the outer gland, the infiltrative pattern of the gland, glandular pleomorphism, biggest gland diameter and median gland diameter.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urology. 1995 Dec;46(6):837-42 [7502426.001]
  • [Cites] Hum Pathol. 1996 Apr;27(4):396-407 [8617484.001]
  • [Cites] Am J Surg Pathol. 1995 Jul;19(7):737-47 [7793471.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1990;417(3):191-6 [1696762.001]
  • [Cites] Indian J Cancer. 2004 Apr-Jun;41(2):60-5 [15318010.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1151-60 [12218571.001]
  • [Cites] Am J Surg Pathol. 2002 Jul;26(7):921-5 [12131160.001]
  • [Cites] Ann N Y Acad Sci. 2002 Jun;963:169-84 [12095942.001]
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1397-404 [11684956.001]
  • [Cites] Anal Quant Cytol Histol. 2000 Dec;22(6):438-44 [11147297.001]
  • [Cites] Pathol Res Pract. 1999;195(12):795-9 [10631713.001]
  • [Cites] Br J Cancer. 1994 Jun;69(6):1098-101 [7515262.001]
  • [Cites] Am J Surg Pathol. 1994 Sep;18(9):863-70 [7520673.001]
  • [Cites] Hum Pathol. 1993 Jun;24(6):618-23 [7684998.001]
  • [Cites] Hum Pathol. 1993 Aug;24(8):819-32 [8375853.001]
  • [Cites] Hum Pathol. 1992 Mar;23(3):273-9 [1555838.001]
  • [Cites] Mod Pathol. 1991 Mar;4(2):220-4 [1710806.001]
  • [Cites] Cancer. 1987 Feb 15;59(4):788-94 [2433020.001]
  • [Cites] J Clin Pathol. 1989 Apr;42(4):383-6 [2469700.001]
  • [Cites] J Postgrad Med. 1989 Jul;35(3):157-61 [2483935.001]
  • [Cites] Am J Surg Pathol. 1988 Dec;12(12):897-906 [3202246.001]
  • [Cites] Am J Surg Pathol. 1985 Jan;9(1):53-5 [3970298.001]
  • [Cites] Nat Clin Pract Urol. 2007 Jun;4(6):321-32 [17551536.001]
  • [Cites] Crit Rev Clin Lab Sci. 2007;44(3):243-70 [17453919.001]
  • [Cites] Asian J Androl. 2007 Mar;9(2):229-33 [16751999.001]
  • [Cites] Ann Saudi Med. 1998 Jan-Feb;18(1):22-7 [17341910.001]
  • [Cites] Int J Surg Pathol. 2005 Apr;13(2):167-73 [15864380.001]
  • [Cites] Hum Pathol. 1999 Sep;30(9):1077-86 [10492043.001]
  • [Cites] Am J Pathol. 1999 Sep;155(3):967-71 [10487854.001]
  • [Cites] Mod Pathol. 1999 May;12(5):472-8 [10349984.001]
  • [Cites] Mod Pathol. 1999 May;12(5):443-4 [10349979.001]
  • [Cites] Am J Surg Pathol. 1999 Feb;23(2):147-52 [9989840.001]
  • [Cites] Urology. 1999 Feb;53(2):351-5 [9933053.001]
  • [Cites] Anal Quant Cytol Histol. 1998 Oct;20(5):417-23 [9801760.001]
  • [Cites] Cancer Res. 1998 Feb 1;58(3):389-91 [9458077.001]
  • [Cites] Am J Clin Pathol. 1997 Feb;107(2):219-23 [9024071.001]
  • [Cites] Pathologica. 1997 Jun;89(3):288-300 [9270265.001]
  • [Cites] Cancer. 1997 Mar 15;79(6):1172-9 [9070495.001]
  • [Cites] Mod Pathol. 1996 Jan;9(1):77-81 [8821962.001]
  • [Cites] Cancer. 1996 Jul 15;78(2):330-6 [8674012.001]
  • [Cites] Am J Surg Pathol. 1995 May;19(5):506-18 [7537024.001]
  • (PMID = 19468392.001).
  • [ISSN] 0970-1591
  • [Journal-full-title] Indian journal of urology : IJU : journal of the Urological Society of India
  • [ISO-abbreviation] Indian J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2684265
  • [Keywords] NOTNLM ; Adenosis / cancer / hyperplasia / low grade / proliferations / prostate / small glandular
  •  go-up   go-down


42. Segawa N, Tsuji M, Nishida T, Takahara K, Azuma H, Katsuoka Y: Basal cell carcinoma of the prostate: report of a case and review of the published reports. Int J Urol; 2008 Jun;15(6):557-9
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma of the prostate: report of a case and review of the published reports.
  • Prostatic basal cell carcinoma (BCC), a distinctive variant of adenocarcinoma, is rare.
  • [MeSH-major] Carcinoma, Basal Cell. Prostatic Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18489650.001).
  • [ISSN] 1442-2042
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 10
  •  go-up   go-down


43. Sitterding SM, Wiseman WR, Schiller CL, Luan C, Chen F, Moyano JV, Watkin WG, Wiley EL, Cryns VL, Diaz LK: AlphaB-crystallin: a novel marker of invasive basal-like and metaplastic breast carcinomas. Ann Diagn Pathol; 2008 Feb;12(1):33-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AlphaB-crystallin: a novel marker of invasive basal-like and metaplastic breast carcinomas.
  • Basal-like tumors are a newly recognized estrogen receptor (ER) negative and HER2 negative breast cancer subtype that express basal epithelial genes and are associated with poor survival.
  • Metaplastic carcinomas are thought to belong within the basal-like group.
  • We have recently demonstrated that the small heat shock protein alphaB-crystallin is commonly expressed in basal-like tumors and contributes to their aggressive phenotype.
  • The current study examined the rates and patterns of alphaB-crystallin expression in whole tissue sections of human breast, including normal tissue, proliferative lesions, in situ and invasive carcinomas (ER positive, HER2 positive, basal-like, and metaplastic cancers).
  • In normal breast tissue, proliferative lesions and in situ carcinomas, alphaB-crystallin expression was restricted to the myoepithelial cell compartment of ductal and lobular units.
  • Most basal-like and metaplastic carcinomas demonstrated cytoplasmic expression of alphaB-crystallin (81% and 86%, respectively).
  • Taken together, our results indicate that alphaB-crystallin is a sensitive (81%) and specific (100%) marker for basal-like breast carcinomas.
  • Moreover, the high rates of expression of alphaB-crystallin in metaplastic breast carcinomas (86%) suggest that these tumors may represent a histologically distinctive subset of basal-like breast tumors with a similar underlying molecular etiology.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Breast Neoplasms / metabolism. Neoplasm Proteins / metabolism. alpha-Crystallin B Chain / metabolism
  • [MeSH-minor] Breast Cyst / metabolism. Breast Cyst / pathology. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Cell Proliferation. Female. Fibrocystic Breast Disease / metabolism. Fibrocystic Breast Disease / pathology. Fluorescent Antibody Technique, Indirect. Humans. Immunoenzyme Techniques. Metaplasia. Neoplasm Invasiveness. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18164413.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50CA89018; United States / NCI NIH HHS / CA / R01CA097198
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / alpha-Crystallin B Chain
  •  go-up   go-down


44. Marci V, Volante M, Cappia S, Righi L, Novello C, Scagliotti GV, Brambilla E, Papotti M: Basaloid adenocarcinoma. A new variant of pulmonary adenocarcinoma. Virchows Arch; 2007 Sep;451(3):729-36
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basaloid adenocarcinoma. A new variant of pulmonary adenocarcinoma.
  • The 2004 WHO classification of lung tumours recognised basaloid carcinoma as a variant of squamous and large cell carcinoma.
  • We report a unique case of primary pulmonary adenocarcinoma with a basaloid component.
  • The patient is disease-free 13 months after diagnosis.
  • The former was an adenocarcinoma with mucus containing spaces lined by columnar mucinous cells and basaloid cells.
  • The solid component was an organoid proliferation of basaloid-type cells, as in cutaneous basal cell carcinoma.
  • (1) The solid areas resemble a conventional basaloid carcinoma, except for the presence of small mucin-containing spaces. (2) The mucinous adenocarcinoma areas contain two layers of columnar and basaloid cells. (3) Both components are neoplastic based on cell morphology, invasive properties and phenotypic profile.
  • These findings indicate that a basaloid variant of adenocarcinoma is also existing in the spectrum of basaloid carcinomas of the lung.
  • [MeSH-major] Adenocarcinoma / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Carcinoma, Basal Cell. Humans. Keratins / analysis. Male. Mucins / analysis. Neoplasm Invasiveness. Phenotype. World Health Organization

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2005 May 4;97(9):643-55 [15870435.001]
  • [Cites] Pathol Res Pract. 2005;201(10):705-11 [16325513.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):442-52 [15087663.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12 ):1668-72 [16327441.001]
  • [Cites] Hum Pathol. 1992 Sep;23(9):993-1003 [1381335.001]
  • [Cites] Am J Dermatopathol. 2003 Feb;25(1):77-80 [12544106.001]
  • [Cites] Diagn Pathol. 2006 Aug 15;1:19 [16911776.001]
  • [Cites] HNO. 1998 Sep;46(9):821-5 [9816537.001]
  • [Cites] J Thorac Oncol. 2015 Sep;10 (9):1240-1242 [26291007.001]
  • [Cites] Arch Pathol Lab Med. 2004 Oct;128(10):1124-30 [15387711.001]
  • [Cites] Am J Surg Pathol. 2003 Dec;27(12):1523-9 [14657711.001]
  • [Cites] Mod Pathol. 2005 May;18(5):645-50 [15529180.001]
  • [Cites] Am J Clin Pathol. 2006 Jun;125(6):847-54 [16690483.001]
  • [Cites] Pathol Int. 2005 Jul;55(7):445-52 [15982222.001]
  • [Cites] Pathol Res Pract. 2006;202(6):475-80 [16487667.001]
  • [Cites] Am J Surg Pathol. 2004 Oct;28(10):1289-98 [15371944.001]
  • [Cites] Virchows Arch. 2005 Mar;446(3):338-41 [15726402.001]
  • (PMID = 17618455.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Mucins; 68238-35-7 / Keratins
  •  go-up   go-down


45. Seigne C, Fontanière S, Carreira C, Lu J, Tong WM, Fontanière B, Wang ZQ, Zhang CX, Frappart L: Characterisation of prostate cancer lesions in heterozygous Men1 mutant mice. BMC Cancer; 2010;10:395
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Six Men1+/- mice (12.8%) developed prostate cancer, including two adenocarcinomas and four in situ carcinomas, while none of the control mice developed cancerous lesions.
  • Using immunostaining for the androgen receptor and p63, a basal epithelial cell marker, we demonstrated that the menin-negative prostate cancer cells did not display p63 expression and that the androgen receptor was expressed but more heterogeneous in these lesions.
  • Furthermore, our data showed that the expression of the cyclin-dependent kinase inhibitor CDKN1B (p27), a Men1 target gene known to be inactivated during prostate cell tumorigenesis, was notably decreased in the prostate cancers that developed in the mutant mice.
  • CONCLUSION: Our work suggests the possible involvement of Men1 inactivation in the tumorigenesis of the prostate gland.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Loss of Heterozygosity. Prostatic Neoplasms / genetics. Prostatic Neoplasms / pathology. Proto-Oncogene Proteins / physiology


46. Seo JO, Han SI, Lim SC: Role of CDK8 and beta-catenin in colorectal adenocarcinoma. Oncol Rep; 2010 Jul;24(1):285-91
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of CDK8 and beta-catenin in colorectal adenocarcinoma.
  • Colorectal adenocarcinoma is a major cause of morbidity and mortality.
  • CDK8 is a cyclin-dependent kinase (CDK) member of the mediator complex that couples transcriptional regulators to the basal transcriptional machinery, and is implicated in the transcriptional regulation of key pathways involved in colon cancers.
  • To determine the relationship between CDK8 and beta-catenin expressions, a population-based study was conducted for immunohistochemical staining analysis of tumor tissues, and Western blot analysis and CDK8 interference studies of colon cancer cell lines.
  • However, beta-catenin expression was not completely suppressed by CDK8 interference in the colon cancer cell lines HCT-116, HT-29 and SNU-C5.
  • [MeSH-major] Adenocarcinoma / metabolism. Colorectal Neoplasms / metabolism. Cyclin-Dependent Kinase 8 / physiology. beta Catenin / physiology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20514474.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / RNA, Small Interfering; 0 / beta Catenin; EC 2.7.11.22 / CDK8 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 8
  •  go-up   go-down


47. Barbera M, Fitzgerald RC: Cellular origin of Barrett's metaplasia and oesophageal stem cells. Biochem Soc Trans; 2010 Apr;38(2):370-3
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Barrett's oesophagus is a metaplastic pre-malignant disorder and the only established precursor lesion for oesophageal adenocarcinoma.
  • These stem cells could be located in the basal layer of the squamous oesophageal epithelium and/or in the neck region of the oesophageal submucosal gland ducts; however, their exact location and identification are still matter of discussion.
  • [MeSH-minor] Animals. Cell Movement / physiology. Cell Transdifferentiation / physiology. Epithelial Cells / cytology. Epithelial Cells / physiology. Gastric Mucosa / cytology. Gastric Mucosa / pathology. Gastric Mucosa / physiology. Humans. Metaplasia / pathology

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20298185.001).
  • [ISSN] 1470-8752
  • [Journal-full-title] Biochemical Society transactions
  • [ISO-abbreviation] Biochem. Soc. Trans.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U105365007; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 36
  •  go-up   go-down


48. Gupta M, de Leval L, Selig M, Oliva E, Nielsen GP: Uterine tumors resembling ovarian sex cord tumors: an ultrastructural analysis of 13 cases. Ultrastruct Pathol; 2010 Feb;34(1):16-24
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Features included cells with frequent organoid, nested or cord-like arrangement (8), lumen formation (2; one of which showed surface microvilli), nuclei with irregular indentations (8), intermediate filaments (13), prominent paranuclear aggregates (5), cell junctions (9), desmosome-like junctions (2), tonofilaments (2), basal lamina (1), and cytoplasmic lipid droplets (7; prominent in 3).
  • [MeSH-major] Adenocarcinoma / diagnosis. Ovarian Neoplasms / diagnosis. Sex Cord-Gonadal Stromal Tumors / diagnosis. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Calbindin 2. Cell Nucleus / ultrastructure. Cytoplasmic Structures / ultrastructure. Desmosomes / ultrastructure. Diagnosis, Differential. Female. Humans. Intermediate Filaments / ultrastructure. Keratins / analysis. Microscopy, Electron, Transmission. S100 Calcium Binding Protein G / analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20070149.001).
  • [ISSN] 1521-0758
  • [Journal-full-title] Ultrastructural pathology
  • [ISO-abbreviation] Ultrastruct Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Calbindin 2; 0 / S100 Calcium Binding Protein G; 68238-35-7 / Keratins
  •  go-up   go-down


49. Lanoy E, Costagliola D, Engels EA: Skin cancers associated with HIV infection and solid-organ transplantation among elderly adults. Int J Cancer; 2010 Apr 1;126(7):1724-31
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The study comprised 29,926 skin cancer cases (excluding basal cell and squamous cell carcinomas) and 119,704 controls, frequency-matched by gender, age and calendar year (1987-2002).
  • Medicare claims identified solid-organ transplantation or HIV infection before cancer diagnosis/control selection.
  • Solid-organ transplantation was also associated with increased risks of Merkel cell carcinoma (N = 1,286; OR [95%CI] 4.95 [2.62-9.34]) and other cutaneous sarcomas (N = 972; 4.19 [1.83-9.56]).
  • [MeSH-major] Adenocarcinoma / etiology. HIV Infections / complications. HIV Infections / therapy. HIV-1 / pathogenicity. Organ Transplantation / adverse effects. Skin Neoplasms / etiology


50. Iwase H, Kurebayashi J, Tsuda H, Ohta T, Kurosumi M, Miyamoto K, Yamamoto Y, Iwase T: Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society. Breast Cancer; 2010 Apr;17(2):118-24
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mucinous, tubular, or secretary carcinomas were frequently found in the hormone receptor positive/HER2 negative subtype, while squamous cell carcinoma, spindle cell carcinoma, and metaplastic carcinoma with bone/cartilage metaplasia were very frequently found in the TN group.
  • CONCLUSIONS: Although TN types are similar to basal-like breast tumor, as determined by gene profiling, their diagnosis needs verification by determination of the level of epidermal growth factor receptor or cytokeratin 5/6 expression.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma, Scirrhous / metabolism. Adenocarcinoma, Scirrhous / pathology. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism. Carcinoma / metabolism. Carcinoma / pathology. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / pathology. Female. Humans. Japan. Middle Aged. Prognosis. Receptor, ErbB-2 / metabolism. Registries. Societies, Medical / statistics & numerical data. Young Adult


51. Schröder W, Wirths K, Gutschow C, Vallböhmer D, Bludau M, Schumacher B, Neuhaus H, Hölscher AH: Transthoracic esophagectomy after endoscopic mucosal resection in patients with early esophageal carcinoma. J Gastrointest Surg; 2009 Feb;13(2):223-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ten patients underwent transthoracic esophagectomy because of submucosal infiltration combined incomplete tumor resection at the lateral/basal resection margin.
  • RESULTS: Three patients had a squamous cell carcinoma (SCC) and 13 patients an adenocarcinoma (AC), nine patients with a long segment Barrett's esophagus.

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Thorac Surg. 2004 Oct;78(4):1177-83 [15464466.001]
  • [Cites] Langenbecks Arch Surg. 2006 Sep;391(5):455-60 [16896830.001]
  • [Cites] Ann Surg. 2000 Dec;232(6):733-42 [11088068.001]
  • [Cites] Ann Surg. 2004 Dec;240(6):962-72; discussion 972-4 [15570202.001]
  • [Cites] Gastrointest Endosc. 2004 Nov;60(5):703-10 [15557945.001]
  • [Cites] AJR Am J Roentgenol. 1999 Aug;173(2):365-7 [10430138.001]
  • [Cites] Gastrointest Endosc. 2003 Dec;58(6 Suppl):S3-43 [14652541.001]
  • [Cites] Jpn J Surg. 1976 Jun;6(2):69-78 [994356.001]
  • [Cites] Virchows Arch. 2005 May;446(5):497-504 [15838647.001]
  • [Cites] Langenbecks Arch Surg. 2006 Aug;391(4):304-21 [16830151.001]
  • [Cites] Am J Surg Pathol. 2006 Jan;30(1):114-8 [16330950.001]
  • [Cites] Ann Surg Oncol. 2002 Oct;9(8):807-11 [12374665.001]
  • [Cites] Dis Esophagus. 2000;13(2):125-9 [14601903.001]
  • [Cites] Can J Gastroenterol. 1998 Jul-Aug;12(5):355-9 [9773215.001]
  • [Cites] Gut. 2001 Oct;49(4):534-9 [11559651.001]
  • [Cites] Gastric Cancer. 1998 Dec;1(1):10-24 [11957040.001]
  • [Cites] Chirurg. 2003 Aug;74(8):726-33 [12928793.001]
  • [Cites] Br J Surg. 1997 Oct;84(10):1470-3 [9361616.001]
  • [Cites] Gut. 2004 May;53(5):634-40 [15082579.001]
  • [Cites] Cancer. 1995 Jul 15;76(2):178-86 [8625089.001]
  • [Cites] Endoscopy. 2004 Sep;36(9):776-81 [15326572.001]
  • [Cites] Endoscopy. 2007 Jan;39(1):77-9 [17323470.001]
  • [Cites] Am J Gastroenterol. 2004 Jul;99(7):1226-32 [15233658.001]
  • [Cites] Endoscopy. 2006 Feb;38(2):149-56 [16479422.001]
  • [Cites] Gastrointest Endosc. 2007 Jan;65(1):3-10 [17185072.001]
  • [Cites] Ann Surg. 2004 Nov;240(5):791-800 [15492560.001]
  • [Cites] World J Surg. 2002 May;26(5):584-7 [12098049.001]
  • [Cites] Ann Surg. 2004 Apr;239(4):483-90 [15024309.001]
  • [Cites] Ann Surg. 2007 Feb;245(2):241-6 [17245177.001]
  • (PMID = 18923875.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Xu XL, Li B, Sun XL, Li LQ, Ren RJ, Gao F: [Clinical and pathological analysis of 2639 cases of eyelid tumors]. Zhonghua Yan Ke Za Zhi; 2008 Jan;44(1):38-41
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The 5 leading eyelid malignant tumors were basal cell carcinoma, sebaceous gland carcinoma, lymphoma, squamous cell carcinoma and melanoma.
  • The mean age at diagnosis was 61 years for basal cell carcinoma and sebaceous gland carcinoma, 57 years and 52 years for squamous cell carcinoma and melanoma, respectively, and 48 years for lymphoma.
  • There was no significant sex predilection in basal cell carcinoma and sebaceous gland carcinoma.
  • Melanoma and lymphoma occurred more commonly in women, whereas squamous cell carcinoma occurred more commonly in men.
  • CONCLUSIONS: Basal cell carcinoma and sebaceous gland carcinoma were the most common malignant eyelid tumors, and lymphoma ranked third and had an increasing trend.
  • [MeSH-major] Adenocarcinoma, Sebaceous / pathology. Carcinoma, Basal Cell / pathology. Eyelid Neoplasms / pathology. Lymphoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18510241.001).
  • [ISSN] 0412-4081
  • [Journal-full-title] [Zhonghua yan ke za zhi] Chinese journal of ophthalmology
  • [ISO-abbreviation] Zhonghua Yan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


53. Wang W, Sun X, Epstein JI: Partial atrophy on prostate needle biopsy cores: a morphologic and immunohistochemical study. Am J Surg Pathol; 2008 Jun;32(6):851-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Partial atrophy on prostate needle biopsy cores: a morphologic and immunohistochemical study.
  • The morphologic features of the 278 cases and immunohistochemistry of 236 cases (198 with prostate cocktail and 38 with only basal cell makers) were analyzed.
  • Of 198 cases with a prostatic cocktail stain, 48 (24.2%) had a cancer pattern for both basal cells and AMACR (p63-, HMWCK-, and AMACR+), 14 (7.1%) had a cancer pattern for basal cells (p63-, HMWCK-, and AMACR-), 89 (44.9%) had a cancer pattern for AMACR (p63+, HMWCK+, and AMACR+), and 47 (23.7%) had a totally benign pattern (p63+, HMWCK+, and AMACR-).
  • Of the 198 cases using the cocktail stain, 136 (68.7%) had positive basal cell staining.
  • The percentage of basal cells labeled with the combination of p63/HMWCK was: <5% in 42 (21.2%) cases, 5% to 75% in 58 (29.3%) cases, and >75% in 36 (18.2%) cases.
  • In conclusion, partial atrophy is a benign mimicker of adenocarcinoma both as a result of its routine morphologic features and its immunohistochemical profile.
  • Recognition of the classic morphology of partial atrophy on routine hematoxylin and eosin-stained sections is critical to avoid misdiagnosing partial atrophy as adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Prostate / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Atrophy. Biopsy, Needle. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18408595.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Heyl J, Mehregan D: Immunolabeling pattern of cytokeratin 19 expression may distinguish sebaceous tumors from basal cell carcinomas. J Cutan Pathol; 2008 Jan;35(1):40-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunolabeling pattern of cytokeratin 19 expression may distinguish sebaceous tumors from basal cell carcinomas.
  • BACKGROUND: Distinction between sebaceous tumors and basal cell carcinomas can often pose diagnostic problems.
  • Our aim was to evaluate the use of CK 19 staining patterns in differentiating between sebaceous tumors and basal cell carcinomas.
  • METHODS: Thirty-seven cases including 5 sebaceous adenomas, 16 sebaceous epitheliomas, 6 sebaceous carcinomas and 14 basal cell carcinomas (7 being of the morpheaform type and 7 nodular basal cell carcinomas) were tested with a monoclonal mouse antibody to human CK 19.
  • CK 19 was found to be strongly positive in 9/14 (64%) and focally positive in 2/14 (14%) of basal cell carcinomas.
  • CONCLUSION: CK 19 expression can be helpful in differentiating sebaceous tumors (including sebaceous adenomas, sebaceous epitheliomas and sebaceous carcinomas) from basal cell carcinomas and may be a useful adjunct when these entities are included in the differential diagnosis.
  • [MeSH-major] Adenocarcinoma, Sebaceous / diagnosis. Adenoma / diagnosis. Biomarkers, Tumor / analysis. Carcinoma, Basal Cell / diagnosis. Keratin-19 / analysis. Sebaceous Gland Neoplasms / diagnosis. Sebaceous Glands / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Humans. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18095993.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-19
  •  go-up   go-down


55. Cabral ES, Cassarino DS: Desmoplastic tricholemmoma of the eyelid misdiagnosed as sebaceous carcinoma: a potential diagnostic pitfall. J Cutan Pathol; 2007 Dec;34 Suppl 1:22-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histologic examination showed a lobular, folliculocentric proliferation of palely eosinophilic to clear cells surrounded by peripheral basal cells with palisading.
  • Therefore, DTL should enter the differential diagnosis of clear-cell neoplasms on the eyelid.
  • [MeSH-major] Adenocarcinoma, Sebaceous / diagnosis. Eyelid Neoplasms / diagnosis. Hair Diseases / diagnosis. Hair Follicle / pathology. Skin Neoplasms / diagnosis
  • [MeSH-minor] Antigens, CD34 / metabolism. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Glycogen / metabolism. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Hair Problems.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17997733.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 9005-79-2 / Glycogen
  •  go-up   go-down


56. Beales IL, Ogunwobi O, Cameron E, El-Amin K, Mutungi G, Wilkinson M: Activation of Akt is increased in the dysplasia-carcinoma sequence in Barrett's oesophagus and contributes to increased proliferation and inhibition of apoptosis: a histopathological and functional study. BMC Cancer; 2007;7:97
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The incidence of oesophageal adenocarcinoma is increasing rapidly in the developed world.
  • Therefore we have examined the activation of Akt in Barrett's oesophagus and oesophageal adenocarcinoma and the functional effects of Akt activation in vitro.
  • The functional effects of Akt were examined using Barrett's adenocarcinoma cells in culture.
  • RESULTS: In normal squamous oesophagus, erosive oesophagitis and non-dysplastic Barrett's oesophagus, phospho-Akt was limited to the basal 1/3 of the mucosa.
  • Image analysis confirmed that Akt activation was significantly increased in non-dysplastic Barrett's oesophagus compared to squamous epithelium and further significantly increased in high-grade dysplasia and adenocarcinoma.
  • In all cases of high grade dysplasia and adenocarcinoma Akt was activated in the luminal 1/3 of the epithelium.
  • CONCLUSION: Akt is abnormally activated in Barrett's oesophagus, high grade dysplasia and adenocarcinoma.
  • Akt activation promotes proliferation and inhibits apoptosis in Barrett's adenocarcinoma cells and both transient acid exposure and leptin stimulate Akt phosphorylation.
  • Activation of Akt in obesity and by reflux of gastric acid may be important in the pathogenesis of Barrett's adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / enzymology. Barrett Esophagus / enzymology. Cell Transformation, Neoplastic / metabolism. Enzyme Activation / physiology. Esophageal Neoplasms / enzymology. Proto-Oncogene Proteins c-akt / metabolism
  • [MeSH-minor] Apoptosis. Cell Proliferation. Humans. Image Processing, Computer-Assisted. Immunohistochemistry. Precancerous Conditions / enzymology. Precancerous Conditions / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2002 Aug 2;277(31):27613-21 [12000750.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2002 Aug;283(2):G327-34 [12121879.001]
  • [Cites] Gastroenterology. 2003 Mar;124(3):615-25 [12612900.001]
  • [Cites] J Surg Res. 2003 Jul;113(1):50-5 [12943810.001]
  • [Cites] J Biol Chem. 2003 Sep 12;278(37):34783-93 [12826665.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 17;95(18):1404-13 [13130116.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1561-9 [14996709.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):1915-9 [15026323.001]
  • [Cites] J Biol Chem. 2004 Apr 16;279(16):16495-502 [14752104.001]
  • [Cites] Br J Cancer. 2004 Aug 16;91(4):714-9 [15266314.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Oct 8;323(1):44-8 [15351698.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Oct;287(4):G743-8 [15231484.001]
  • [Cites] Life Sci. 2004 Nov 5;75(25):2983-95 [15474551.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4217-26 [15483033.001]
  • [Cites] Am J Clin Pathol. 1995 Mar;103(3):295-9 [7872251.001]
  • [Cites] N Engl J Med. 1996 Feb 1;334(5):292-5 [8532024.001]
  • [Cites] Gastroenterology. 1996 Jul;111(1):85-92 [8698230.001]
  • [Cites] J Clin Invest. 1996 Nov 1;98(9):2120-8 [8903332.001]
  • [Cites] Cell. 1997 Oct 17;91(2):231-41 [9346240.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Cell. 1999 Mar 19;96(6):857-68 [10102273.001]
  • [Cites] J Biol Chem. 1999 Jun 11;274(24):16741-6 [10358014.001]
  • [Cites] Ann Intern Med. 1999 Jun 1;130(11):883-90 [10375336.001]
  • [Cites] Gastrointest Endosc. 1999 Jul;50(1):23-6 [10385717.001]
  • [Cites] Am J Gastroenterol. 1999 Aug;94(8):2043-53 [10445526.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Gut. 2005 Mar;54 Suppl 1:i21-6 [15711004.001]
  • [Cites] Gut. 2005 Mar;54 Suppl 1:i27-32 [15711005.001]
  • [Cites] Gastroenterology. 2005 May;128(5):1471-505 [15887129.001]
  • [Cites] J Surg Res. 2005 Jul 1;127(1):53-8 [15964304.001]
  • [Cites] Nat Clin Pract Gastroenterol Hepatol. 2004 Dec;1(2):106-12 [16265072.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2005 Dec;289(6):G991-7 [16081761.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2006 Feb;290(2):G335-42 [16239404.001]
  • [Cites] Mol Cell Endocrinol. 2006 Mar 9;247(1-2):140-9 [16442704.001]
  • [Cites] Regul Pept. 2006 Mar 15;134(1):1-8 [16169610.001]
  • [Cites] Endocrinology. 2006 Sep;147(9):4505-16 [16740977.001]
  • [Cites] Int J Colorectal Dis. 2007 Apr;22(4):401-9 [16912864.001]
  • [Cites] Br J Surg. 2007 Mar;94(3):346-54 [17212381.001]
  • [Cites] Exp Cell Res. 1999 Nov 25;253(1):210-29 [10579924.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2001 Feb;280(2):G298-307 [11208554.001]
  • [Cites] Br J Cancer. 2001 Mar 23;84(6):748-53 [11259087.001]
  • [Cites] Gastroenterology. 2002 Feb;122(2):299-307 [11832445.001]
  • [Cites] Am J Gastroenterol. 2002 Jun;97(6):1319-27 [12094844.001]
  • [Cites] Am J Gastroenterol. 2002 Jun;97(6):1328-31 [12094845.001]
  • [Cites] Gut. 2003 Feb;52(2):174-80 [12524396.001]
  • (PMID = 17559672.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  • [Other-IDs] NLM/ PMC1899509
  •  go-up   go-down


57. Donadelli M, Costanzo C, Beghelli S, Scupoli MT, Dandrea M, Bonora A, Piacentini P, Budillon A, Caraglia M, Scarpa A, Palmieri M: Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine. Biochim Biophys Acta; 2007 Jul;1773(7):1095-106
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine.
  • We investigated the ability of the histone deacetylase (HDAC) inhibitor trichostatin A (TSA) to interact with gemcitabine (GEM) in inducing pancreatic cancer cell death.
  • The combined treatment with TSA and GEM synergistically inhibited growth of four pancreatic adenocarcinoma cell lines and induced apoptosis.
  • The functional role of ROS in cell growth inhibition by GEM was supported by (i) a significantly reduced GEM-associated growth inhibition by the free radical scavenger N-acetyl-L-cysteine, and (ii) a positive correlation between the basal level of ROS and sensitivity to GEM in 10 pancreatic cancer cell lines.
  • The functional role of both Bim and 5'-nucleotidase UMPH type II in cell growth inhibition by TSA and GEM was assessed by RNA interference assays.
  • In vivo studies on xenografts of pancreatic adenocarcinoma cells in nude mice showed that the association of TSA and GEM reduced to 50% the tumour mass and did not cause any apparent form of toxicity, while treatments with TSA or GEM alone were ineffective.
  • [MeSH-major] Adenocarcinoma / metabolism. Cell Proliferation / drug effects. Deoxycytidine / analogs & derivatives. Enzyme Inhibitors. Hydroxamic Acids. Pancreatic Neoplasms / metabolism
  • [MeSH-minor] 5'-Nucleotidase / genetics. 5'-Nucleotidase / metabolism. Animals. Apoptosis / physiology. Apoptosis Regulatory Proteins / metabolism. Cell Cycle / physiology. Cell Line, Tumor. Glycoproteins / genetics. Glycoproteins / metabolism. Histone Deacetylase Inhibitors. Humans. Membrane Proteins / metabolism. Mice. Proto-Oncogene Proteins / metabolism. Reactive Oxygen Species / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17555830.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Bcl-2-like protein 11; 0 / Enzyme Inhibitors; 0 / Glycoproteins; 0 / Histone Deacetylase Inhibitors; 0 / Hydroxamic Acids; 0 / Membrane Proteins; 0 / Proto-Oncogene Proteins; 0 / Reactive Oxygen Species; 0W860991D6 / Deoxycytidine; 3X2S926L3Z / trichostatin A; B76N6SBZ8R / gemcitabine; EC 3.1.3.5 / 5'-Nucleotidase; EC 3.1.3.5 / NT5C3 protein, human
  •  go-up   go-down


58. Narayana A, Cohen GN, Zaider M, Chan K, Lee N, Wong RJ, Boyle J, Shaha A, Kraus D, Shah J, Zelefsky MJ: High-dose-rate interstitial brachytherapy in recurrent and previously irradiated head and neck cancers--preliminary results. Brachytherapy; 2007 Apr-Jun;6(2):157-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenocarcinoma / radiotherapy. Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Female. Follow-Up Studies. Humans. Male. Melanoma / radiotherapy. Middle Aged. Radiation Injuries / etiology. Radiotherapy Dosage. Retrospective Studies. Sarcoma / radiotherapy. Survival Analysis. Time Factors. Treatment Outcome. Tumor Burden / radiation effects

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17434110.001).
  • [ISSN] 1538-4721
  • [Journal-full-title] Brachytherapy
  • [ISO-abbreviation] Brachytherapy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Gerdes MJ, Yuspa SH: The contribution of epidermal stem cells to skin cancer. Stem Cell Rev; 2005;1(3):225-31
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The use of transgenic and knockout gene technologies with mice is unraveling some of the specific genes regulating fate determination in stem cells other than squamous lineage, including basal cell carcinoma and sebaceous adenomas.
  • The following review examines the evidence for the stem cell origin of epidermal tumors and the contribution of some specific gene families toward stem cell fate decisions during epidermal tumor progression.
  • [MeSH-major] Adenocarcinoma, Sebaceous / genetics. Carcinoma, Basal Cell / genetics. Epidermis. Epigenesis, Genetic. Neoplastic Stem Cells. Skin Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12483-8 [12221288.001]
  • [Cites] Nat Genet. 2000 Sep;26(1):114-7 [10973262.001]
  • [Cites] Development. 2004 Apr;131(8):1787-99 [15084463.001]
  • [Cites] Dev Biol. 1999 Jan 1;205(1):1-9 [9882493.001]
  • [Cites] Cancer Res. 1988 Nov 15;48(22):6285-90 [2460219.001]
  • [Cites] EMBO J. 1997 May 1;16(9):2365-75 [9171350.001]
  • [Cites] Exp Biol Med (Maywood). 2001 Sep;226(8):753-7 [11520941.001]
  • [Cites] Curr Biol. 2001 Apr 17;11(8):558-68 [11369200.001]
  • [Cites] J Invest Dermatol. 1999 Dec;113(6):1099-105 [10594758.001]
  • [Cites] Exp Cell Res. 2004 Apr 15;295(1):79-90 [15051492.001]
  • [Cites] J Invest Dermatol. 1999 Apr;112(4):470-5 [10201531.001]
  • [Cites] Nat Genet. 1999 Apr;21(4):410-3 [10192393.001]
  • [Cites] J Invest Dermatol. 2003 Apr;120(4):501-11 [12648211.001]
  • [Cites] Nature. 1999 Apr 22;398(6729):708-13 [10227293.001]
  • [Cites] Cell. 2001 Jan 26;104(2):233-45 [11207364.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Aug 2;91(16):7822-6 [8052666.001]
  • [Cites] Stem Cells. 2002;20(1):21-31 [11796919.001]
  • [Cites] J Invest Dermatol. 1994 Nov;103(5 Suppl):90S-95S [7963691.001]
  • [Cites] Oncogene. 2001 Aug 30;20(38):5341-9 [11536046.001]
  • [Cites] Cancer Res. 1993 Jul 1;53(13):2961-4 [8319202.001]
  • [Cites] Cancer Res. 1993 Oct 15;53(20):4803-10 [8402665.001]
  • [Cites] J Dermatol. 2004 May;31(5):368-75 [15187303.001]
  • [Cites] Nat Biotechnol. 2004 Apr;22(4):411-7 [15024388.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4742-7 [10758156.001]
  • [Cites] J Invest Dermatol. 1993 Oct;101(4):591-4 [8409528.001]
  • [Cites] Science. 2004 Jan 16;303(5656):359-63 [14671312.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10960-5 [11005869.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 30;100 Suppl 1:11873-80 [12917489.001]
  • [Cites] Cell Tissue Res. 1985;242(3):551-6 [2416451.001]
  • [Cites] Mol Carcinog. 1997 Sep;20(1):151-8 [9328446.001]
  • [Cites] Cell. 2004 Sep 3;118(5):635-48 [15339667.001]
  • [Cites] J Invest Dermatol. 1996 Apr;106(4):759-65 [8618017.001]
  • [Cites] Cell. 1993 May 21;73(4):713-24 [8500165.001]
  • [Cites] Nat Med. 1999 Nov;5(11):1285-91 [10545995.001]
  • [Cites] Hum Mol Genet. 2003 Nov 15;12(22):2931-40 [14506134.001]
  • [Cites] Nature. 1999 Apr 22;398(6729):714-8 [10227294.001]
  • [Cites] Development. 2004 Oct;131(20):5009-19 [15371305.001]
  • [Cites] EMBO J. 2003 Jun 16;22(12):2981-91 [12805213.001]
  • [Cites] Cancer Res. 1986 Jun;46(6):3061-6 [3698024.001]
  • [Cites] Mol Cell. 1998 Sep;2(3):305-16 [9774969.001]
  • [Cites] Cell. 1998 Nov 25;95(5):605-14 [9845363.001]
  • [Cites] J Cell Biol. 2000 Sep 4;150(5):1149-60 [10974002.001]
  • [Cites] J Cell Biol. 1998 Oct 19;143(2):469-86 [9786956.001]
  • [Cites] Cancer. 1999 Nov 15;86(10):2038-44 [10570429.001]
  • [Cites] J Invest Dermatol. 2001 May;116(5):739-42 [11348463.001]
  • [Cites] J Invest Dermatol. 2000 Nov;115(5):788-94 [11069615.001]
  • [Cites] J Cell Sci. 1987 Oct;88 ( Pt 3):305-12 [3129440.001]
  • [Cites] Cell. 1990 Jun 29;61(7):1329-37 [2364430.001]
  • [Cites] J Cell Sci. 1978 Feb;29:249-69 [627606.001]
  • [Cites] Mol Cell Biol. 2004 Feb;24(4):1608-13 [14749376.001]
  • [Cites] EMBO J. 2001 Jun 1;20(11):2619-30 [11387197.001]
  • [Cites] Carcinogenesis. 1991 Jun;12(6):1119-24 [2044193.001]
  • [Cites] EMBO J. 2001 Mar 15;20(6):1215-22 [11250888.001]
  • [Cites] Mol Carcinog. 1993;7(2):99-110 [7681293.001]
  • [Cites] Cancer Res. 1997 Aug 15;57(16):3436-43 [9270010.001]
  • [Cites] J Invest Dermatol. 1999 Oct;113(4):595-9 [10504446.001]
  • [Cites] EMBO J. 2000 Aug 1;19(15):3990-4003 [10921880.001]
  • [Cites] Differentiation. 2004 Oct;72(8):371-80 [15606496.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):226-9 [10667563.001]
  • [Cites] J Invest Dermatol. 1998 Dec;111(6):1045-52 [9856815.001]
  • [Cites] Nature. 1983 Jul 7-13;304(5921):69-71 [6408484.001]
  • [Cites] Int J Cancer. 1987 Jun 15;39(6):778-84 [3294611.001]
  • [Cites] Genes Dev. 2005 Jan 15;19(2):214-23 [15625189.001]
  • [Cites] Cell. 2000 Aug 18;102(4):451-61 [10966107.001]
  • [Cites] Dev Biol. 2003 Nov 15;263(2):203-15 [14597196.001]
  • [Cites] J Invest Dermatol. 2003 Nov;121(5):963-8 [14708593.001]
  • [Cites] J Cell Sci. 1996 May;109 ( Pt 5):1017-28 [8743949.001]
  • [Cites] Cell. 2001 May 18;105(4):533-45 [11371349.001]
  • [Cites] Cell Biol Int. 2004;28(7):523-9 [15261160.001]
  • [Cites] Hum Mol Genet. 2001 Apr;10 (7):757-62 [11257109.001]
  • [Cites] Curr Biol. 1998 Apr 23;8(9):516-24 [9560338.001]
  • [Cites] Cancer Detect Prev. 1996;20(1):20-30 [8907200.001]
  • [Cites] Nat Genet. 2001 Jun;28(2):165-8 [11381265.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):843-50 [15829953.001]
  • [Cites] Mol Cell Biol. 2000 Feb;20(4):1436-47 [10648628.001]
  • [Cites] Pathol Res Pract. 1994 Oct;190(9-10):950-4 [7899145.001]
  • [Cites] Development. 2002 Jan;129(1):95-109 [11782404.001]
  • [Cites] J Cutan Pathol. 1994 Dec;21(6):500-6 [7699116.001]
  • [Cites] J Invest Dermatol. 2003 Nov;121(5):1095-103 [14708612.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3156-61 [11248048.001]
  • [Cites] Am J Pathol. 2003 Dec;163(6):2173-8 [14633591.001]
  • [Cites] J Cell Sci. 1998 Nov;111 ( Pt 21):3179-88 [9763512.001]
  • [Cites] Oncogene. 1996 Feb 15;12(4):765-73 [8632898.001]
  • [Cites] J Invest Dermatol. 1997 Jan;108(1):113-7 [8980299.001]
  • [Cites] Cancer Res. 1984 Sep;44(9):3779-82 [6430553.001]
  • [Cites] J Natl Cancer Inst. 1986 Jan;76(1):151-8 [3455737.001]
  • [Cites] Am J Pathol. 1997 May;150(5):1791-803 [9137102.001]
  • [Cites] Mol Cell. 1999 May;3(5):565-77 [10360173.001]
  • [Cites] Br J Cancer. 1999 Jul;80 Suppl 1:28-33 [10466758.001]
  • [Cites] Trends Mol Med. 2004 Dec;10(12):577-80 [15567325.001]
  • [Cites] Cell. 1990 Aug 24;62(4):697-708 [1696852.001]
  • [Cites] Acta Derm Venereol. 1994 Mar;74(2):101-5 [7911612.001]
  • (PMID = 17142859.001).
  • [ISSN] 1550-8943
  • [Journal-full-title] Stem cell reviews
  • [ISO-abbreviation] Stem Cell Rev
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] United States
  • [Number-of-references] 92
  •  go-up   go-down


60. Tijink BM, De Bree R, Van Dongen GA, Leemans CR: How we do it: Chemo-electroporation in the head and neck for otherwise untreatable patients. Clin Otolaryngol; 2006 Oct;31(5):447-51
Hazardous Substances Data Bank. BLEOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenocarcinoma / secondary. Adenocarcinoma / therapy. Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / secondary. Carcinoma, Basal Cell / therapy. Carcinoma, Merkel Cell / secondary. Carcinoma, Merkel Cell / therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Melanoma / secondary. Melanoma / therapy. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Netherlands. Salivary Gland Neoplasms / secondary. Salivary Gland Neoplasms / therapy. Sarcoma / secondary. Sarcoma / therapy. Skin Neoplasms / secondary. Skin Neoplasms / therapy. Treatment Outcome. Tumor Burden / drug effects

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17014460.001).
  • [ISSN] 1749-4478
  • [Journal-full-title] Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery
  • [ISO-abbreviation] Clin Otolaryngol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 11056-06-7 / Bleomycin
  •  go-up   go-down


61. Emuss V, Garnett M, Mason C, Marais R: Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF. Cancer Res; 2005 Nov 1;65(21):9719-26
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF.
  • Here we show that presumptive mutants of the closely related kinase, C-RAF, were detected in only 4 of 545 (0.7%) cancer cell lines.
  • The basal and B-RAF-stimulated kinase activities of a third variant are unaltered but its activation by RAS is significantly reduced, suggesting that it may act in a dominant-negative manner to modulate pathway signaling.
  • The fourth variant has elevated basal kinase activity and is hypersensitive to activation by RAS but does not transform mammalian cells.
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / genetics. Amino Acid Sequence. Animals. COS Cells. Carcinoma / enzymology. Carcinoma / genetics. Cercopithecus aethiops. Colorectal Neoplasms / enzymology. Colorectal Neoplasms / genetics. Enzyme Activation. Fibrosarcoma / enzymology. Fibrosarcoma / genetics. Humans. Lung Neoplasms / enzymology. Lung Neoplasms / genetics. Mice. Molecular Sequence Data. Mutagenesis, Site-Directed. NIH 3T3 Cells


62. Yazgan S, Gürsoy S, Yaldiz S, Basok O: Outcome of surgery for lung cancer in young and elderly patients. Surg Today; 2005;35(10):823-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We conducted this study to determine whether the basal characteristics and survival of young patients undergoing surgical resection of lung cancer differ from those of elderly patients.
  • The patients' medical records were reviewed with respect to age, gender, histological diagnosis, coexisting diseases, smoking history, postoperative staging, type of operation, and postoperative morbidity, mortality, and survival results.
  • However, the 5-year survival rates for patients who underwent surgery for non-small cell lung cancer did not differ between groups 1 and 2, at 33.3% versus 21.3%, respectively (P = 0.09).
  • CONCLUSIONS: The incidence of adenocarcinoma was higher in the young patients, whose prognosis was slightly better than that of the elderly patients.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / mortality. Carcinoma, Non-Small-Cell Lung / surgery. Carcinoma, Small Cell / mortality. Carcinoma, Small Cell / surgery. Lung Neoplasms / mortality. Lung Neoplasms / surgery

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Today. 2001;31(10):860-5 [11759878.001]
  • [Cites] Clin Chest Med. 1993 Sep;14(3):453-78 [8222563.001]
  • [Cites] Chest. 1999 May;115(5):1232-6 [10334132.001]
  • [Cites] Am J Epidemiol. 1998 Jun 1;147(11):1028-37 [9620046.001]
  • [Cites] Ann Thorac Surg. 1997 Jul;64(1):193-8 [9236359.001]
  • [Cites] Ann Thorac Surg. 1992 Jan;53(1):127-31 [1309414.001]
  • [Cites] Chest. 1992 Dec;102(6):1723-9 [1446479.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):651-7 [9469354.001]
  • [Cites] Chest. 1993 Nov;104(5):1477-81 [8222810.001]
  • [Cites] Ann Thorac Surg. 1997 Apr;63(4):944-50 [9124968.001]
  • [Cites] Cancer Detect Prev. 1988;11(3-6):235-8 [3390846.001]
  • [Cites] J Surg Oncol. 1999 May;71(1):29-31 [10362088.001]
  • [Cites] Ann Thorac Surg. 1989 Mar;47(3):391-3 [2467630.001]
  • [Cites] J Surg Oncol. 2001 Jul;77(3):208-12 [11455559.001]
  • [Cites] Respir Med. 1992 Nov;86(6):499-502 [1335158.001]
  • [Cites] Chest. 1997 Jun;111(6):1710-7 [9187198.001]
  • [Cites] Chest. 2001 Jul;120(1):32-6 [11451812.001]
  • [Cites] Chest. 1985 Apr;87(4):456-9 [2983952.001]
  • [Cites] J Thorac Cardiovasc Surg. 1981 Feb;81(2):187-93 [7453228.001]
  • [Cites] J Thorac Cardiovasc Surg. 1974 Apr;67(4):634-48 [4361990.001]
  • [Cites] Ann Thorac Surg. 1992 Jul;54(1):99-103 [1610262.001]
  • [Cites] Ann Thorac Surg. 1990 Dec;50(6):919-22 [2173502.001]
  • [Cites] J Gerontol. 1987 Sep;42(5):540-5 [3624814.001]
  • [Cites] Ann Thorac Surg. 1997 Jan;63(1):193-7 [8993264.001]
  • [Cites] J Thorac Cardiovasc Surg. 1982 Mar;83(3):372-6 [6278230.001]
  • [Cites] Ann Thorac Surg. 1997 May;63(5):1405-9; discussion 1409-10 [9146334.001]
  • (PMID = 16175462.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


63. Helpap B: [Small suggestive lesions of the prostate. Histological and immunohistochemical analyses -- report of the uropathology consultation service]. Pathologe; 2005 Nov;26(6):398-404
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To check the diagnosis of "small two- or three-gland carcinoma" we prepared new H and E sections and, when the atypical glands were no longer available, also performed immunohistochemical analyses in 1,041 cases referred to our uropathology consultation service, comparing the diagnoses supplied by the referring doctors with the final diagnoses.
  • In 61.6 of these cases histology confirmed the diagnosis of adenocarcinoma of the prostate; the diagnosis recorded when the basal cell marker was absent and the tumour marker P504S was strongly expressed was atypical microglandular proliferation or suspected carcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / analysis. Precancerous Conditions / pathology. Prostate / pathology. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Biopsy. Cell Division / physiology. Cell Transformation, Neoplastic / pathology. Diagnosis, Differential. Humans. Immunoenzyme Techniques. Male. Prostatic Hyperplasia / pathology. Referral and Consultation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1995 Mar;19(3):251-60 [7532918.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1588-96 [12459625.001]
  • [Cites] Hum Pathol. 2003 Aug;34(8):792-6 [14506641.001]
  • [Cites] Urology. 1998 May;51(5):749-57; discussion 757-8 [9610588.001]
  • [Cites] Hum Pathol. 1995 Feb;26(2):223-9 [7860053.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1169-74 [12218573.001]
  • [Cites] Pathol Res Pract. 1999;195(12):795-9 [10631713.001]
  • [Cites] Am J Clin Pathol. 2004 Jan;121(1):99-107 [14750247.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1161-8 [12218572.001]
  • [Cites] Histopathology. 2004 Sep;45(3):218-25 [15330799.001]
  • [Cites] Virchows Arch. 1998 Nov;433(5):397-405 [9849853.001]
  • [Cites] Histopathology. 2004 Apr;44(4):403-4 [15049912.001]
  • [Cites] Hum Pathol. 2004 Jan;35(1):43-6 [14745723.001]
  • [Cites] Pathologe. 1996 Nov;17(6):417-24 [9082362.001]
  • [Cites] Am J Surg Pathol. 2002 Jul;26(7):926-31 [12131161.001]
  • [Cites] J Clin Pathol. 2003 Dec;56(12):892-7 [14645345.001]
  • [Cites] J Pathol. 2001 Mar;193(3):350-3 [11241415.001]
  • [Cites] Am J Surg Pathol. 2003 Aug;27(8):1128-33 [12883245.001]
  • [Cites] JAMA. 2002 Apr 3;287(13):1662-70 [11926890.001]
  • [Cites] J Urol. 2001 Aug;166(2):402-10 [11458037.001]
  • [Cites] Verh Dtsch Ges Pathol. 1999;83:162-7 [10714207.001]
  • [Cites] Am J Clin Pathol. 1997 Dec;108(6):633-40 [9384444.001]
  • [Cites] Verh Dtsch Ges Pathol. 2004;88:152-7 [16892546.001]
  • [Cites] Am J Surg Pathol. 2004 Feb;28(2):239-43 [15043314.001]
  • [Cites] Am J Clin Pathol. 2004 Aug;122(2):275-89 [15323145.001]
  • [Cites] Histopathology. 2005 Jul;47(1):1-16 [15982318.001]
  • (PMID = 16163479.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


64. Cavalcanti Fde B, Alves VA, Pereira J, Kanamura CT, Wakamatsu A, Saldanha LB: Proliferative lesions of prostate: a multivariate approach to differential diagnosis. Pathol Oncol Res; 2005;11(2):103-7
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proliferative lesions of prostate: a multivariate approach to differential diagnosis.
  • Prostatic needle biopsies from 142 patients were studied: 61 cases were "benign", 19 atypical small acinar proliferation, 31 high-grade prostatic intraepithelial neoplasia, and 31 adenocarcinoma.
  • Of these parameters, seven (glandular fusion, crystalloids, nucleolomegaly, papillary architecture, visibility of basal cell layer, areas of normal luminal cell nucleus/cytoplasm ratio and areas of high luminal cell nucleus/cytoplasm ratio) remained significant in discriminating the groups.
  • Multivariate analysis selected a small panel of histological features as those most helpful in the differential diagnosis of proliferative lesions in prostate biopsies.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Acinar Cell / diagnosis. Prostatic Intraepithelial Neoplasia / diagnosis. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Biopsy, Needle. Cell Proliferation. Diagnosis, Differential. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1998 Jul;22(7):840-8 [9669346.001]
  • [Cites] Am J Surg Pathol. 1995 Mar;19(3):251-60 [7532918.001]
  • [Cites] Am J Surg Pathol. 1999 Aug;23(8):925-31 [10435562.001]
  • [Cites] Cancer Res. 1985 Aug;45(8):3663-7 [2410099.001]
  • [Cites] J Urol. 1974 Jan;111(1):58-64 [4813554.001]
  • [Cites] Hum Pathol. 1992 Mar;23(3):273-9 [1555838.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1990;417(3):191-6 [1696762.001]
  • [Cites] J Clin Pathol. 2003 Mar;56(3):230-2 [12610105.001]
  • [Cites] Arch Pathol Lab Med. 1994 Mar;118(3):260-4 [7510946.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1489-95 [9414193.001]
  • [Cites] Am J Clin Pathol. 1983 Dec;80(6):850-4 [6195916.001]
  • [Cites] Urology. 1998 May;51(5):749-57; discussion 757-8 [9610588.001]
  • [Cites] Am J Surg Pathol. 1999 Feb;23(2):147-52 [9989840.001]
  • [Cites] Cancer. 1987 Feb 15;59(4):788-94 [2433020.001]
  • [Cites] Am J Surg Pathol. 1995 Sep;19(9):1068-76 [7544958.001]
  • [Cites] Am J Surg Pathol. 1994 Aug;18(8):821-31 [8037296.001]
  • [Cites] Hum Pathol. 1993 Aug;24(8):819-32 [8375853.001]
  • [Cites] J Clin Pathol. 1997 Sep;50(9):775-82 [9389981.001]
  • [Cites] Virchows Arch. 1998 Nov;433(5):397-405 [9849853.001]
  • [Cites] Hum Pathol. 1993 Mar;24(3):298-310 [8454275.001]
  • [Cites] AMA Arch Pathol. 1953 Feb;55(2):131-41 [13007281.001]
  • [Cites] Am J Surg Pathol. 1998 Sep;22(9):1073-7 [9737239.001]
  • [Cites] Hum Pathol. 1988 Dec;19(12):1425-33 [2461340.001]
  • [Cites] Hum Pathol. 1992 Mar;23(3):242-8 [1372878.001]
  • [Cites] Arch Pathol Lab Med. 2002 May;126(5):554-61 [11958660.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1151-60 [12218571.001]
  • [Cites] Hum Pathol. 1986 Jan;17(1):64-71 [3943853.001]
  • [Cites] Urology. 1995 Jun;45(6):981-6 [7539563.001]
  • [Cites] In Vivo. 2002 Nov-Dec;16(6):557-66 [12494901.001]
  • [Cites] Am J Clin Pathol. 1997 Feb;107(2):219-23 [9024071.001]
  • [Cites] Am J Surg Pathol. 1999 Oct;23 (10 ):1173-83 [10524518.001]
  • [Cites] Am J Surg Pathol. 1999 Aug;23(8):932-6 [10435563.001]
  • [Cites] Rev Invest Clin. 1997 Jan-Feb;49(1):37-40 [9114721.001]
  • [Cites] Histopathology. 1996 Jul;29(1):11-9 [8818689.001]
  • [Cites] Am J Pathol. 1987 Feb;126(2):384-95 [2435158.001]
  • (PMID = 15999155.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


65. Guillem PG: How to make a Barrett esophagus: pathophysiology of columnar metaplasia of the esophagus. Dig Dis Sci; 2005 Mar;50(3):415-24

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although mechanisms by which Barrett metaplasia evolves toward dysplasia and adenocarcinoma have been extensively studied, the process by which squamous epithelium is replaced by specialized intestinal metaplasia is poorly understood.
  • Areas of destroyed squamous epithelium are then progressively reepithelized by a columnar epithelium that may originate from multipotent stem cells located within the basal layer of the normal esophageal mucosa or in the ducts of submucosal glands.
  • [MeSH-major] Barrett Esophagus / pathology. Cell Transformation, Neoplastic / pathology. Esophagus / pathology. Precancerous Conditions / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 1996 Nov 1;98(9):2120-8 [8903332.001]
  • [Cites] Gastroenterology. 1995 Aug;109(2):414-21 [7615190.001]
  • [Cites] Ann Surg. 1992 Jul;216(1):35-43 [1632700.001]
  • [Cites] Dig Dis Sci. 1985 Sep;30(9):884-90 [3928289.001]
  • [Cites] Gastroenterology. 1983 Sep;85(3):621-8 [6307806.001]
  • [Cites] Gastroenterology. 1995 Mar;108(3):662-72 [7875468.001]
  • [Cites] Surgery. 1982 Aug;92(2):276-84 [6808683.001]
  • [Cites] Dig Dis Sci. 1986 Oct;31(10):1105-13 [3757726.001]
  • [Cites] Science. 1999 May 21;284(5418):1362-5 [10334992.001]
  • [Cites] Gastroenterology. 1989 May;96(5 Pt 1):1249-56 [2703113.001]
  • [Cites] Gastroenterology. 1978 Oct;75(4):683-7 [710836.001]
  • [Cites] Gastroenterology. 1992 Apr;102(4 Pt 1):1400-2 [1551547.001]
  • [Cites] J Gastroenterol. 2003;38(1):14-22 [12560917.001]
  • [Cites] Gastroenterology. 1993 Jan;104(1):185-95 [8419242.001]
  • [Cites] Gut. 1993 Jan;34(1):11-5 [8432439.001]
  • [Cites] Am J Med Sci. 1997 Feb;313(2):90-8 [9030674.001]
  • [Cites] Gastroenterology. 1987 Jan;92(1):118-24 [3781178.001]
  • [Cites] Ann Surg. 1990 Oct;212(4):528-40; discussion 540-2 [2222018.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):569-78 [11342767.001]
  • [Cites] Proc Soc Exp Biol Med. 1991 Sep;197(4):393-9 [1871149.001]
  • [Cites] Surgery. 1993 Aug;114(2):285-93; discussion 293-4 [7688153.001]
  • [Cites] Gastroenterology. 1997 Mar;112(3):760-5 [9041237.001]
  • [Cites] Gastroenterology. 1977 Apr;72(4 Pt 1):669-75 [838221.001]
  • [Cites] Gastroenterology. 1993 Jul;105(1):102-10 [8514028.001]
  • [Cites] Gut. 1995 May;36(5):649-53 [7797111.001]
  • [Cites] Int J Cancer. 2000 Dec 15;88(6):856-61 [11093805.001]
  • [Cites] Am J Dig Dis. 1977 Jul;22(7):582-8 [18006.001]
  • [Cites] J Thorac Cardiovasc Surg. 1993 Jan;105(1):107-11 [8419690.001]
  • [Cites] Endoscopy. 1979 May;11(2):121-6 [446424.001]
  • [Cites] Dig Dis Sci. 1989 Sep;34(9):1329-34 [2766898.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3375-80 [11248086.001]
  • [Cites] J Thorac Cardiovasc Surg. 1962 Jun;43:703-15 [13865246.001]
  • [Cites] Am J Physiol. 1984 Jun;246(6 Pt 1):G718-24 [6331171.001]
  • [Cites] Gastroenterology. 1985 Aug;89(2):352-6 [4007426.001]
  • [Cites] Am J Gastroenterol. 1993 Nov;88(11):1934-8 [8237944.001]
  • [Cites] Dig Dis Sci. 1981 Jan;26(1):65-72 [7460707.001]
  • [Cites] Endoscopy. 1993 Nov;25(9):637-41 [8119221.001]
  • [Cites] Biochim Biophys Acta. 1963 Feb 12;67:295-304 [14026386.001]
  • [Cites] J Clin Invest. 1981 Jul;68(1):286-93 [6788804.001]
  • [Cites] Dig Dis Sci. 1993 Jan;38(1):97-108 [8420766.001]
  • [Cites] J Anat. 1952 Oct;86(4):431-42 [12999645.001]
  • [Cites] Surgery. 1994 Feb;115(2):176-81 [8310406.001]
  • [Cites] Br J Surg. 1993 Apr;80(4):467-70 [8495313.001]
  • [Cites] Yale J Biol Med. 1996 Mar-Apr;69(2):147-53 [9112746.001]
  • [Cites] Ann Surg. 1995 Oct;222(4):525-31; discussion 531-3 [7574932.001]
  • [Cites] Dig Dis Sci. 1990 Oct;35(10):1185-9 [2209285.001]
  • [Cites] Gastroenterology. 1986 Mar;90(3):622-7 [3943693.001]
  • [Cites] Gastroenterology. 1993 Oct;105(4):1035-44 [8405846.001]
  • [Cites] Lab Invest. 1981 Aug;45(2):198-208 [7265916.001]
  • [Cites] J Surg Res. 1977 Jan;22(1):5-8 [319297.001]
  • [Cites] Lab Invest. 1989 Mar;60(3):418-32 [2927081.001]
  • [Cites] Gut. 1999 May;44(5):598-602 [10205192.001]
  • [Cites] Br J Surg. 1950 Oct;38(150):175-82 [14791960.001]
  • [Cites] J Lab Clin Med. 1987 Aug;110(2):172-9 [3598346.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jan 7;100(1):223-8 [12509506.001]
  • [Cites] Br J Surg. 1988 Feb;75(2):113-5 [3349294.001]
  • [Cites] Surgery. 1970 Jul;68(1):209-16 [10483471.001]
  • [Cites] J Gastrointest Surg. 1997 Jan-Feb;1(1):27-32; discussion 33 [9834327.001]
  • [Cites] Gastroenterology. 1975 Apr;68(4 Pt 1):728-33 [235483.001]
  • [Cites] Br J Surg. 1991 Dec;78(12):1461-6 [1773326.001]
  • [Cites] Surgery. 1983 May;93(5):660-3 [6845170.001]
  • [Cites] Am J Physiol. 1994 Dec;267(6 Pt 1):G1050-7 [7810652.001]
  • [Cites] Surgery. 1980 Mar;87(3):280-5 [6767288.001]
  • [Cites] Dig Dis Sci. 1994 Dec;39(12):2523-9 [7995174.001]
  • [Cites] Am J Pathol. 1999 Apr;154(4):965-73 [10233832.001]
  • [Cites] Gastrointest Endosc. 1996 Jul;44(1):91-5 [8836727.001]
  • [Cites] Acta Chir Scand. 1975;141(7):683-7 [1211042.001]
  • [Cites] Gastroenterology. 1996 Nov;111(5):1192-9 [8898632.001]
  • [Cites] Dig Dis Sci. 1996 Jun;41(6):1088-98 [8654139.001]
  • (PMID = 15810619.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 70
  •  go-up   go-down


66. Wu XM, Liu X, Bu YQ, Sengupta J, Cui HJ, Yi FP, Liu T, Yuan CF, Shi YY, Song FZ: RNAi-mediated silencing of the Bmi-1 gene causes growth inhibition and enhances doxorubicin-induced apoptosis in MCF-7 cells. Genet Mol Biol; 2009 Oct;32(4):697-703
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, RNAi was introduced to down-regulate the expression of Bmi-1 in a highly malignant breast adenocarcinoma cell line, MCF-7.
  • The number of target cells was found to increase in phase G (0) /G (1) and decrease in the S phase, but no increase in the basal level of apoptosis was noticed.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Mol Cell Biol. 2001 Oct;2(10):731-7 [11584300.001]
  • [Cites] Br J Cancer. 2001 May 18;84(10):1372-6 [11355949.001]
  • [Cites] Nature. 2003 May 15;423(6937):255-60 [12714970.001]
  • [Cites] Nature. 2003 May 15;423(6937):302-5 [12714971.001]
  • [Cites] Cancer Lett. 2004 Jan 20;203(2):217-24 [14732230.001]
  • [Cites] Cell. 2004 Aug 20;118(4):409-18 [15315754.001]
  • [Cites] Breast. 2004 Oct;13(5):383-8 [15454193.001]
  • [Cites] Cancer Cell. 2005 Jun;7(6):505-12 [15950900.001]
  • [Cites] Genes Dev. 2005 Jun 15;19(12):1432-7 [15964994.001]
  • [Cites] Breast Cancer Res. 2005;7(3):86-95 [15987436.001]
  • [Cites] Chin Med J (Engl). 2005 Aug 20;118(16):1346-50 [16157028.001]
  • [Cites] Oncogene. 2006 Jul 20;25(31):4370-5 [16501599.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6063-71 [16778178.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6225-32 [16778197.001]
  • [Cites] J Biol Chem. 2006 Nov 10;281(45):34696-704 [16982619.001]
  • [Cites] Br J Cancer. 2007 Jan 15;96(1):126-33 [17179983.001]
  • [Cites] Am J Pathol. 2007 Apr;170(4):1370-8 [17392175.001]
  • [Cites] Breast Cancer Res. 2007;9(4):R55 [17711569.001]
  • [Cites] Oligonucleotides. 2007 Fall;17(3):327-35 [17854272.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Jul 4;371(3):531-5 [18452707.001]
  • [Cites] Cell. 1991 May 31;65(5):737-52 [1904008.001]
  • [Cites] Oncogene. 1993 Nov;8(11):3161-4 [8414519.001]
  • [Cites] Nature. 1999 Jan 14;397(6715):164-8 [9923679.001]
  • [Cites] Mol Cell Biol. 2000 Jan;20(1):273-85 [10594030.001]
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4736-45 [12183433.001]
  • (PMID = 21637439.001).
  • [ISSN] 1678-4685
  • [Journal-full-title] Genetics and molecular biology
  • [ISO-abbreviation] Genet. Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Other-IDs] NLM/ PMC3036904
  • [Keywords] NOTNLM ; Bmi-1 / RNA interference / breast cancer / doxorubicin / retrovirus vector
  •  go-up   go-down


67. Nasir S, Aydin MA: Versatility of free SCIA/SIEA flaps in head and neck defects. Ann Plast Surg; 2010 Jul;65(1):32-7
MedlinePlus Health Information. consumer health - After Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenocarcinoma / surgery. Adolescent. Adult. Aged. Bone Transplantation. Burns / surgery. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Child. Cicatrix / surgery. Facial Neoplasms / surgery. Female. Follow-Up Studies. Humans. Male. Maxilla / surgery. Maxillary Neoplasms / surgery. Middle Aged. Neck Injuries / surgery. Neoplasm Recurrence, Local / surgery. Reoperation. Scalp / surgery. Skin Neoplasms / surgery. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20574218.001).
  • [ISSN] 1536-3708
  • [Journal-full-title] Annals of plastic surgery
  • [ISO-abbreviation] Ann Plast Surg
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Lovrić E, Gatalica Z, Eyzaguirre E, Kruslin B: Expression of maspin and glutathionine-S-transferase-pi in normal human prostate and prostatic carcinomas. Appl Immunohistochem Mol Morphol; 2010 Oct;18(5):429-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN: Maspin and GST-pi expression were assessed in needle core and transurethral resection prostatic biopsies from 42 patients (34 with carcinoma, and 8 with normal prostate gland) using immunohistochemical methods.
  • RESULTS: Maspin and GST-pi were strongly and consistently coexpressed in the cytoplasm of basal cells of normal prostatic glands, whereas normal luminal cells were inconsistently weakly positive.
  • Prostatic adenocarcinomas overexpressed maspin in 27/34 cases (79%).
  • CONCLUSION: Consistent coexpression of maspin and GST-pi was observed in basal cells of the prostatic glands, which could be used as an additional immunohistochemical test in the evaluation of prostatic malignancy.
  • Prostatic adenocarcinomas express maspin in an aberrant nuclear distribution without coexpresion of GST-pi.
  • These results indicate a deregulation of expression of maspin and GST-pi in prostatic adenocarcinomas.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20453817.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / SERPIN-B5; 0 / Serpins; EC 2.5.1.18 / Glutathione S-Transferase pi
  •  go-up   go-down


69. McCormick DL, Rao KV, Johnson WD, Bosland MC, Lubet RA, Steele VE: Null activity of selenium and vitamin e as cancer chemopreventive agents in the rat prostate. Cancer Prev Res (Phila); 2010 Mar;3(3):381-92
Hazardous Substances Data Bank. N-NITROSO-N-METHYLUREA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After stimulation of prostate epithelial cell proliferation by a sequential regimen of cyproterone acetate followed by testosterone propionate, male Wistar-Unilever rats received a single i.v. injection of N-methyl-N-nitrosourea (MNU) followed by chronic androgen stimulation via subcutaneous implantation of testosterone pellets.
  • At 1 week post-MNU, groups of carcinogen-treated rats (39-44/group) were fed either a basal diet or a basal diet supplemented with l-selenomethionine (3 or 1.5 mg/kg diet; study 1), dl-alpha-tocopherol (vitamin E, 4,000 or 2,000 mg/kg diet; study 2), l-selenomethionine + vitamin E (3 + 2,000 mg/kg diet or 3 + 500 mg/kg diet; study 3), or selenized yeast (target selenium levels of 9 or 3 mg/kg diet; study 4).

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Vitamin E.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SELENIUM COMPOUNDS .
  • Hazardous Substances Data Bank. SELENIUM METHIONINE .
  • Hazardous Substances Data Bank. CYPROTERONE ACETATE .
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • Hazardous Substances Data Bank. VITAMIN E .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Epidemiol. 1991 Aug;1(5):385-93 [1669519.001]
  • [Cites] Cancer Res. 1990 Feb 1;50(3):700-9 [2105161.001]
  • [Cites] JAMA. 1996 Dec 25;276(24):1957-63 [8971064.001]
  • [Cites] Am J Clin Oncol. 1997 Feb;20(1):36-9 [9020285.001]
  • [Cites] Br J Urol. 1998 May;81(5):730-4 [9634050.001]
  • [Cites] Cancer Res. 1998 Aug 1;58(15):3282-8 [9699656.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):521-4 [9973192.001]
  • [Cites] Eur Urol. 1999;35(5-6):459-63 [10325505.001]
  • [Cites] Eur Urol. 1999;35(5-6):464-7 [10325506.001]
  • [Cites] Cancer Res. 1999 Jul 1;59(13):3084-9 [10397249.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 19;97(2):94-102 [15657339.001]
  • [Cites] Proc Nutr Soc. 2005 Nov;64(4):527-42 [16313696.001]
  • [Cites] Annu Rev Med. 2006;57:49-63 [16409136.001]
  • [Cites] Am J Clin Nutr. 2007 Jan;85(1):209-17 [17209198.001]
  • [Cites] Carcinogenesis. 2007 Feb;28(2):398-403 [16952912.001]
  • [Cites] Nutr Cancer. 2007;57(2):184-93 [17571952.001]
  • [Cites] Cancer Causes Control. 2008 Feb;19(1):75-87 [17943452.001]
  • [Cites] J Toxicol Environ Health B Crit Rev. 2008 Mar;11(3-4):242-59 [18368555.001]
  • [Cites] Urologe A. 2008 May;47(5):616-9 [18231770.001]
  • [Cites] Mini Rev Med Chem. 2008 Jun;8(7):657-68 [18537721.001]
  • [Cites] Am J Clin Nutr. 2008 Dec;88(6):1567-75 [19064517.001]
  • [Cites] JAMA. 2009 Jan 7;301(1):52-62 [19066368.001]
  • [Cites] JAMA. 2009 Jan 7;301(1):39-51 [19066370.001]
  • [Cites] Urology. 2009 May;73(5 Suppl):S36-43 [19375625.001]
  • [Cites] Urology. 2009 May;73(5 Suppl):S4-10 [19375626.001]
  • [Cites] J Urol. 2001 Oct;166(4):1311-5 [11547064.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Oct;10(10):1069-76 [11588133.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Jul;11(7):630-9 [12101110.001]
  • [Cites] Prostate. 2003 Feb 15;54(3):238-47 [12518329.001]
  • [Cites] Eur J Cancer Prev. 2002 Aug;11 Suppl 2:S18-27 [12570331.001]
  • [Cites] N Engl J Med. 2003 Jul 17;349(3):215-24 [12824459.001]
  • [Cites] J Natl Cancer Inst. 2004 May 5;96(9):696-703 [15126606.001]
  • [Cites] Science. 1973 Feb 9;179(4073):588-90 [4686466.001]
  • [Cites] Fed Proc. 1975 Oct;34(11):2083-9 [1100437.001]
  • [Cites] Bioinorg Chem. 1977;7(1):23-31 [856291.001]
  • [Cites] Am J Clin Nutr. 1982 May;35(5):1076-88 [7044092.001]
  • [Cites] J Chromatogr. 1982 Sep 10;231(2):439-44 [7130321.001]
  • [Cites] Anal Biochem. 1982 Nov 1;126(2):242-5 [6297332.001]
  • [Cites] Fed Proc. 1983 Apr;42(6):1721-5 [6832393.001]
  • [Cites] Lancet. 1983 Jul 16;2(8342):130-4 [6134981.001]
  • [Cites] J Assoc Off Anal Chem. 1983 Jul;66(4):918-26 [6885699.001]
  • [Cites] J Biol Chem. 1984 Jan 25;259(2):1043-50 [6693375.001]
  • [Cites] J Natl Cancer Inst. 1986 Dec;77(6):1281-6 [3467117.001]
  • [Cites] Proc Soc Exp Biol Med. 1986 Dec;183(3):311-20 [3540970.001]
  • [Cites] Nutr Cancer. 1988;11(1):21-33 [2832833.001]
  • [Cites] Pathol Res Pract. 1995 Sep;191(9):838-41 [8606862.001]
  • (PMID = 20145190.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CN / N01-CN-95113; United States / NCI NIH HHS / CA / P30 CA016087; United States / NCI NIH HHS / CN / N01 CN095113; United States / NIEHS NIH HHS / ES / P30-ES-00260; United States / NCI NIH HHS / CN / N01 CN065120; United States / NIEHS NIH HHS / ES / P30 ES000260; United States / NCI NIH HHS / CA / P30-CA-16087; United States / NCI NIH HHS / CA / N01 CN35566; United States / NCI NIH HHS / CN / CN35566-02; United States / NCI NIH HHS / CN / N01-CN-65120; United States / NCI NIH HHS / CN / N01 CN35566-02; United States / NCI NIH HHS / CN / N01-CN-35566-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Alkylating Agents; 0 / Androgens; 0 / Antioxidants; 0 / Selenium Compounds; 1406-18-4 / Vitamin E; 3XMK78S47O / Testosterone; 4KM2BN5JHF / Cyproterone Acetate; 684-93-5 / Methylnitrosourea; 964MRK2PEL / Selenomethionine; H4N855PNZ1 / alpha-Tocopherol
  • [Other-IDs] NLM/ NIHMS161245; NLM/ PMC2945242
  •  go-up   go-down


70. Burrows N, Resch J, Cowen RL, von Wasielewski R, Hoang-Vu C, West CM, Williams KJ, Brabant G: Expression of hypoxia-inducible factor 1 alpha in thyroid carcinomas. Endocr Relat Cancer; 2010 Mar;17(1):61-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We evaluated the regulation of HIF-1 alpha and target gene expression in primary thyroid carcinomas and thyroid carcinoma cell lines (BcPAP, WRO, FTC-133 and 8505c).
  • High basal and hypoxia-induced expression of HIF-1 alpha in FTC-133 cells that harbour a phosphatase and tensin homologue (PTEN) mutation was reduced by introduction of wild-type PTEN.
  • Similarly, pharmacological inhibition of the phosphoinositide 3-kinase (PI3K) pathway using LY294002 inhibited HIF-1 alpha and HIF-1 alpha targets in all cell lines, including those with B-RAF mutations (BcPAP and 8505c).

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. COBALT, ELEMENTAL .
  • Hazardous Substances Data Bank. COBALTOUS CHLORIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Thyroid. 2002 Sep;12(9):747-54 [12481939.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Apr;87(4):1737-42 [11932308.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1454-7 [12670889.001]
  • [Cites] Oncogene. 2003 May 22;22(21):3213-20 [12761491.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4561-7 [12907632.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):1873-85 [14578187.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Nov;88(11):5392-8 [14602779.001]
  • [Cites] Cancer Res. 2004 Feb 15;64(4):1396-402 [14973055.001]
  • [Cites] J Clin Pathol. 2004 May;57(5):504-12 [15113858.001]
  • [Cites] J Natl Cancer Inst. 1993 Feb 3;85(3):200-6 [8423624.001]
  • [Cites] Cytogenet Cell Genet. 1995;69(3-4):220-2 [7698017.001]
  • [Cites] Cell Cycle. 2004 Sep;3(9):1107-10 [15326390.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1197-207 [15752902.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):213-22 [15850924.001]
  • [Cites] Radiother Oncol. 2005 Apr;75(1):89-98 [15878106.001]
  • [Cites] Biochim Biophys Acta. 2005 Jul 25;1755(2):107-20 [15994012.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7259-66 [16103077.001]
  • [Cites] Oncol Rep. 2005 Dec;14(6):1499-504 [16273245.001]
  • [Cites] Mol Pharmacol. 2006 Feb;69(2):411-8 [16254058.001]
  • [Cites] Nat Rev Cancer. 2006 Apr;6(4):292-306 [16557281.001]
  • [Cites] Nature. 2006 May 25;441(7092):437-43 [16724055.001]
  • [Cites] Sci STKE. 2006 May 30;2006(337):pe25 [16738063.001]
  • [Cites] Pathol Res Pract. 2006;202(11):759-65 [17029809.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1161-70 [17317825.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):3177-84 [17409425.001]
  • [Cites] Cancer. 2007 Jul 1;110(1):38-46 [17520704.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Jul;92(7):2840-3 [17488796.001]
  • [Cites] Endocrinol Metab Clin North Am. 2008 Jun;37(2):375-87, viii-ix [18502332.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Oct;93(10):3943-9 [18682506.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Nov;93(11):4331-41 [18713817.001]
  • [Cites] Cancer Res. 2009 Jan 1;69(1):358-68 [19118021.001]
  • [Cites] Cancer Lett. 2009 Sep 8;282(1):109-15 [19342157.001]
  • [Cites] Hum Mol Genet. 2001 Feb 1;10(3):251-8 [11159944.001]
  • [Cites] Int J Cancer. 2003 Mar 10;104(1):85-91 [12532423.001]
  • (PMID = 19808899.001).
  • [ISSN] 1479-6821
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] ENG
  • [Grant] United Kingdom / Cancer Research UK / / C7820/A8696
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Chromones; 0 / Glucose Transporter Type 1; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Morpholines; 0 / Neoplasm Proteins; 0 / RNA, Small Interfering; 154447-36-6 / 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; 3G0H8C9362 / Cobalt; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases; EVS87XF13W / cobaltous chloride
  • [Other-IDs] NLM/ PMC2828807
  •  go-up   go-down


71. Immonen E, Serpi R, Vähäkangas K, Myllynen P: Responses of PhIP (2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine) in MCF-7 cells are culture condition dependent. Chem Biol Interact; 2009 Nov 10;182(1):73-83
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Effects of PhIP and estradiol on cell viability and proliferation were determined by ATP analysis and Ki-67 immunocytochemistry.
  • Expression of estrogen receptor alpha, cell stress markers (p53 and ERK) and estrogen responsive proteins (c-myc and ERK) were immunoblotted.
  • All concentrations of estradiol induced cell proliferation, viability and changes in protein expression, typical for estrogenic responses.
  • No changes in protein expressions by PhIP were noted, not even when switching cells from steroid-containing to -deprived medium which down-regulated the expression of proteins at basal level.
  • [MeSH-major] Carcinogens / pharmacology. Cell Culture Techniques / methods. Estrogen Receptor alpha / metabolism. Imidazoles / pharmacology
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenosine Triphosphate / metabolism. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Cell Line, Tumor. Cell Survival / drug effects. Cell Survival / physiology. Dose-Response Relationship, Drug. Estradiol / pharmacology. Extracellular Signal-Regulated MAP Kinases / metabolism. Humans. Immunoblotting. Immunohistochemistry. Ki-67 Antigen / metabolism. Proto-Oncogene Proteins c-myc / metabolism. Tumor Suppressor Protein p53 / metabolism

  • Hazardous Substances Data Bank. 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19647730.001).
  • [ISSN] 1872-7786
  • [Journal-full-title] Chemico-biological interactions
  • [ISO-abbreviation] Chem. Biol. Interact.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Estrogen Receptor alpha; 0 / Imidazoles; 0 / Ki-67 Antigen; 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-myc; 0 / Tumor Suppressor Protein p53; 4TI98Z838E / Estradiol; 8L70Q75FXE / Adenosine Triphosphate; 909C6UN66T / 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
  •  go-up   go-down


72. Zheng HC, Saito H, Masuda S, Wang ZG, Takano Y: Cytoplasmic and nuclear maspin expression in lung carcinomas: an immunohistochemical study using tissue microarrays. Appl Immunohistochem Mol Morphol; 2008 Oct;16(5):459-65
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, maspin expression was examined on tissue microarrays containing lung carcinoma (n=155) and adjacent noncancerous tissue (n=20) and also 4 lung carcinoma cell lines (LC-1/Sq, LC-IF, PC-14, and AoI) by immunohistochemistry.
  • Maspin expression showed positive nuclear staining in basal cells, LC-IF, and PC-14 cell lines, and also cytoplasmic immunoreactivity in secretory and ciliated cells, LC-1/Sq cell line.
  • Cytoplasmic staining was the lowest in adenocarcinoma (AD) and the highest in squamous cell carcinoma as compared with other types of lung carcinoma (P<0.05), and positively correlated with expression of p53 and caspase-3 (P<0.05).
  • The nuclear maspin expression gradually increased through squamous cell carcinoma, AD, large cell carcinoma to small cell carcinoma (P<0.05) and was also positively associated with the levels of vascular epithelial growth factor and extracellular matrix metalloproteinase inducer expression (P<0.05).
  • Kaplan-Meier analysis indicated that the cytoplasmic or nuclear maspin expression was not a good prognostic marker for lung carcinomas overall (P>0.05), but the cytoplasmic pattern pointed to good survival for AD cases (P<0.05).
  • The cytoplasmic maspin may play an important role in lung carcinomas by regulating apoptosis and thus is a favorable prognostic marker for AD patients, whereas the nuclear location may be linked to promotion of angiogenesis.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18665036.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / SERPIN-B5; 0 / Serpins
  •  go-up   go-down


73. Abdel-Fatah TM, Powe DG, Hodi Z, Reis-Filho JS, Lee AH, Ellis IO: Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: further evidence to support the concept of low nuclear grade breast neoplasia family. Am J Surg Pathol; 2008 Apr;32(4):513-23
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: further evidence to support the concept of low nuclear grade breast neoplasia family.
  • Precursor lesions including columnar cell lesions, atypical ductal hyperplasia, ductal carcinoma in situ, usual epithelial hyperplasia, and lobular neoplasia were compared with matching "morphologically normal" terminal lobular duct units and matching invasive carcinoma.
  • The epithelial cells in the putative precursor flat epithelial atypia, atypical ductal hyperplasia, lobular neoplasia, ductal carcinoma in situ lesions, and their coexisting LNGBC were negative for basal and myoepithelial markers, but positive for CK19/18/8, estrogen receptor (ER)-alpha, Bcl-2, and cyclin D1.
  • Our findings support the concept that progression of LNGBC to HNGBC (basal-like or HER2+) phenotype is an unlikely biologic phenomenon.
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / pathology. Ataxia Telangiectasia Mutated Proteins. Carcinoma, Intraductal, Noninfiltrating / chemistry. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / chemistry. Carcinoma, Lobular / pathology. Cell Cycle Proteins / analysis. Cyclin D. Cyclins / analysis. DNA-Binding Proteins / analysis. Estrogen Receptor alpha / analysis. Estrogen Receptor beta / analysis. Evolution, Molecular. Female. Humans. Hyperplasia. Immunohistochemistry. Keratin-18 / analysis. Keratin-19 / analysis. Keratin-8 / analysis. Neoplasm Invasiveness. Neoplasm Staging. Phenotype. Protein-Serine-Threonine Kinases / analysis. Proto-Oncogene Proteins c-bcl-2 / analysis. Tissue Array Analysis. Tumor Suppressor Protein p53 / analysis. Tumor Suppressor Proteins / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18223478.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Cyclin D; 0 / Cyclins; 0 / DNA-Binding Proteins; 0 / Estrogen Receptor alpha; 0 / Estrogen Receptor beta; 0 / KRT18 protein, human; 0 / KRT8 protein, human; 0 / Keratin-18; 0 / Keratin-19; 0 / Keratin-8; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


74. Martinez VG, Williams KJ, Stratford IJ, Clynes M, O'Connor R: Overexpression of cytochrome P450 NADPH reductase sensitises MDA 231 breast carcinoma cells to 5-fluorouracil: possible mechanisms involved. Toxicol In Vitro; 2008 Apr;22(3):582-8
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MDA 231 breast adenocarcinoma cells transfected with human P450R (MDA R4) or an empty vector (MDA EV) were exposed to a series of commonly used chemotherapeutic drugs.
  • Overexpression of P450R did not affect cell sensitivity to cisplatin, mitoxantrone, paclitaxel, docetaxel, vincristine or etoposide.
  • Levels of NADPH were considerably decreased in MDA R4 as compared to MDA EV cells, while reactive oxygen species (ROS) production was increased in MDA R4 cells in basal conditions, showing no significant further increase after treatment with mitomycin C or 5-fluorouracil.
  • [MeSH-minor] Antibiotics, Antineoplastic / metabolism. Antibiotics, Antineoplastic / pharmacology. Antineoplastic Agents, Phytogenic / metabolism. Antineoplastic Agents, Phytogenic / pharmacology. Blotting, Western. Cell Line, Tumor. Cell Survival. Female. Glutathione / metabolism. Humans. Microsomes / metabolism. Mitomycin / metabolism. Mitomycin / pharmacology. NADP / metabolism. Reactive Oxygen Species / metabolism. Transfection. Vincristine / metabolism. Vincristine / pharmacology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18191533.001).
  • [ISSN] 0887-2333
  • [Journal-full-title] Toxicology in vitro : an international journal published in association with BIBRA
  • [ISO-abbreviation] Toxicol In Vitro
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0500366; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / Reactive Oxygen Species; 50SG953SK6 / Mitomycin; 53-59-8 / NADP; 5J49Q6B70F / Vincristine; EC 1.6.2.4 / NADPH-Ferrihemoprotein Reductase; GAN16C9B8O / Glutathione; U3P01618RT / Fluorouracil
  •  go-up   go-down


75. Dentice M, Luongo C, Huang S, Ambrosio R, Elefante A, Mirebeau-Prunier D, Zavacki AM, Fenzi G, Grachtchouk M, Hutchin M, Dlugosz AA, Bianco AC, Missero C, Larsen PR, Salvatore D: Sonic hedgehog-induced type 3 deiodinase blocks thyroid hormone action enhancing proliferation of normal and malignant keratinocytes. Proc Natl Acad Sci U S A; 2007 Sep 4;104(36):14466-71
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Sonic hedgehog (Shh) pathway plays a critical role in hair follicle physiology and is constitutively active in basal cell carcinomas (BCCs), the most common human malignancy.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Feb 1;97(3):1287-92 [10655523.001]
  • [Cites] Neuron. 1999 Dec;24(4):871-8 [10624950.001]
  • [Cites] Nature. 2001 May 17;411(6835):349-54 [11357142.001]
  • [Cites] Endocr Rev. 2002 Feb;23(1):38-89 [11844744.001]
  • [Cites] Nature. 2002 May 16;417(6886):299-304 [12015606.001]
  • [Cites] Nat Rev Cancer. 2002 May;2(5):361-72 [12044012.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5308-16 [12235001.001]
  • [Cites] Genes Dev. 2002 Nov 1;16(21):2743-8 [12414725.001]
  • [Cites] J Invest Dermatol. 2002 Dec;119(6):1449-55 [12485453.001]
  • [Cites] Curr Top Dev Biol. 2003;53:1-114 [12509125.001]
  • [Cites] Genes Dev. 2003 Jan 15;17(2):282-94 [12533516.001]
  • [Cites] Dev Biol. 2003 Mar 15;255(2):238-48 [12648487.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jun;88(6):2825-30 [12788895.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):903-11 [14737121.001]
  • [Cites] Cancer Lett. 2004 Feb 20;204(2):145-57 [15013214.001]
  • [Cites] Mol Cell Biol. 2004 Sep;24(18):7863-77 [15340050.001]
  • [Cites] Hum Mol Genet. 2004 Nov 1;13(21):2595-606 [15367491.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Nov;77(5):1198-202 [8077312.001]
  • [Cites] Curr Biol. 1998 Sep 24;8(19):1058-68 [9768360.001]
  • [Cites] Development. 1999 Sep;126(17):3915-24 [10433919.001]
  • [Cites] Oncogene. 2004 Nov 18;23(54):8756-65 [15467737.001]
  • [Cites] Mol Cell Biol. 2005 Jan;25(1):124-35 [15601836.001]
  • [Cites] Genes Dev. 2005 Jan 15;19(2):214-23 [15625189.001]
  • [Cites] Dev Cell. 2005 Feb;8(2):143-51 [15736317.001]
  • [Cites] Nat Cell Biol. 2005 Jul;7(7):698-705 [15965468.001]
  • [Cites] N Engl J Med. 2005 Aug 25;353(8):811-22 [16120861.001]
  • [Cites] Thyroid. 2005 Aug;15(8):815-21 [16131324.001]
  • [Cites] Thyroid. 2005 Aug;15(8):823-34 [16131325.001]
  • [Cites] Endocrinology. 2005 Dec;146(12):5128-34 [16150911.001]
  • [Cites] Mol Endocrinol. 2005 Dec;19(12):3126-36 [16037131.001]
  • [Cites] J Clin Invest. 2006 Jan;116(1):249-60 [16395407.001]
  • [Cites] Nat Rev Cancer. 2006 Apr;6(4):270-80 [16541145.001]
  • [Cites] Exp Dermatol. 2006 Sep;15(9):667-77 [16881963.001]
  • [Cites] J Clin Invest. 2006 Oct;116(10):2571-9 [17016550.001]
  • [Cites] Genes Dev. 1999 Nov 1;13(21):2828-37 [10557210.001]
  • [Cites] Endocrinology. 2000 Jan;141(1):229-37 [10614643.001]
  • [Cites] N Engl J Med. 2000 Jul 20;343(3):185-9 [10900278.001]
  • (PMID = 17720805.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK044128; United States / NIDDK NIH HHS / DK / DK44128; United States / NCI NIH HHS / CA / CA087837-07; United States / NIAMS NIH HHS / AR / R01 AR045973; United States / NCI NIH HHS / CA / R01 CA087837; United States / NIAMS NIH HHS / AR / AR45973; United States / NCI NIH HHS / CA / R01 CA087837-07; United States / NCI NIH HHS / CA / CA87837
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gli protein; 0 / Hedgehog Proteins; 0 / Hormone Antagonists; 0 / Oncogene Proteins; 0 / Shh protein, mouse; 0 / Thyroid Hormones; 0 / Trans-Activators; EC 1.11.1.- / iodothyronine deiodinase type III; EC 1.11.1.8 / Iodide Peroxidase
  • [Other-IDs] NLM/ PMC1964817
  •  go-up   go-down


76. Guay S, Akoum A: Stable inhibition of interleukin 1 receptor type II in Ishikawa cells augments secretion of matrix metalloproteinases: possible role in endometriosis pathophysiology. Reproduction; 2007 Sep;134(3):525-34
MedlinePlus Health Information. consumer health - Endometriosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Stable clones of Ishikawa adenocarcinoma endometrial cells transfected with IL1R2 antisense and showing downregulation of IL1R2 protein expression, or with the empty expression vector alone and showing no noticeable difference in IL1R2 expression, were selected.
  • In these cells, IL1R2 expression was markedly reduced, compared with non-transfected cells or cells transfected with the empty vector, and there was a significant increase in the basal and the IL1-beta (IL1B)-induced levels of matrix metalloproteinase (MMP)-2 and MMP-9 secretion.
  • [MeSH-minor] Blotting, Western / methods. Cell Line, Tumor. Electrophoresis, Polyacrylamide Gel. Female. Fluorescent Antibody Technique. Humans. Interleukin-1beta / pharmacology. Matrix Metalloproteinase 2 / secretion. Matrix Metalloproteinase 9 / secretion. Oligonucleotides, Antisense. Receptors, Interleukin-1 Type I / analysis. Receptors, Interleukin-1 Type I / metabolism. Tissue Inhibitor of Metalloproteinase-1 / analysis. Tissue Inhibitor of Metalloproteinase-1 / secretion. Transfection / methods

  • Genetic Alliance. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17709570.001).
  • [ISSN] 1470-1626
  • [Journal-full-title] Reproduction (Cambridge, England)
  • [ISO-abbreviation] Reproduction
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Interleukin-1beta; 0 / Oligonucleotides, Antisense; 0 / Receptors, Interleukin-1 Type I; 0 / Receptors, Interleukin-1 Type II; 0 / Tissue Inhibitor of Metalloproteinase-1; EC 3.4.24.- / Matrix Metalloproteinases; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


77. Morton JP, Lewis BC: Shh signaling and pancreatic cancer: implications for therapy? Cell Cycle; 2007 Jul 1;6(13):1553-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hedgehog signaling has been implicated in the development of several human cancers, including small cell lung carcinomas, medulloblastomas, basal cell carcinomas, and digestive tract tumors.
  • Elevated levels of pathway components are observed in pancreatic ductal adenocarcinoma (PDAC) precursor lesions, and these levels increase further as lesions progress to more advanced stages.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17611415.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Hedgehog Proteins; 0 / SHH protein, human
  • [Number-of-references] 41
  •  go-up   go-down


78. Cappello F, Di Stefano A, David S, Rappa F, Anzalone R, La Rocca G, D'Anna SE, Magno F, Donner CF, Balbi B, Zummo G: Hsp60 and Hsp10 down-regulation predicts bronchial epithelial carcinogenesis in smokers with chronic obstructive pulmonary disease. Cancer; 2006 Nov 15;107(10):2417-24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A higher frequency of adenocarcinoma has been reported in patients with COPD.
  • Heat shock proteins (Hsps) are implicated in tumoral cell growth and differentiation.
  • METHOD: An immunohistochemical study was performed for Hsp60 and Hsp10 in bronchial biopsies from 35 COPD (postbronchodilator forced expiratory volume in 1 second [FEV(1)]: 53 +/- 19% [mean +/- SD]) patients with a history of smoking (53 +/- 34 pack/years) and in 10 patients with adenocarcinoma or adenosquamous carcinoma (ASC).
  • RESULTS.: In smokers with COPD, 10 out of 35 patients had a normal bronchial epithelium (NBE), 12 showed basal cell hyperplasia (BCH), 5 squamous metaplasia (SM), and 8 dysplasia (Dy).
  • [MeSH-major] Carcinoma, Bronchogenic / diagnosis. Chaperonin 10 / metabolism. Chaperonin 60 / metabolism. Lung Neoplasms / diagnosis. Pulmonary Disease, Chronic Obstructive / complications. Smoking / adverse effects
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Aged. Blotting, Western. Carcinoma, Adenosquamous / complications. Carcinoma, Adenosquamous / diagnosis. Carcinoma, Adenosquamous / pathology. Disease Progression. Down-Regulation. Humans. Middle Aged. Prognosis. Respiratory Mucosa / pathology


79. Mrena J, Wiksten JP, Nordling S, Kokkola A, Ristimäki A, Haglund C: MMP-2 but not MMP-9 associated with COX-2 and survival in gastric cancer. J Clin Pathol; 2006 Jun;59(6):618-23
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND AIM: Matrix metalloproteinases (MMPs) MMP-2 and MMP-9 can degrade type IV collagen of extracellular matrix and basal membranes.
  • [MeSH-major] Adenocarcinoma / enzymology. Biomarkers, Tumor / metabolism. Cyclooxygenase 2 / metabolism. Matrix Metalloproteinase 2 / metabolism. Stomach Neoplasms / enzymology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 1999 Nov;189(3):300-8 [10547590.001]
  • [Cites] Clin Cancer Res. 2003 May;9(5):1741-9 [12738729.001]
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4705-8 [10987272.001]
  • [Cites] Clin Cancer Res. 2000 Sep;6(9):3581-4 [10999748.001]
  • [Cites] Ann Surg. 2001 Feb;233(2):183-8 [11176123.001]
  • [Cites] Br J Cancer. 2001 Feb 2;84(3):335-9 [11161397.001]
  • [Cites] Cancer Lett. 2003 May 30;195(1):43-51 [12767510.001]
  • [Cites] Cancer Res. 2003 Jun 15;63(12):3032-6 [12810622.001]
  • [Cites] J Clin Gastroenterol. 2003 Jul;37(1):28-33 [12811205.001]
  • [Cites] World J Gastroenterol. 2003 Jul;9(7):1421-6 [12854133.001]
  • [Cites] Br J Surg. 2003 Sep;90(9):1055-67 [12945071.001]
  • [Cites] Gut. 2004 Feb;53(2):195-200 [14724149.001]
  • [Cites] Am J Clin Pathol. 2004 Jan;121(1):78-86 [14750244.001]
  • [Cites] EMBO J. 2004 Apr 7;23(7):1669-78 [15014433.001]
  • [Cites] Histopathology. 2004 May;44(5):490-7 [15139997.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):6938-45 [15501972.001]
  • [Cites] Breast Cancer Res Treat. 1993;24(3):209-18 [8435476.001]
  • [Cites] Mod Pathol. 1994 Feb;7(2):220-5 [8008747.001]
  • [Cites] Semin Oncol. 1996 Jun;23(3):316-24 [8658215.001]
  • [Cites] Br J Cancer. 1996 Aug;74(3):413-7 [8695357.001]
  • [Cites] Cell. 1996 Nov 29;87(5):803-9 [8945508.001]
  • [Cites] Cancer Res. 1997 Apr 1;57(7):1276-80 [9102213.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3336-40 [9096394.001]
  • [Cites] Oncology. 1998 Mar-Apr;55(2):152-60 [9499190.001]
  • [Cites] Clin Exp Metastasis. 1998 Jan;16(1):62-73 [9502078.001]
  • [Cites] FASEB J. 1998 Sep;12(12):1063-73 [9737710.001]
  • [Cites] Gut. 1998 Dec;43(6):791-7 [9824606.001]
  • [Cites] Am J Gastroenterol. 1999 Feb;94(2):451-5 [10022645.001]
  • [Cites] Int J Cancer. 1999 Aug 20;84(4):400-3 [10404093.001]
  • [Cites] Breast Cancer Res Treat. 2005 Feb;89(3):215-20 [15754118.001]
  • [Cites] Biochimie. 2005 Mar-Apr;87(3-4):287-97 [15781315.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2234-42 [15781636.001]
  • [Cites] World J Gastroenterol. 2005 Jun 7;11(21):3197-203 [15929167.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):519-25 [10690533.001]
  • [Cites] Hepatology. 2001 Apr;33(4):860-7 [11283850.001]
  • [Cites] Cancer Lett. 2001 Jul 26;168(2):133-40 [11403917.001]
  • [Cites] Clin Cancer Res. 2001 Jul;7(7):1923-31 [11448905.001]
  • [Cites] J Pathol. 2002 Feb;196(2):171-9 [11793368.001]
  • [Cites] Nat Rev Cancer. 2001 Oct;1(1):11-21 [11900248.001]
  • [Cites] Histopathology. 2001 Dec;39(6):597-602 [11903578.001]
  • [Cites] Digestion. 2002;66(4):222-9 [12592098.001]
  • [Cites] World J Gastroenterol. 2003 Apr;9(4):674-7 [12679908.001]
  • [Cites] World J Gastroenterol. 2003 May;9(5):899-904 [12717827.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7362-8 [16243808.001]
  • (PMID = 16731602.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.14.99.1 / Cyclooxygenase 2; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  • [Other-IDs] NLM/ PMC1860392
  •  go-up   go-down


80. Zhang Z, Huettner PC, Nguyen L, Bidder M, Funk MC, Li J, Rader JS: Aberrant promoter methylation and silencing of the POU2F3 gene in cervical cancer. Oncogene; 2006 Aug 31;25(39):5436-45
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is also a candidate tumor suppressor gene in cervical cancer (CC) because it lies in a critical loss of heterozygosity region on 11q23.3 in that cancer, and its expression is lost in more than 50% of CC tumors and cell lines.
  • POU2F3 expression was downregulated and inversely correlated with promoter hypermethylation in 10 out of 11 CC cell lines.
  • Immunohistochemical analysis on a cervical tissue microarray detected POU2F3 protein in the epithelium above the basal layer.
  • As the disease progressed, expression also decreased, especially in invasive squamous cell cancer (70% loss).
  • [MeSH-minor] Adenocarcinoma / genetics. Biopsy. Carcinoma, Squamous Cell / genetics. Cell Line, Tumor. DNA Methylation. DNA Primers. Female. Gene Expression Regulation, Neoplastic. Gene Silencing. Genes, Tumor Suppressor. Genome, Human. Humans. Oligonucleotide Array Sequence Analysis. Restriction Mapping

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16607278.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA94141-04; United States / NCI NIH HHS / CA / P30 CA91842
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Homeodomain Proteins; 0 / POU Domain Factors; 0 / transcription factor Brn-2
  •  go-up   go-down


81. Gold BD: Is gastroesophageal reflux disease really a life-long disease: do babies who regurgitate grow up to be adults with GERD complications? Am J Gastroenterol; 2006 Mar;101(3):641-4
MedlinePlus Health Information. consumer health - Reflux in Infants.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The infants, part of a larger therapeutic trial, were originally referred to the investigators for GERD evaluation, failed a 2-wk lifestyle modification trial, and were randomized to placebo or intervention (acid suppression and prokinetic therapy).
  • However, none of the 10 completers had normalization of biopsy assessments, i.e., basal cell layer <25% and papillary height <53% of epithelial thickness.
  • The lack of concordant improvement of the esophageal histology should raise concern regarding sub-clinical persistence of ongoing esophageal insult, which might in the long-term, predispose the individual to GERD-related complications, such as strictures, Barrett's esophagus, and/or esophageal adenocarcinoma.
  • (1) population-based, epidemiological studies of GERD with appropriate case and control definitions, (2) characterization of genetically "at-risk" individuals (i.e., with childhood-onset GERD) for severe GERD sequelae (e.g., Barrett's esophagus, esophageal adenocarcinoma), or potentially, (3) longitudinal, family cohort natural history studies with index pediatric GERD cases.
  • [MeSH-major] Gastroesophageal Reflux / diagnosis

  • Genetic Alliance. consumer health - Gastroesophageal Reflux.
  • MedlinePlus Health Information. consumer health - GERD.
  • MedlinePlus Health Information. consumer health - Reflux in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Am J Gastroenterol. 2006 Mar;101(3):628-40 [16542296.001]
  • (PMID = 16542297.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Ulcer Agents; 0 / Histamine Antagonists
  •  go-up   go-down


82. Wang GF, Lai MD, Yang RR, Chen PH, Su YY, Lv BJ, Sun LP, Huang Q, Chen SZ: Histological types and significance of bronchial epithelial dysplasia. Mod Pathol; 2006 Mar;19(3):429-37
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Squamous dysplasia and atypical adenomatous hyperplasia have been identified and classified as preinvasive lesions of squamous cell carcinoma and peripheral pulmonary adenocarcinoma, respectively.
  • By examining 114 resection lung specimens, we concluded that there are four histological patterns of bronchial epithelial dysplasia based on morphological features (basal cell dysplasia, columnar cell dysplasia, bronchial epithelial dysplasia with transitional differentiation, and squamous dysplasia).
  • Basal cell dysplasia was focally positive for cytokeratin (CK) 17 and 10/13; columnar cell dysplasia was generally positive for CK7, 8, and 18; bronchial epithelial dysplasia with transitional differentiation had a heterogeneous immunoprofile, while squamous dysplasia was positive for CK10/13 and focally positive for CK17.
  • (1) bronchial epithelium can develop various patterns of dysplasia with abnormal/ambiguous cell differentiation and abnormal expressions of p53 and Ki-67.
  • [MeSH-minor] Adult. Aged. Bronchial Neoplasms / metabolism. Bronchial Neoplasms / pathology. Carcinoma, Bronchogenic / metabolism. Carcinoma, Bronchogenic / pathology. Cell Differentiation. Epithelial Cells / chemistry. Epithelial Cells / pathology. Female. Humans. Immunohistochemistry. Keratins / analysis. Ki-67 Antigen / analysis. Male. Middle Aged. Respiratory Mucosa / chemistry. Respiratory Mucosa / pathology. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16415791.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; 68238-35-7 / Keratins
  •  go-up   go-down


83. Ozawa MG, Yao VJ, Chanthery YH, Troncoso P, Uemura A, Varner AS, Kasman IM, Pasqualini R, Arap W, McDonald DM: Angiogenesis with pericyte abnormalities in a transgenic model of prostate carcinoma. Cancer; 2005 Nov 15;104(10):2104-15
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Previous studies of the TRansgenic Adenocarcinoma of the Mouse Prostate (TRAMP) model vasculature suggest that, as tumors develop, vessels invade the glandular epithelium.
  • The authors used a new approach to characterize morphologic and architectural changes of blood vessels and pericytes during tumor development in TRAMP mice.
  • METHODS: Eighty-micron cryostat sections of normal prostate and three histopathologic stages of TRAMP tumor sections, classified by epithelial cell E-cadherin immunoreactivity, were immunostained with vascular endothelial cell and pericyte receptor antibodies and evaluated by confocal microscopy.
  • In the prostatic intraepithelial neoplasia (PIN) stage, vessels accompanied epithelial cell protrusions into the ductule lumen but remained in the connective tissue at the basal side of the epithelium.
  • Angiogenic blood vessels from poorly differentiated adenocarcinomas were tortuous, variable in caliber, and lacked the normal hierarchy.
  • [MeSH-major] Adenocarcinoma / blood supply. Neovascularization, Pathologic. Pericytes / pathology. Prostatic Intraepithelial Neoplasia / blood supply. Prostatic Neoplasms / blood supply

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society
  • (PMID = 16208706.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / P01 HL024136; United States / NHLBI NIH HHS / HL / HL-59157; United States / NHLBI NIH HHS / HL / HL-24136; United States / NCI NIH HHS / CA / P50 CA90270
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cadherins
  •  go-up   go-down


84. Takamura H, Yamashita H: Clinicopathological analysis of malignant eyelid tumor cases at Yamagata university hospital: statistical comparison of tumor incidence in Japan and in other countries. Jpn J Ophthalmol; 2005 Sep-Oct;49(5):349-54

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Data from our clinic: Among the total of 38 cases, 15 cases (39.5%) were diagnosed as basal cell carcinoma, 11 cases (28.9%) as sebaceous gland carcinoma, and 4 cases (10.5%) as squamous cell carcinoma.
  • In addition, three cases were malignant melanoma, two adenocarcinoma, one Merkel cell carcinoma, one malignant peripheral nerve sheath tumor, and one malignant lymphoma.
  • The prognosis of the cases with basal cell carcinoma and squamous cell carcinoma was good, and that of the other tumors was relatively poor.
  • During the same period, in Caucasians, basal cell carcinoma constituted about 80%-90% of the malignant eyelid tumors, whereas in Japan and Asian countries, basal cell carcinoma, sebaceous gland carcinoma, and squamous cell carcinoma each constituted about 20%-40%.
  • CONCLUSIONS: A racial difference in the incidence of basal cell carcinoma, sebaceous gland carcinoma, and squamous cell carcinoma can be considered in making a diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eye (Lond). 2004 Feb;18(2):135-8 [14762403.001]
  • [Cites] Br J Ophthalmol. 1999 May;83(5):595-7 [10216061.001]
  • [Cites] Bull Soc Ophtalmol Fr. 1986 Mar;86(3):323-4, 329-33 [3802345.001]
  • [Cites] Arch Ophthalmol. 1996 Jan;114(1):108-9 [8540844.001]
  • [Cites] Korean J Ophthalmol. 1988 Jun;2(1):27-31 [3071636.001]
  • [Cites] Ophthalmology. 2001 Nov;108(11):2088-98; quiz 2099-100, 2121 [11713084.001]
  • [Cites] Ophthalmology. 1999 Apr;106(4):746-50 [10201597.001]
  • [Cites] Cancer. 1979 Jul;44(1):293-303 [455254.001]
  • [Cites] Br J Ophthalmol. 1968 Jan;52(1):43-53 [5710508.001]
  • [Cites] Int Ophthalmol Clin. 1982 Spring;22(1):23-61 [7061198.001]
  • [Cites] Oftalmologia. 1996 Oct-Dec;40(4):361-7 [8962866.001]
  • [Cites] Jpn J Ophthalmol. 2000 May;44(3):320 [10913665.001]
  • [Cites] Arch Ophthalmol. 1963 Jun;69:693-7 [13927762.001]
  • [Cites] J Indian Med Assoc. 1996 Nov;94(11):405-9, 416, 418 [9141864.001]
  • [Cites] Arch De Vecchi Anat Patol. 1977 Dec;62(2-3):327-30 [756225.001]
  • [Cites] Jpn J Ophthalmol. 1983;27(1):175-84 [6855011.001]
  • [Cites] J Maxillofac Surg. 1977 Jun;5(2):93-107 [267708.001]
  • [Cites] Ophthalmologica. 1995;209(5):280-3 [8570154.001]
  • [Cites] Aust J Ophthalmol. 1984 May;12(2):121-7 [6487181.001]
  • (PMID = 16187033.001).
  • [ISSN] 0021-5155
  • [Journal-full-title] Japanese journal of ophthalmology
  • [ISO-abbreviation] Jpn. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


85. McCarthy TC, Li X, Sinal CJ: Vitamin D receptor-dependent regulation of colon multidrug resistance-associated protein 3 gene expression by bile acids. J Biol Chem; 2005 Jun 17;280(24):23232-42
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Analysis of Mrp3 mRNA levels in various mouse tissues with known relevance and/or exposure to bile acids revealed the highest levels of basal expression in the colon followed in order by the liver, duodenum, jejunum, ileum, and kidney.
  • Functional analysis of a murine Mrp3 promoter reporter construct revealed vitamin D receptor (VDR)-dependent activation by 1,25-dihydroxyvitamin D(3) (VD3), 9-cis-retinoic acid (RA), and the cholestatic secondary bile acid, lithocholic acid (LCA).
  • Reduction of endogenous VDR expression in colon adenocarcinoma MCA-38 cells by siRNA transfection was associated with reduced constitutive and inducible expression of the Mrp3 gene.
  • [MeSH-minor] Animals. Base Sequence. Calcitriol / metabolism. Cell Line, Tumor. Cloning, Molecular. DNA, Complementary / metabolism. Dimerization. Dose-Response Relationship, Drug. Exons. Gene Deletion. Gene Expression Regulation. Genes, Reporter. Humans. Intestines / metabolism. Kidney / metabolism. Ligands. Liver / metabolism. Male. Mice. Mice, Inbred C57BL. Models, Biological. Models, Genetic. Molecular Sequence Data. Mutagenesis, Site-Directed. Promoter Regions, Genetic. RNA Interference. RNA, Messenger / metabolism. RNA, Small Interfering / metabolism. Transfection

  • Hazardous Substances Data Bank. 1,25-DIHYDROXYCHOLECALCIFEROL .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15824121.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bile Acids and Salts; 0 / DNA, Complementary; 0 / Ligands; 0 / Multidrug Resistance-Associated Proteins; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / Receptors, Calcitriol; 0 / multidrug resistance-associated protein 3; FXC9231JVH / Calcitriol
  •  go-up   go-down


86. Lynch MC, Anderson BE: Ileocecal adenocarcinoma and ureteral transitional cell carcinoma with multiple sebaceous tumors and keratoacanthomas in a case of muir-torre syndrome. Dermatol Res Pract; 2010;2010

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ileocecal adenocarcinoma and ureteral transitional cell carcinoma with multiple sebaceous tumors and keratoacanthomas in a case of muir-torre syndrome.
  • Cutaneous neoplasms including sebaceous tumors, keratoacanthomas, and basal cell carcinomas with sebaceous differentiation can be markers of internal malignancy associated with the Muir-Torre Syndrome (MTS).
  • We report a 56-year-old man with a diagnosis of hereditary nonpolyposis colorectal cancer (HNPCC) and ureteral transitional cell carcinoma who subsequently developed two sebaceous gland neoplasms and several keratoacanthomas, leading to the diagnosis of MTS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20814549.001).
  • [ISSN] 1687-6113
  • [Journal-full-title] Dermatology research and practice
  • [ISO-abbreviation] Dermatol Res Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2931389
  •  go-up   go-down


87. Fassan M, Pizzi M, Battaglia G, Giacomelli L, Parente P, Bocus P, Ancona E, Rugge M: Programmed cell death 4 (PDCD4) expression during multistep Barrett's carcinogenesis. J Clin Pathol; 2010 Aug;63(8):692-6
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Programmed cell death 4 (PDCD4) expression during multistep Barrett's carcinogenesis.
  • AIM: To test the contribution of programmed cell death 4 (PDCD4) tumour suppressor gene in Barrett's carcinogenesis.
  • METHODS: PDCD4 immunohistochemical expression was assessed in 88 biopsy samples obtained from histologically proven long-segment Barrett's mucosa (BM; 25 non-intestinal columnar metaplasia, 25 intestinal metaplasia (IM), 16 low-grade intraepithelial neoplasia (LG-IEN), 12 high-grade IEN (HG-IEN) and 10 Barrett's adenocarcinoma (BAc)).
  • Normal basal squamous epithelial layers featured strong PDCD4 nuclear immunoreaction (mostly coexisting with weak-moderate cytoplasmic staining).
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Biopsy. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / metabolism. Disease Progression. Down-Regulation. Gene Expression Regulation, Neoplastic. Humans. MicroRNAs / genetics. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism. Oligonucleotide Array Sequence Analysis / methods. RNA, Neoplasm / genetics. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Int. 1999 Dec;49(12):1067-77 [10632927.001]
  • [Cites] Oncol Rep. 2010 Jul;24(1):135-9 [20514454.001]
  • [Cites] Lancet. 2000 Dec 16;356(9247):2079-85 [11145505.001]
  • [Cites] Am J Gastroenterol. 2002 Aug;97(8):1888-95 [12190150.001]
  • [Cites] Am J Pathol. 2003 Jan;162(1):255-61 [12507908.001]
  • [Cites] Oncogene. 2003 Jun 12;22(24):3712-20 [12802278.001]
  • [Cites] Oncogene. 2003 Jul 31;22(31):4905-10 [12894233.001]
  • [Cites] J Pathol. 2003 Aug;200(5):640-6 [12898601.001]
  • [Cites] Am J Gastroenterol. 2003 Sep;98(9):1931-9 [14499768.001]
  • [Cites] N Engl J Med. 2003 Dec 4;349(23):2241-52 [14657432.001]
  • [Cites] Neoplasia. 2004 Jan-Feb;6(1):1-6 [15068665.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9309-14 [15184677.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):11-6 [15261138.001]
  • [Cites] Oncogene. 2004 Sep 30;23(45):7484-93 [15334056.001]
  • [Cites] Oncogene. 2004 Oct 21;23(49):8135-45 [15361828.001]
  • [Cites] Am J Pathol. 1999 Apr;154(4):965-73 [10233832.001]
  • [Cites] Am J Physiol Cell Physiol. 2004 Dec;287(6):C1541-6 [15317660.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3146-54 [15833844.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6034-41 [16024603.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61 [16461460.001]
  • [Cites] Oncogene. 2006 Jun 1;25(23):3346-56 [16449976.001]
  • [Cites] Gastroenterology. 2006 Sep;131(3):925-33 [16952561.001]
  • [Cites] Oncogene. 2006 Oct 5;25(45):6101-12 [16682950.001]
  • [Cites] Science. 2006 Oct 20;314(5798):467-71 [17053147.001]
  • [Cites] Gut. 2006 Dec;55(12):1810-20 [17124160.001]
  • [Cites] Dig Liver Dis. 2007 Jan;39(1):18-25 [17141593.001]
  • [Cites] Cancer. 2007 Oct 15;110(8):1697-707 [17849461.001]
  • [Cites] Clin Cancer Res. 2008 Jan 1;14(1):149-54 [18172265.001]
  • [Cites] J Biol Chem. 2008 Jan 11;283(2):1026-33 [17991735.001]
  • [Cites] J Thorac Cardiovasc Surg. 2008 Feb;135(2):255-60; discussion 260 [18242245.001]
  • [Cites] Oncogene. 2008 Mar 6;27(11):1527-35 [17828298.001]
  • [Cites] J Biol Chem. 2008 Mar 28;283(13):8601-10 [18223253.001]
  • [Cites] Oncogene. 2008 Apr 3;27(15):2128-36 [17968323.001]
  • [Cites] Oncogene. 2008 Jul 17;27(31):4373-9 [18372920.001]
  • [Cites] Oncogene. 2008 Aug 14;27(35):4820-9 [18427550.001]
  • [Cites] Oncogene. 2009 Jan 8;28(1):73-84 [18850008.001]
  • [Cites] Breast Cancer Res Treat. 2009 Mar;114(2):203-9 [18386173.001]
  • [Cites] Clin Cancer Res. 2009 Mar 15;15(6):1915-22 [19276261.001]
  • [Cites] Clin Cancer Res. 2009 Jun 15;15(12):4009-16 [19509156.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] J Pathol. 2009 Oct;219(2):214-21 [19593777.001]
  • [ErratumIn] J Clin Pathol. 2011 Mar;64(3):274
  • (PMID = 20702469.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / MIRN21 microRNA, human; 0 / MicroRNAs; 0 / Neoplasm Proteins; 0 / PDCD4 protein, human; 0 / RNA, Neoplasm; 0 / RNA-Binding Proteins
  • [Other-IDs] NLM/ PMC2976066
  •  go-up   go-down


88. Biermann K, Montironi R, Lopez-Beltran A, Zhang S, Cheng L: Histopathological findings after treatment of prostate cancer using high-intensity focused ultrasound (HIFU). Prostate; 2010 Aug;70(11):1196-200
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In benign glands, histological examination revealed a heterogeneous cellular damage and cellular response including cytologic atypia and basal cell hyperplasia.
  • In cases with residual adenocarcinoma, the majority of the cases (9/11, 88%) do no have apparent treatment effects.
  • There were minimal morphologic changes in residual adenocarcinoma after HIFU treatments.
  • [MeSH-major] Adenocarcinoma / therapy. Prostatic Neoplasms / therapy. Ultrasound, High-Intensity Focused, Transrectal / methods

  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010. (c) 2010 Wiley-Liss, Inc.
  • (PMID = 20564422.001).
  • [ISSN] 1097-0045
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Roy JW, Cowley EA, Blay J, Linsdell P: The intermediate conductance Ca2+-activated K+ channel inhibitor TRAM-34 stimulates proliferation of breast cancer cells via activation of oestrogen receptors. Br J Pharmacol; 2010 Feb 1;159(3):650-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have investigated the effects of specific K(+) channel inhibitors on basal and oestrogen-stimulated proliferation of breast cancer cells.
  • EXPERIMENTAL APPROACH: Using the mammary adenocarcinoma cell line MCF-7 we assayed cell proliferation by radiolabelled thymidine incorporation in the absence or presence of various K(+) channel inhibitors with or without 17beta-oestradiol.
  • KEY RESULTS: Inhibitors of K(v)10.1 and K(Ca)3.1 K(+) channels suppressed basal proliferation of MCF-7 cells, but not oestrogen-stimulated proliferation.
  • TRAM-34, a specific inhibitor of K(Ca)3.1 channels increased or decreased cell proliferation depending on the concentration.
  • At intermediate concentrations (3-10 microM) TRAM-34 increased cell proliferation, whereas at higher concentrations (20-100 microM) TRAM-34 decreased cell proliferation.
  • The enhancement of cell proliferation caused by TRAM-34 was blocked by the oestrogen receptor antagonists ICI182,780 and tamoxifen.
  • CONCLUSIONS AND IMPLICATIONS: Our results demonstrate that K(+) channels K(v)10.1 and K(Ca)3.1 play a role in basal, but not oestrogen-stimulated MCF-7 cell proliferation.
  • TRAM-34, as well as inhibiting K(Ca)3.1, directly interacts with the oestrogen receptor and mimics the effects of 17beta-oestradiol on MCF-7 cell proliferation and gene modulation.
  • [MeSH-minor] Calcium / metabolism. Calcium / pharmacology. Calcium / therapeutic use. Cell Line, Tumor. Cells / metabolism. Cells / pathology. Cellular Structures / metabolism. Cellular Structures / pathology. Estrogen Receptor alpha / metabolism. Estrogens / metabolism. Estrogens / pharmacology. Estrogens / therapeutic use. Female. Gene Expression / drug effects. Humans. Ion Transport / drug effects. Pyrazoles. RNA, Messenger / metabolism. RNA, Messenger / pharmacology. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):8151-6 [10884437.001]
  • [Cites] Oncogene. 2009 Apr 16;28(15):1792-806 [19270724.001]
  • [Cites] Receptors Channels. 2001;7(5):345-56 [11697078.001]
  • [Cites] Endocr Relat Cancer. 2003 Jun;10(2):179-86 [12790780.001]
  • [Cites] Mol Pharmacol. 2004 Mar;65(3):630-8 [14978241.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Mar 26;316(1):244-51 [15003537.001]
  • [Cites] Pflugers Arch. 2004 Jun;448(3):274-86 [15048575.001]
  • [Cites] Am J Physiol Cell Physiol. 2004 Jul;287(1):C125-34 [14985237.001]
  • [Cites] Steroids. 2004 Jun;69(6):401-18 [15219790.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6996-7001 [15466192.001]
  • [Cites] J Biol Chem. 1973 Sep 10;248(17):6251-3 [4353636.001]
  • [Cites] Endocrinology. 1989 May;124(5):2577-83 [2651098.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5925-30 [8650195.001]
  • [Cites] J Membr Biol. 1996 Nov;154(2):91-107 [8929284.001]
  • [Cites] Toxicol Appl Pharmacol. 1997 Jun;144(2):363-76 [9194421.001]
  • [Cites] J Membr Biol. 1999 Sep 15;171(2):107-15 [10489423.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2005 Apr;25(4):704-9 [15662023.001]
  • [Cites] FEBS Lett. 2005 Jun 6;579(14):2995-3000 [15893312.001]
  • [Cites] Eur Biophys J. 2005 Aug;34(6):515-29 [16184309.001]
  • [Cites] J Membr Biol. 2005 Jun;205(3):115-24 [16362499.001]
  • [Cites] J Membr Biol. 2005 Jun;205(3):159-73 [16362504.001]
  • [Cites] J Membr Biol. 2005 Jun;205(3):175-84 [16362505.001]
  • [Cites] J Biol Chem. 2006 May 12;281(19):13030-7 [16537547.001]
  • [Cites] FEBS Lett. 2006 May 22;580(12):2850-2 [16783874.001]
  • [Cites] Cancer Detect Prev. 2006;30(4):375-85 [16971052.001]
  • [Cites] Pflugers Arch. 2006 Nov;453(2):167-76 [17047984.001]
  • [Cites] Curr Med Chem. 2007;14(13):1437-57 [17584055.001]
  • [Cites] J Cell Physiol. 2007 Sep;212(3):690-701 [17520698.001]
  • [Cites] Oncogene. 2007 Aug 2;26(35):5107-14 [17310992.001]
  • [Cites] Pflugers Arch. 2007 Sep;454(6):945-56 [17429684.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Sep;293(3):C1010-9 [17596298.001]
  • [Cites] J Membr Biol. 2008 Jan;221(1):1-6 [18060344.001]
  • [Cites] Br J Pharmacol. 2008 Mar;153 Suppl 2:S1-209 [18347570.001]
  • [Cites] Expert Rev Mol Diagn. 2008 Mar;8(2):179-87 [18366304.001]
  • [Cites] Oncol Rep. 2008 Jun;19(6):1511-6 [18497958.001]
  • [Cites] J Clin Invest. 2008 Sep;118(9):3025-37 [18688283.001]
  • [Cites] J Biol Chem. 2000 Nov 24;275(47):37137-49 [10961988.001]
  • (PMID = 20050851.001).
  • [ISSN] 1476-5381
  • [Journal-full-title] British journal of pharmacology
  • [ISO-abbreviation] Br. J. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Estrogens; 0 / Potassium Channels, Calcium-Activated; 0 / Pyrazoles; 0 / RNA, Messenger; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / TRAM 34; 0 / estrogen receptor alpha, human; 094ZI81Y45 / Tamoxifen; 4TI98Z838E / Estradiol; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ PMC2828028
  •  go-up   go-down


90. Scharmach E, Hessel S, Niemann B, Lampen A: Glutathione S-transferase expression and isoenzyme composition during cell differentiation of Caco-2 cells. Toxicology; 2009 Nov 30;265(3):122-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glutathione S-transferase expression and isoenzyme composition during cell differentiation of Caco-2 cells.
  • The human colon adenocarcinoma cell line Caco-2 is frequently used to study human intestinal metabolism and transport of xenobiotica.
  • The aim of this study was to investigate the basal expression of further cytosolic GSTs in Caco-2 cells during cell differentiation.
  • In addition, a comparison was made with expression levels in MCF-7 and HepG2, two other cell types with barrier functions.
  • In Caco-2, gene and protein expression levels of GST alpha increased during cell differentiation.
  • No expression of GSTA5, GSTM5, or GSTP1 was detected in either cell.
  • GSTA1-A4 have been identified as good markers for cell differentiation.
  • The Caco-2 cell line is a useful model for assessing the potential of food-related substances to modulate the GST expression pattern.
  • [MeSH-major] Cell Differentiation / physiology. Glutathione Transferase / classification. Glutathione Transferase / metabolism. Isoenzymes / chemistry. Isoenzymes / metabolism


91. Uke M, Rekhi B, Ajit D, Jambhekar NA: The use of p63 as an effective immunomarker in the diagnosis of pulmonary squamous cell carcinomas on de-stained bronchial lavage cytological smears. Cytopathology; 2010 Feb;21(1):56-63
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of p63 as an effective immunomarker in the diagnosis of pulmonary squamous cell carcinomas on de-stained bronchial lavage cytological smears.
  • OBJECTIVES: A diagnosis in pulmonary onco-cytopathology primarily necessitates distinguishing small cell carcinoma (SCLC) from non-small cell carcinoma (NSCLC), which includes squamous cell carcinoma and adenocarcinoma.
  • Lately, p63 antibody has been used for distinguishing squamous cell carcinoma from SCLC and adenocarcinoma.
  • METHODS: A single Papanicolaou-stained conventional smear was de-stained and re-fixed with cold acetone and methanol for immunocytochemical staining with p63 antibody.
  • RESULTS: Out of 100 cases, 21 were cytologically diagnosed as squamous cell carcinoma.
  • Twenty of these showed 2+ or 3+ p63 positivity, whereas one, which was adenocarcinoma on histology, showed 1+ staining.
  • Of seven cases cytologically diagnosed as adenocarcinoma, six showed no p63 staining, whereas one, which was squamous cell carcinoma on histology, showed 1+ staining.
  • The former three were found to be SCLC on histology while the latter was squamous cell carcinoma.
  • The former eight were adenocarcinoma on histology and the latter two were squamous cell carcinoma.
  • The 10 cases that showed 1+ p63 staining were adenocarcinomas (n = 5), squamous cell carcinoma (n = 4) and NSCLC, not otherwise specified (n = 1).
  • Positive staining was seen in normal basal cells, which acted as an internal control.
  • Overall sensitivity of p63 for squamous cell carcinoma was 100% and specificity was 90.4%.
  • CONCLUSIONS: p63 immunostaining on processed cytology smears can be used to help identify squamous cell carcinoma.
  • Its diffuse expression was specific for squamous cell carcinoma while focal staining was also seen in adenocarcinoma.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Squamous Cell / pathology. Lung Neoplasms / pathology. Trans-Activators / metabolism. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adult. Aged. Aged, 80 and over. Bronchoalveolar Lavage / methods. Bronchoalveolar Lavage Fluid / cytology. Carcinoma, Non-Small-Cell Lung / diagnosis. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Transcription Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19744186.001).
  • [ISSN] 1365-2303
  • [Journal-full-title] Cytopathology : official journal of the British Society for Clinical Cytology
  • [ISO-abbreviation] Cytopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


92. Akino Y, Teshima T, Kihara A, Kodera-Suzumoto Y, Inaoka M, Higashiyama S, Furusawa Y, Matsuura N: Carbon-ion beam irradiation effectively suppresses migration and invasion of human non-small-cell lung cancer cells. Int J Radiat Oncol Biol Phys; 2009 Oct 1;75(2):475-81
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carbon-ion beam irradiation effectively suppresses migration and invasion of human non-small-cell lung cancer cells.
  • The purpose of this study was to investigate the effect of carbon beam on non-small-cell lung cancer (NSCLC) cell aggressiveness and gene expression.
  • METHODS AND MATERIALS: A549 (lung adenocarcinoma) and EBC-1 (lung squamous cell carcinoma) cells were treated with 290 MeV/nucleon carbon ion beam at the Heavy Ion Medical Accelerator in Chiba or with 4-MV X-ray at Osaka University.
  • We tested proliferative, migratory, and invasive activities by cell proliferation assay, Boyden chamber assay, and Matrigel chemoinvasion assay, respectively. cDNA microarray and reverse transcription polymerase chain reaction were also performed to assess mRNA expression alteration.
  • RESULTS: X-irradiation increased cell proliferation of A549 cells at 0.5 Gy, whereas high-dose X-ray reduced migration and invasion of A549 cells.
  • Carbon beam irradiation induced alteration of various gene expression profiles differently from X-ray irradiation. mRNA expression of ANLN, a homologue of anillin, was suppressed to 60% levels of basal expression in carbon beam-irradiated A549 cells after 12 h.
  • [MeSH-major] Carbon Radioisotopes / therapeutic use. Carcinoma, Non-Small-Cell Lung / radiotherapy. Cell Movement / radiation effects. Lung Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adenocarcinoma / secondary. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / secondary. Cell Adhesion / radiation effects. Cell Line, Tumor. Cell Proliferation / radiation effects. Collagen. Drug Combinations. Gene Expression Profiling / methods. Humans. Laminin. Neoplasm Invasiveness / prevention & control. Proteoglycans. RNA, Messenger / metabolism. Relative Biological Effectiveness. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19735871.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbon Radioisotopes; 0 / Drug Combinations; 0 / Laminin; 0 / Proteoglycans; 0 / RNA, Messenger; 119978-18-6 / matrigel; 9007-34-5 / Collagen
  •  go-up   go-down


93. Pearson HB, Phesse TJ, Clarke AR: K-ras and Wnt signaling synergize to accelerate prostate tumorigenesis in the mouse. Cancer Res; 2009 Jan 01;69(1):94-101
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we report the generation of a compound model of prostate cancer to define the synergism of activated K-ras (K-ras(+/V12)) and dominant stabilized beta-catenin (Catnb(+/lox(ex3))) in the murine prostate.
  • Concomitant with elevated mitogen-activated protein kinase (MAPK) signaling, PBCre(+)K-ras(+/V12) mice developed AH at 100 days (100% incidence) and low-grade prostate intraepithelial neoplasia and adenocarcinoma (60% and 7% incidence) by 500 days.
  • PBCre(+)Catnb(+/lox(ex3)) mice showed reduced longevity (average 428 days) and were predisposed to PIN-like keratinized squamous metaplasia at 100 days (100% incidence) and adenocarcinoma (100% incidence) at end-point.
  • These lesions displayed elevated Wnt signaling and basal levels of MAPK signaling.
  • Synchronous activation of K-ras and beta-catenin significantly reduced survival (average 189 days), reflecting accelerated tumorigenesis and the development of invasive carcinoma that displayed activated Wnt and MAPK signaling.
  • Notably, expression of the basal cell marker p63 negatively correlated with tumor grade, resembling human prostate adenocarcinoma.
  • Taken together, our data show that combinatorial oncogenic mutations of K-ras and beta-catenin drive rapid progression of prostate tumorigenesis to invasive carcinoma, characterized by the synergistic elevation of androgen receptor, cyclooxygenase-2, and c-Myc.
  • [MeSH-major] Cell Transformation, Neoplastic / metabolism. Prostatic Neoplasms / metabolism. Wnt Proteins / metabolism. ras Proteins / metabolism
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Animals. Cyclooxygenase 2 / metabolism. Female. Genes, ras. Inbreeding. MAP Kinase Signaling System. Male. Metaplasia. Mice. Mice, Transgenic. Proto-Oncogene Proteins c-myc / metabolism. Receptors, Androgen / metabolism. Signal Transduction. Urogenital System / pathology. beta Catenin / metabolism

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19117991.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0301154
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CTNNB1 protein, mouse; 0 / Myc protein, mouse; 0 / Proto-Oncogene Proteins c-myc; 0 / Receptors, Androgen; 0 / Wnt Proteins; 0 / beta Catenin; EC 1.14.99.1 / Cyclooxygenase 2; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


94. Bermudo R, Abia D, Ferrer B, Nayach I, Benguria A, Zaballos A, del Rey J, Miró R, Campo E, Martínez-A C, Ortiz AR, Fernández PL, Thomson TM: Co-regulation analysis of closely linked genes identifies a highly recurrent gain on chromosome 17q25.3 in prostate cancer. BMC Cancer; 2008;8:315
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we describe transcriptional signatures identifying distinct normal and tumoral prostate tissue compartments, and the inference and demonstration of a new, highly recurrent copy number gain on chromosome 17q25.3.
  • METHODS: We have applied transcriptional profiling to tumoral and non-tumoral prostate samples with relatively homogeneous epithelial representations as well as pure stromal tissue from peripheral prostate and cultured cell lines, followed by quantitative RT-PCR validations and immunohistochemical analysis.
  • RESULTS: The transcriptomic analysis has allowed us to identify signatures corresponding to non-tumoral luminal and tumoral epithelium, basal epithelial cells, and prostate stromal tissue.
  • In addition, in silico analysis of co-regulated expression of physically linked genes has allowed us to predict the occurrence of a copy number gain at chromosomal region 17q25.3.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosome Aberrations. Chromosomes, Human, Pair 17. Gene Expression Regulation, Neoplastic. Prostatic Neoplasms / genetics
  • [MeSH-minor] Cell Line, Tumor. Gene Dosage. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Nucleic Acid Hybridization. Reverse Transcriptase Polymerase Chain Reaction. Transcription, Genetic

  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Prostate. 1999 Dec 1;41(4):275-80 [10544301.001]
  • [Cites] Nat Biotechnol. 2008 Mar;26(3):305-12 [18327244.001]
  • [Cites] Am J Pathol. 2001 Feb;158(2):399-406 [11159178.001]
  • [Cites] Prostate. 2001 Feb 15;46(3):249-56 [11170154.001]
  • [Cites] Oncogene. 2001 Jan 4;20(1):48-57 [11244503.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5692-6 [11479199.001]
  • [Cites] Nature. 2001 Aug 23;412(6849):822-6 [11518967.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6331-4 [11522620.001]
  • [Cites] BJU Int. 2002 Feb;89(3):310-6 [11856117.001]
  • [Cites] Am J Pathol. 2002 Jun;160(6):2169-80 [12057920.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):203-9 [12086878.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4499-506 [12154061.001]
  • [Cites] Eur Urol. 2002 Mar;41(3):328-34 [12180237.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6A):3149-57 [12530058.001]
  • [Cites] Bioinformatics. 2003 Jan 22;19(2):185-93 [12538238.001]
  • [Cites] Biostatistics. 2003 Apr;4(2):249-64 [12925520.001]
  • [Cites] Curr Opin Cell Biol. 2003 Oct;15(5):583-9 [14519393.001]
  • [Cites] Urology. 2003 Nov;62(5 Suppl 1):11-20 [14607213.001]
  • [Cites] Genome Res. 2004 Jan;14(1):179-87 [14672980.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):615-20 [14722351.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):811-6 [14711987.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):5963-72 [15342375.001]
  • [Cites] Oncogene. 1996 Jan 4;12(1):53-62 [8552399.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Jun;6(6):443-50 [9184779.001]
  • [Cites] Cancer Res. 1998 Jan 1;58(1):23-8 [9426051.001]
  • [Cites] J Biol Chem. 2005 Feb 11;280(6):4483-90 [15574414.001]
  • [Cites] Genomics. 2005 Mar;85(3):401-12 [15718107.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):725-30 [16079851.001]
  • [Cites] BMC Genomics. 2005;6:109 [16107210.001]
  • [Cites] Science. 2005 Oct 28;310(5748):644-8 [16254181.001]
  • [Cites] Br J Cancer. 2006 Jan 16;94(1):128-35 [16404366.001]
  • [Cites] Cell Cycle. 2006 Jan;5(2):138-41 [16357539.001]
  • [Cites] Hum Pathol. 2006 Apr;37(4):401-9 [16564913.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):5977-80 [16778164.001]
  • [Cites] J Pathol. 2006 Aug;209(4):492-500 [16721726.001]
  • [Cites] Int J Cancer. 2006 Sep 15;119(6):1322-9 [16642477.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Sep;7(9):644-56 [16896351.001]
  • [Cites] J Biol Chem. 2007 Feb 2;282(5):2776-84 [17145757.001]
  • [Cites] N Engl J Med. 2008 Feb 28;358(9):910-9 [18199855.001]
  • [Cites] Nat Genet. 2008 Mar;40(3):310-5 [18264096.001]
  • [Cites] Nat Genet. 2008 Mar;40(3):316-21 [18264097.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1677-82 [10749139.001]
  • (PMID = 18973659.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2585097
  •  go-up   go-down


95. Pires MM, Emmert D, Hrycyna CA, Chmielewski J: Inhibition of P-glycoprotein-mediated paclitaxel resistance by reversibly linked quinine homodimers. Mol Pharmacol; 2009 Jan;75(1):92-100
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The designed agents were potent inhibitors of rhodamine 123 efflux in cultured cancer cell lines that display high levels of P-gp expression at the cell surface and in transfected cells expressing P-gp.
  • Further studies revealed that Q2 inhibited the efflux of a range of fluorescent substrates (rhodamine 123, doxorubicin, mitoxantrone, and BODIPY-FL-prazosin) from MCF-7/DX1 cells.
  • The reversibility of the tether was confirmed in experiments showing that Q2 was readily hydrolyzed by esterases in vitro (t(1/2) approximately 20 h) while demonstrating high resistance to nonenzymatic hydrolysis in cell culture media (t(1/2) approximately 21 days).
  • In addition, low concentrations of Q2 stimulated basal P-gp ATPase levels.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. QUININE .
  • Hazardous Substances Data Bank. VERAPAMIL HYDROCHLORIDE .
  • Hazardous Substances Data Bank. PRAZOSIN HYDROCHLORIDE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Methods Enzymol. 1998;292:456-73 [9711574.001]
  • [Cites] Pharm Biotechnol. 1998;11:345-65 [9760687.001]
  • [Cites] Eur J Biochem. 1999 Feb;259(3):841-50 [10092872.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1999;39:361-98 [10331089.001]
  • [Cites] Biochemistry. 1999 Oct 19;38(42):13887-99 [10529234.001]
  • [Cites] Mol Pharmacol. 2005 Mar;67(3):902-11 [15598974.001]
  • [Cites] Nat Rev Neurosci. 2005 Aug;6(8):591-602 [16025095.001]
  • [Cites] Biochemistry. 2006 Sep 26;45(38):11695-702 [16981729.001]
  • [Cites] J Med Chem. 2006 Nov 16;49(23):6742-59 [17154505.001]
  • [Cites] Cancer Res. 1983 Sep;43(9):4413-9 [6135505.001]
  • [Cites] J Immunol Methods. 1983 Dec 16;65(1-2):55-63 [6606682.001]
  • [Cites] Cancer Res. 1987 Oct 1;47(19):5141-8 [2441861.001]
  • [Cites] Mol Pharmacol. 1988 Feb;33(2):144-7 [2893251.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 May;85(10):3580-4 [3368466.001]
  • [Cites] J Biol Chem. 1988 Sep 5;263(25):12163-6 [2900833.001]
  • [Cites] Cancer Res. 1990 Mar 15;50(6):1748-56 [1968358.001]
  • [Cites] Biochemistry. 1990 Mar 6;29(9):2295-303 [1970935.001]
  • [Cites] Annu Rev Cell Biol. 1992;8:67-113 [1282354.001]
  • [Cites] Biochem Pharmacol. 1993 Sep 14;46(6):1096-9 [8105783.001]
  • [Cites] Biochim Biophys Acta. 1994 Jan 3;1189(1):1-6 [7905747.001]
  • [Cites] J Natl Cancer Inst Monogr. 1993;(15):55-61 [7912530.001]
  • [Cites] J Biol Chem. 1995 Sep 29;270(39):22957-61 [7559432.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):2031-5 [9050899.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10594-9 [9380680.001]
  • [Cites] N Engl J Med. 1998 Jan 1;338(1):35-45 [9414330.001]
  • [Cites] Eur J Biochem. 1997 Nov 15;250(1):130-7 [9432000.001]
  • [Cites] Biochemistry. 1998 Mar 17;37(11):3594-601 [9530286.001]
  • [Cites] Mol Pharmacol. 2000 Sep;58(3):624-32 [10953057.001]
  • [Cites] Semin Cell Dev Biol. 2001 Jun;12(3):247-56 [11428917.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5 [11716514.001]
  • [Cites] Mol Pharmacol. 2002 Mar;61(3):637-48 [11854445.001]
  • [Cites] Nat Rev Cancer. 2002 Jan;2(1):48-58 [11902585.001]
  • [Cites] Adv Drug Deliv Rev. 2003 Jan 21;55(1):3-29 [12535572.001]
  • [Cites] J Exp Biol. 2003 Nov;206(Pt 21):3753-9 [14506210.001]
  • [Cites] J Biol Chem. 2003 Oct 10;278(41):39706-10 [12909621.001]
  • [Cites] J Biol Chem. 2003 Dec 12;278(50):50136-41 [14522974.001]
  • [Cites] Biochemistry. 2004 Mar 2;43(8):2262-71 [14979722.001]
  • [Cites] Leukemia. 2004 Mar;18(3):401-8 [14724652.001]
  • [Cites] J Biol Chem. 2004 Apr 30;279(18):18232-8 [14749322.001]
  • (PMID = 18945821.001).
  • [ISSN] 1521-0111
  • [Journal-full-title] Molecular pharmacology
  • [ISO-abbreviation] Mol. Pharmacol.
  • [Language] ENG
  • [Grant] United States / NEI NIH HHS / EY / R21 EY018481; United States / NCI NIH HHS / CA / 2P30-CA23168; United States / NEI NIH HHS / EY / EY018481
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Affinity Labels; 0 / Fluorescent Dyes; 0 / P-Glycoprotein; 1N3CZ14C5O / Rhodamine 123; 80168379AG / Doxorubicin; A7V27PHC7A / Quinine; CJ0O37KU29 / Verapamil; EC 3.6.1.- / Adenosine Triphosphatases; P88XT4IS4D / Paclitaxel; XM03YJ541D / Prazosin
  • [Other-IDs] NLM/ PMC2685053
  •  go-up   go-down


96. Mazzucchelli R, Lopez-Beltran A, Cheng L, Scarpelli M, Kirkali Z, Montironi R: Rare and unusual histological variants of prostatic carcinoma: clinical significance. BJU Int; 2008 Nov;102(10):1369-74
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We review the clinicopathological features of the following unusual histological variants of prostatic carcinoma: small cell carcinoma, ductal adenocarcinoma, sarcomatoid (carcinosarcoma), basal cell, squamous cell and adenosquamous, and urothelial carcinoma.
  • Some develop from acinar adenocarcinoma after hormonal or radiation therapy.
  • Only basal cell carcinoma is seen as a low-grade carcinoma.
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Carcinoma, Acinar Cell / pathology. Carcinoma, Small Cell / pathology. Carcinoma, Squamous Cell / pathology. Carcinoma, Transitional Cell / pathology. Carcinosarcoma / pathology. Humans. Male. Middle Aged. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18793296.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 56
  •  go-up   go-down


97. Romics I, Bánfi G, Székely E, Krenács T, Szende B: Expression of p21(waf1/cip1), p27 (kip1), p63 and androgen receptor in low and high Gleason score prostate cancer. Pathol Oncol Res; 2008 Sep;14(3):307-11
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Biopsies of patients suffering from prostate adenocarcinoma of low (3 + 3 to 3 + 4) and high (5 + 4 to 5 + 5) Gleason scores (13 cases each group) were immunostained for positive regulators of cell cycle control (p21(waf1/cip1) and p27(kip1)), and essential markers of normal prostate gland ontogeny (p63) and growth (androgen receptor) to find differentially expressed markers of malignant progression.
  • P63 and p21(waf1/cip1) proteins detected in normal basal cell nuclei were lost in all but one studied tumors respectively.
  • The low to high grade dedifferentiation of prostate adenocarcinoma is accompanied with the down-regulation of p27(kip1) protein, which may be an important molecular sign of the lost cell cycle control.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. Intracellular Signaling Peptides and Proteins / metabolism. Membrane Proteins / metabolism. Prostatic Neoplasms / metabolism. Receptors, Androgen / metabolism
  • [MeSH-minor] Aged. Aged, 80 and over. Cell Cycle. Cyclin-Dependent Kinase Inhibitor p27. Disease Progression. Down-Regulation. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Prostate-Specific Antigen / blood

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1999 May;80(3-4):546-55 [10408865.001]
  • [Cites] BJU Int. 2004 May;93(8):1151-5 [15142130.001]
  • [Cites] J Androl. 1992 Nov-Dec;13(6):457-64 [1293127.001]
  • [Cites] Oncogene. 2001 Jul 12;20(31):4138-49 [11464280.001]
  • [Cites] Prostate. 2002 Jan 1;50(1):54-63 [11757036.001]
  • [Cites] J Pathol. 2001 Jan;193(1):73-9 [11169518.001]
  • [Cites] Clin Cancer Res. 1997 Dec;3(12 Pt 1):2269-74 [9815624.001]
  • [Cites] Prostate. 2001 Oct 1;49(2):93-100 [11582587.001]
  • [Cites] J Cell Biochem. 2000 Sep 7;79(3):347-54 [10972973.001]
  • [Cites] Br J Cancer. 1999 Nov;81(6):1052-8 [10576664.001]
  • [Cites] Mol Endocrinol. 2001 May;15(5):765-82 [11328857.001]
  • [Cites] J Biol Chem. 2003 Jun 6;278(23):21221-31 [12637563.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 2;90(17):1284-91 [9731735.001]
  • [Cites] J Urol. 2001 Dec;166(6):2171-7 [11696729.001]
  • [Cites] Clin Cancer Res. 2002 Mar;8(3):775-81 [11895908.001]
  • [Cites] Am J Pathol. 2000 Dec;157(6):1769-75 [11106548.001]
  • [Cites] J Cell Biol. 2000 Dec 11;151(6):1131-40 [11121430.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2705-15 [12782571.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):494-501 [11839669.001]
  • [Cites] Histochem Cell Biol. 2005 Jun;123(6):573-83 [15895240.001]
  • [Cites] BJU Int. 2006 Mar;97(3):644-8 [16469041.001]
  • [Cites] Eur Urol. 2001 Sep;40(3):241-51 [11684838.001]
  • (PMID = 18415709.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDKN1A protein, human; 0 / CDKN1B protein, human; 0 / CKAP4 protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Intracellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / Receptors, Androgen; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


98. Sramek B, Lisle A, Loy T: Immunohistochemistry in ocular carcinomas. J Cutan Pathol; 2008 Jul;35(7):641-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The distinction between ocular sebaceous carcinoma, poorly differentiated ocular squamous cell carcinoma and ocular basal cell carcinoma can be challenging.
  • RESULTS: Positive staining for cytokeratin (CK)7 was seen in 100% of sebaceous carcinomas, 77.8% of basal cell carcinomas and 67.7% of squamous cell carcinomas.
  • One hundred percent of sebaceous and basal cell carcinomas were positive for cytokeratin CAM 5.2, while only 83.3% of squamous cell carcinomas were positive.
  • Using epithelial membrane antigen (EMA), 100% of squamous cell carcinomas and 80% of sebaceous carcinomas were positive, while basal cell carcinomas were uniformly negative.
  • One hundred percent of basal cell carcinomas and 80% of sebaceous carcinomas were positive for Ber-EP4, while all squamous cell carcinomas were negative.
  • Finally, 77.8%, 20% and 16.7% of basal cell carcinomas, sebaceous carcinomas and squamous cell carcinomas showed immunoreactivity for the androgen receptor.
  • CONCLUSION: An EMA positive, Ber-EP4 positive immunophenotype supports sebaceous carcinoma, EMA positive, Ber-EP4 negative result supports squamous cell carcinoma and an EMA negative, Ber-EP4 positive result supports basal cell carcinoma.
  • [MeSH-major] Adenocarcinoma, Sebaceous / pathology. Biomarkers, Tumor / metabolism. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Eye Neoplasms / pathology. Sebaceous Gland Neoplasms / pathology. Skin / pathology
  • [MeSH-minor] Biomarkers / metabolism. Diagnosis, Differential. Humans. Immunohistochemistry. Keratin-7 / metabolism. Keratins / metabolism. Mucin-1 / metabolism. Receptors, Androgen / metabolism

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18201230.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / CAM 5.2 antigen; 0 / Keratin-7; 0 / Mucin-1; 0 / Receptors, Androgen; 0 / human epithelial antigen-125; 68238-35-7 / Keratins
  •  go-up   go-down


99. Aréchaga-Ocampo E, Pereira-Suárez AL, del Moral-Hernández O, Cedillo-Barrón L, Rodríguez-Sastre MA, Castillo-Alvarez A, López-Bayghen E, Villegas-Sepúlveda N: HPV+ cervical carcinomas and cell lines display altered expression of caspases. Gynecol Oncol; 2008 Jan;108(1):10-8
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HPV+ cervical carcinomas and cell lines display altered expression of caspases.
  • We analyzed here, the basal expression of precursors of apoptotic Caspases in normal cervical epithelium, HPV+ cervical tumor samples and HPV+ tumor-derived cell lines.
  • METHODS: Expression of initiator and effector Caspases was analyzed by immunochemistry in normal cervical epithelium and three types of cervical tumors (squamous cell carcinoma, adenocarcinoma and adenosquamous cell carcinoma) whereas expression of Caspases in HeLa, SiHa and CaSki cells was by immunofluorescence, Western blot and RT-PCR.
  • RESULTS: Expression of Caspases 3 and 9 was undetectable in adenocarcinoma and adenosquamous cell carcinoma, respectively.
  • Whereas in squamous cell carcinoma, the expression of Caspases was similar those observed in normal samples.
  • We did not observe an effect of the E6/E7 oncogenes on the expression of Caspases in C33-A cell.
  • CONCLUSION: Our results showed a differential expression of several Caspases in carcinoma samples and cell lines, suggesting multiple alterations of the Caspase pathways in cervical cancer.
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / pathology. Adenocarcinoma / virology. Blotting, Western. Carcinoma, Adenosquamous / enzymology. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / virology. Carcinoma, Squamous Cell / enzymology. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / virology. Cell Line, Tumor. Female. Fluorescent Antibody Technique. HeLa Cells. Human papillomavirus 16. Human papillomavirus 18. Humans. Immunohistochemistry. Isoenzymes / biosynthesis. Paraffin Embedding. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17936882.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Isoenzymes; EC 3.4.22.- / Caspases
  •  go-up   go-down


100. Yu Z, Shah DM: Curcumin down-regulates Ets-1 and Bcl-2 expression in human endometrial carcinoma HEC-1-A cells. Gynecol Oncol; 2007 Sep;106(3):541-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The present study was undertaken to determine the effect of curcumin on the expression of the proto-oncogene Ets-1 and the anti-apoptotic molecule Bcl-2 in human endometrial adenocarcinoma HEC-1-A cells.
  • At the end of the designated treatments, changes in cell morphology, DNA fragmentation and protein contents of Ets-1 and Bcl-2 were determined, respectively, by light microscopy, DNA laddering assay and Western blot analysis.
  • As an initial step towards understanding whether Ets-1 was a possible up-stream regulator of Bcl-2 expression in HEC-1-A cells and if so, whether curcumin could attenuate the Ets-1-induced up-regulation of Bcl-2 expression, cells were transiently transfected with an Ets-1/GFP (Green Fluorescence Protein) fusion construct and the transfectants were treated with 60 microM curcumin for 16 h, followed by whole cell lysate preparation for Western blot analysis of Bcl-2 protein contents.
  • RESULTS: Curcumin induced apoptosis-like morphological changes and DNA degradation and decreased basal levels of Ets-1 and Bcl-2 protein contents in HEC-1-A cells in a time- and dose-dependent manner.
  • Overexpression of Ets-1 in the cell resulted in an increase in Bcl-2 protein contents and that increase was attenuated by curcumin treatment.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / pharmacology. Curcumin / pharmacology. Endometrial Neoplasms / drug therapy. Proto-Oncogene Protein c-ets-1 / biosynthesis. Proto-Oncogene Proteins c-bcl-2 / biosynthesis

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CURCUMIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17590421.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / ETS1 protein, human; 0 / Proto-Oncogene Protein c-ets-1; 0 / Proto-Oncogene Proteins c-bcl-2; IT942ZTH98 / Curcumin
  •  go-up   go-down






Advertisement